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Abstract
This thesis describes molecular cloning and characterisation studies of
two G-protein coupled receptors (GPRs), the thyrotrophin-releasing
hormone receptor (TRH-R) and the dopamine D2 receptor (D2-R). These
two receptors are both expressed in the pituitary gland where they
mediate the actions of TRH and dopamine on the regulation of prolactin
and thyrotrophin (TSH) secretion. A human TRH-R clone was isolated
from a pituitary cDNA library (Duthie et al., 1993a). Sequence analysis
identified the clone as a TRH-R encoding a putative protein of 398 amino
acids. The human pituitary TRH-R had high sequence homology with the
rat and mouse TRH-Rs, except at the 3' end of the carboxy (COOH) tail.
In this region, residue 392 is a common point of sequence divergence, after
which the human, rat and mouse TRH-Rs encode variant amino acids.
The COOH tail of GPRs has been implicated in functionally significant
events including receptor phosphorylation, desensitisation and possibly
second messenger coupling. The human TRH-R clone was transiently
expressed in COS-1 cells and showed high affinity receptor binding using
[3H](3-Met-His2)TRH. Stimulation of these cells with TRH produced a
typical phosphoinositide response with mobilisation of intracellular
calcium. In addition to its role as a pituitary releasing factor, TRH
appears to act as a neurotransmitter/neuromodulator in brain, retina and
the gastro-intestinal and reproductive systems. The distribution of TRH-
R messenger RNA (mRNA) was therefore studied by in situ hybridisation
and Northern blot analysis, in several human tissues, using radio-labelled
probes based on the human TRH-R cDNA. Positive hybridisation to the
TRH-R probe was found in glandular epithelium and stroma of human
prostate tissue (benign and malignant) using in situ hybridisation. The
expression of TRH-R mRNA transcripts in the prostate was further
supported by Northern blotting, suggesting a possible biological role for
TRH in human prostate. The identification of TRH-Rs with variant
COOH tails raised the possibility of alternative splicing in the TRH-R
gene in this region of the receptor. To answer this question, a TRH-R
gene was cloned from a mouse genomic library (Duthie et al., 1993b).
Characterisation of the gene focused on the COOH terminal region. A
consensus splice junction was identified at the common point of sequence
x
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divergence (amino acid 392) found in the mouse, rat and human TRH-R
COOH tails. This splice site separated a 228bp exon (putative Exon 3),
encoding the final amino acid and stop codon of the mouse TRH-R, from
the rest of the coding region. This exon corresponded exactly to a deletion
in the rat TRH-R cDNA, which was 19 amino acids longer than the mouse
cDNA, in spite of the deletion. The nucleotides encoding these extra 19
residues were found on Exon 4 of the mouse gene, suggesting a possible
splicing event in this region. To date there is no evidence of a second form
of the mouse receptor. The mouse D2-R gene was also cloned and
characterised. The gene was structurally similar to the rat D2-R gene
with the coding region contained on 7 exons, spanning approximately 12kb
of the genome. The first exon, encoding 5' untranslated sequence, was not
identified due to the presence of an unusually large intron between the
first and second exons of the receptor. Like the rat D2-R, but unlike the
human receptor, the mouse gene encoded a variant donor splice site (gc
instead of gt) on Exon 4. Ultimately, the mouse TRH-R and D2-R genomic
clones may be used to study the significance of possible splicing events in
the regulation of prolactin secretion using transgenic mouse models.
Information relating to the sequence and structural organisation of the
genes encoding these GPRs will facilitate the identification of mutant
receptors which may be involved in disease states. Analysis of receptor
structure/function relationships will facilitate the study of ligand/receptor
interactions, leading to the design of agonists and antagonists selective for
a particular receptor subtype.
Duthie, S.M., Taylor, P.L., Anderson, L., Cook, J. & Eidne, K.A. (1993a)
Molecular and Cellular Endocrinology 95:R11-R15.
Duthie, S.M., Taylor, P.L. & Eidne, K.A. (1993b) Journal of Molecular
Endocrinology 11:141-149.
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One of the fundamental requirements of living organisms is the need to
communicate with the external environment and to transmit the
information received to internal signalling systems. The ability to
communicate requires the same three basic steps in all organisms, from
simple yeasts to complex, multicellular mammals with sophisticated
nervous systems. Firstly, an external stimulus is received by a specific
receptor molecule, secondly, the information must be transmitted to the
interior of the cell and finally the message has to be processed such that
the cell produces an appropriate physiological response.
A wide variety of external stimuli are known to exert their
biological effects via membrane-bound receptors coupled to intracellular
guanine-nucleotide binding proteins, or G-proteins. These G-protein-
coupled receptors (GPRs) have a common seven membrane-spanning
domain secondary structure and belong to an increasingly large
superfamily of molecules that respond to such diverse stimuli as light,
odourants, hormones, neurotransmitters and growth factors. Receptors
that receive the yeast MATa or MAToc mating pheromones are members of
the GPR superfamily (Blumer et al., 1988) while in mammals, GPRs are
known to be involved in almost every process required for the normal
functioning of higher organisms, including the transmission of
information to the visual and olfactory systems, to endocrine pathways
and to the nervous and cardiovascular systems.
Many drugs used in clinical practice bind and activate GPRs,
making the study of these receptor structures, and their mechanisms of
interaction with external stimuli and internal signalling systems, of prime
importance. Initially, receptors were classified using pharmacological
tools which characterised receptors with respect to ligands that acted as
agonists or antagonists. These methods were able to discriminate
between receptors that produced different responses when activated by
the same ligand, for example the alpha- and beta-adrenergic receptors
(Alquist, 1948), and the dopamine D1 and D2 receptors (Kebabian &
Calne, 1979), but were unable to resolve the confusion caused by the
ambiguous pharmacological profiles and overlapping distribution patterns
of some receptors.
1
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The explosion of recombinant DNA technology in the 1980s has
enabled receptors to be cloned and characterised using transfected cell
lines, without first identifying the ligand. Sequence analysis has
confirmed the existence of multiple receptor subtypes for several
receptors, including the muscarinic, adrenergic and dopamine receptors,
an important consideration when designing drugs specific for a particular
pathway. There have been several recent reports of GPR mutations that
are directly responsible for conditions such as familial male precocious
puberty (Shenker et al., 1993) and hyperfunctioning thyroid adenoma
(Parma et al., 1993) and thus sequence information is also of first
importance when assessing the involvement of GPRs in disease.
GPRs play a major role in reproductive biology and are involved in
the regulation of lactation and fertility. Hypothalamic hormones
controlling the release of prolactin, follicle stimulating hormone (FSH) and
luteinising hormone (LH) from the anterior pituitary gland all act via
GPRs. These include the dopamine D2-receptor (Bunzow et al., 1988), the
thyrotrophin-releasing hormone (TRH) receptor (Straub et al., 1990), and
the gonadotrophin-releasing hormone receptor (Tsutsumi et al., 1992)
amongst others. The LH receptor (McFarland et al., 1989) and FSH
receptor (Sprengel et al., 1990) which mediate the secretion of oestrogens
and androgens in the ovary and testis respectively, are also seven
membrane-spanning domain GPRs.
Researchers are becoming increasingly aware that results obtained
using cloned receptors in transfected cell lines may not accurately
represent the in vivo situation (Yamada et al., 1992), while marked
species differences in the responses of GPRs to different synthetic
analogues have been demonstrated (Oksenberg et al., 1992). These
observations stress the importance of not only studying human GPRs, but
also of characterising receptors in appropriate animal models.
One aim of this research project was to clone and characterise the
human TRH receptor (TRH-R) cDNA (Chpt. 4) in order to compare its
structure/function relationships with the previously cloned mouse (Straub
et al., 1990) and rat TRH-R (Zhao et al., 1992; de la Pena et al., 1992a,b;
Sellar et al., 1993). The chromosomal localisation of the human TRH-R
was also undertaken in collaboration with Professor Mike Connor's group
at the Duncan Guthrie Institute in Glasgow (Chpt. 4).
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Until recently, studying receptor distribution has been difficult due
to the lack of available antibodies, and low levels of receptor expression.
The cloned human receptor was therefore developed for use as a sensitive
probe to localise TRH-R mRNA to various human tissues by in situ
hybridisation and Northern blot analysis (Chpt 5).
The analysis of receptors in vivo as well as in vitro will provide
more accurate information on mechanisms of receptor function and control
and to this end the cloning and characterisation of the mouse TRH-R
(Chpt. 6) and dopamine D2-R (Chpt. 7) genomic structures was
undertaken. Knowledge of genomic splicing mechanisms and of
regulatory regions such as promotors and enhancers will help to
understand receptor regulation and expression. Ultimately, modified
receptor genes may be expressed in transgenic animal models to achieve a
more realistic picture of GPR function than can be obtained by using
transfected cell lines in isolation.
Chapter 2 attempts a general review of the relevant literature
providing a background for the work undertaken. Each experimental
chapter includes an introduction encompassing recent literature on the
particular topic, together with specific methods used. General techniques
that are relevant to more than one section are described in Chpt. 3. The
final chapter discusses the aims and achievements of the project in the
context of current research and suggests possible areas of future research.
2 Literature Review
2.1 Neuropeptides and neurotransmitters
In the 1930s, work by Ernst Scharrer and colleagues (Reichlin, 1987)
suggested the concept of neurosecretion. They idealised that certain
neurons in the brain/neurohypophyseal system resembled cells of
endocrine glands in that they could secrete chemical transmitters directly
into the circulation. It was known that the rapid transmission of electrical
impulses along neuronal axons in the nervous system required the release
of chemical neurotransmitter from the axon terminal across a synapse, or
close point of contact, between two neurons. Endocrine tissues, on the
other hand, were known to secrete their hormones directly into the blood
stream which transported them to target organs throughout the body.
The discovery that neurons could secrete chemical transmitters into the
vascular system seemed to combine these two processes and the chemical
transmitters of the hypothalamus were therefore termed neurohormones,
and the new science, neuroendocrinology.
2.2 The Hypothalamic-Pituitary Axis
2.2.1 The pituitary gland
Pioneer work by Green and Harris in the 1940s introduced the concept of
the hypothalamic-pituitary axis (Fig. 2.1). They demonstrated the
direction of blood flow from the hypothalamus to the pars distalis of the
adenohypophysis in living rats (Green & Harris, 1949) which supported
the concept of neurovascular control of the anterior pituitary (Green &
Harris, 1947). It was then proposed that neurons located in the
hypothalamus might secrete certain humoral substances into the portal
circulation to regulate normal function of the pituitary gland (Harris,
1955). The nature of the substance(s) was unknown, it was even
suggested that the hypothalamus supplied only a general stimulation to
the anterior pituitary, with specific control being provided by feedback
from the target organs of the pituitary hormones (Harris, 1955).
The knowledge that the posterior 'lobe' of the pituitary was not a
gland, but was composed of nerve cell endings with cell bodies originating
4
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third ventricle
Fig. 2.1
Diagrammatic representation of the hypothalamic-pituitary axis. The releasing or
inhibiting factors of the hypothalamus are synthesised within the nuclei of the
hypothalamus (1-4) and transported to the median eminence and then to the anterior
pituitary via the dense capillary network and long portal veins. The hypothalamic
hormones bind to specific receptors on the cells of the anterior pituitary leading to the
release or inhibition of the pituitary trophic hormone secretion. The products of the
posterior pituitary are synthesised in the supra optic and paraventricular nuclei (5).
After packaging, they are transported by axoplasmic flow to the nerve terminals in the
posterior pituitary where they are released directly into the circulation to act as classical
neurohormones on distinct target sites (adapted from Reichlin, 1987).
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in the hypothalamus, which released their hormones directly into the
circulation, supported the concept of a hypothalamic-pituitary axis. The
neurohypophyseal hormones, oxytocin and vasopressin, were purified in
1950 and 1954 respectively, from the posterior lobe, by du Vigneaud and
co-workers, representing the first direct evidence of an endocrine function
of the hypothalamus (Brownstein et al., 1980).
2.2.2 Hormones of the anterior pituitary
Anterior pituitary reproductive hormones controlled by the hypothalamus
include luteinising hormone (LH) and follicle stimulating hormone (FSH)
secreted by gonadotrophs and prolactin (PRL) secreted by lactotrophs (Fig.
2.2). LH and FSH are released together and act synergistically,
promoting ovulation and the secretion of oestrogens from the ovary in
females, and sperm production and androgen secretion in males. PRL is a
lactogenic hormone which stimulates and maintains lactation in
mammals, and (in some) the secretion of progesterone from the corpus
luteum.
Metabolic hormones of the anterior pituitary include thryotrophin
stimulating hormone (TSH) secreted by thyrotrophs, adrenocorticotrophic
hormone (ACTH) secreted by corticotrophs and growth hormone (GH)
secreted by somatotrophs (Fig. 2.2). TSH stimulates the growth of the
thyroid gland, the uptake of iodine and the secretion of its hormones.
Stress results in the release of ACTH which then stimulates the synthesis
and release of corticosteroid hormones from the adrenal cortex, melanin
production in pigment cells and lipolysis in fatty tissue. Finally, GH
stimulates skeletal and general body growth and also potentiates the
effects of other pituitary hormones.
2.2.3 The Hypothalamus
The hypothalamus is formed from the thickened floor and sides of the
posterior part of the vertebrate forebrain, and is situated below the third
ventricle of the brain and above the pituitary gland (Fig. 2.1). The
maintenance of a stable internal environment requires the co-ordinated
regulation of numerous biochemical signals. These signals converge upon
the neuronal systems of the hypothalamus, which respond by releasing











The hormones produced in the anterior pituitary and the hypothalamic hormones that
regulate their secretion (Adapted from Reichlin, 1987).
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neurohormones into the pituitary portal circulation, resulting in hormonal
secretions by the pituitary gland. This in turn, elicits the appropriate
metabolic responses. The hypothalamus, therefore acts as an
intermediary between the neuronal circuitry of the brain and the
endocrine secretion of hormones from the pituitary gland into the general
circulation (Reichlin, 1987; Yen, 1991).
2.2.4 Hypopthalmic Hormones
The first of these hormones to be described was corticotrophin releasing
factor (CRF, now called CRH) in 1955 (Saffran et ah, 1955) which
stimulated the release of ACTH from pituitary fragments maintained in
organ culture. Thyrotrophin releasing factor (TRF, now called TRH), was
the first neurohormone to be isolated and purified (Guillemin, 1971). This
discovery paved the way for the purification of the other major
hypophysiotrophic hormones which included gonadotrophin-releasing
hormone (GnRH), (Matsuo et al, 1971), somatostatin (Brazeau et al.,
1973), CRH, (Vale et ah, 1981), and growth hormone releasing hormone
(GHRH), (Guillemin et ah, 1983).
These peptide hormones were thought to be unique to the
hypothalamic-pituitary axis, but many have now been found in various
regions of the brain and spinal cord. They have also been discovered in
the autonomic nervous system, in the gastro-intestinal, reproductive and
respiratory tracts and in the placenta (Yen, 1991a). Such peptides may
have been involved in cellular communication before the development of
neuronal or endocrine systems (Krieger, 1983).
The catecholamines (biogenic amines) - dopamine (DA),
noradrenaline (norepinephrine) and adrenaline (epinephrine), classified as
neurotransmitters, may also be considered as hypothalamic hormones
because they are present in hypophyseal portal blood, and affect pituitary
hormone secretion (Paradisi et al., 1989).
2.2.5 Hormonal regulation of the anterior pituitary gland
Each of the known anterior pituitary hormones is regulated by
hypothalamic factors interacting with specific receptors on their target
cells (Fig. 2.2). One hypothalamic hozanone may regulate more than one
pituitary hormone, for example, TRH stimulates the release of TSH and
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prolactin and in some disease states, such as acromegaly and Cushing's
disease, can produce paradoxical rises in GH and ACTH, respectively
(Hershman, 1974; Jackson, 1982). Also, one pituitary hormone may be
regulated by more than one hypothalamic hormone, as hypothalamic
releasing and inhibiting factors interact with each other to exert dual
control. For example, the main control over prolactin secretion exerted by
the hypothalamus is a tonic inhibition by DA, but prolactin release is
stimulated by TRH, vasoactive intestinal peptide (VIP) and peptide
histidine isoleucine (PHI) (Fig. 2.2).
Neurons secreting hypothalamic hormones are themselves
influenced by neuropeptides, neurotransmitters such as DA, and feedback
effects of various pituitary hormones (Krieger & Liotta, 1979; Page, 1983).
The anterior pituitary hormones are also regulated by feedback effects,
generally from circulating levels of hormones from their target glands.
The aim of this research project has been to study anterior
pituitary gland, G-protein-linked receptors for neurotransmitters and
neuropeptides, and has chosen to focus on the thyrotrophin-releasing
hormone, TRH (a neuropeptide) receptor and the dopamine (a
neurotransmitter) D2 receptor. These hormones are involved in the
inhibition (dopamine) and stimulation (TRH) of prolactin and TSH
secretion, and a brief outline of their origins and functions is given below.
2.3 Thyrotrophin-releasing hormone
A hypothalamic releasing factor for thyrotrophin, (thyroid stimulating
hormone, TSH) was proposed in the 1950s (Greer, 1951) and was the first
of these peptides to be purified, chemically characterised, synthesised and
administered to humans to alleviate disruptions of the thyroid axis
(Guillemin, 1971; Schally et al., 1966). This peptide was named
thyrotrophin-releasing factor (TRF) and is now more commonly known as
thyrotrophin-releasing hormone (TRH) since it is released directly into the
pituitary portal circulation from the hypothalamus, to stimulate the
release of TSH and also prolactin from its target organ, the anterior
pituitary gland (Steiner et al., 1970; Tashjian et al., 1971). The
characterisation of porcine TRH (Folkers et al., 1969) and ovine TRH
(Burgus et al., 1970) showed that TRH was a weakly basic tripeptide
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amide with the structure pyroglutamyl-histidyl-proline-amide (pyroGlu-
His-Pro-NH2) (Fig. 2.3), and that the cyclised glutamic acid residue and an
intact amide were essential for activity.
Fig. 2.3
The chemical structure ofTRH [pyroGlu-His-Pro-NH2l (from Folkers et ah, 1969).
2.3.1 Structure, synthesis and metabolism of TRH
In common with other neuropeptides such as the enkephalins and opioids
(Krieger, 1983), TRH was shown to be derived from the post-translational
cleavage of a larger precursor molecule, or pro-hormone (Richter et al.,
1984; Jackson & Wu, 1985; Nillni et al., 1993). Several TRH-like peptides
have recently been characterised, some of which may be produced by
alternative post-translational processing of the TRH pro-hormone. Others
appear to be the products of distinct genes (Bilek et al., 1992; Fuse et al.,
1990).
TRH has a short half-life and is rapidly degraded in tissues and
serum into TRH-free acid (diamido-TRH), histidyl-proline-
diketopiperazine (His-Pro-DKP) and constituent amino acids (Bower et al.,
1978; Jackson et al., 1979; Jikihara et al., 1993). His-Pro-DKP is an
active metabolite of TRH and may, or may not, have a possible role as a
dopamine-uptake blocker in the rat hypothalamus (Peters et al., 1985;
Jikihara et al., 1993).
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2.3.2 Localisation of TRH to the hypothalamus
TRH has been localised to the hypothalamus and stalk medium eminence
with particularly high concentrations in the paraventricular nucleus, the
classic 'thyrotrophic area' of the hypothalamus (Jackson & Reichlin, 1974;
Lechan & Jackson, 1982). Ablation of the thyrotrophic area induces
hypothyroidism in the rat as a result of 70% depletion of total
hypothalamic TRH (Jackson & Reichlin, 1977). TRH is also present in the
nerve fibres of the posterior pituitary, where its concentration is second
only to the hypothalamus (Jackson & Reichlin, 1974; Lechan & Jackson,
1982). Ablation of the thyrotrophic area also reduces posterior pituitary
TRH, thus the hypothalamus is probably the source for both anterior and
posterior pituitary TRH (Jackson & Reichlin, 1977). It has been suggested
that TRH may be also be produced by the anterior pituitary gland itself,
and may act as a paracrine regulator of anterior pituitary hormonal
secretion as well as having an endocrine function (Childs et al., 1976).
2.3.3 TRH and the hypothalamic-pituitary-thyroid axis
In the 1940s, Hoskins (1949) proposed a 'servo' or feedback mechanism for
the regulation of pituitary TSH release by thyroid hormones. It was
known that increased levels of 3,5,3'-triiodothyronine (T3), following
increased secretion of TSH, resulted in the selective inhibition of TSH
from the anterior pituitary, and decreased T3 release. Thus steady state
levels of circulating thyroid hormone were maintained (Fig. 2.4).
Additional control over pituitary-thyroid function was proposed by
Green & Harris (Harris, 1955) when a role for the hypothalamus in
regulating pituitary hormone release was discovered. Greer produced
direct evidence to support this theory in 1951 (Greer, 1951), when he
demonstrated that inducing lesions in the hypothalami of rats prevented
the stimulation of pituitary TSH release. This work supported the
existence of a hypothalamic TSH-releasing factor. This factor (TRH)
(Guillemin et al., 1971), was shown to act as a sort of 'thermostatic
secondary regulator' of TSH, by counter-balancing the negative feed-back
effects of the thyroid hormones, the primary regulators of TSH secretion,
on the anterior pituitary (Bowers et al., 1967). TRH is a potent
hypophysiotrophic factor, which binds to specific receptors on pituitary
thyrotrophs, activating the phospholipase C-inositol phosphate
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Fig. 2.4
Diagrammatic representation of the neuroendocrine regulation of TSH secretion. The
rate of secretion of TSH is modulated by a positive signal from the hypothalamus (TRH)
and two negative feedback mechanisms, one from brain (somatostatin) and one from
thyroid (thyroid hormones T3/T4). The thyroid hormones act on pituitary and
hypothalamus. The thyroid hormones have a negative effect on the hypothalamus with
respect to the control of TSH secretion (Adapted from Reichlin, 1987).
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intracellular second messenger signalling system (see section 2.6.8)
resulting in a characteristic TSH surge.
2.3.4 Feedback regulation of hypothalamic TRH
As well as their negative feed-back effects on the pituitary gland, the
thyroid hormones are involved in feedback at the hypothalamic level.
Administration of T3 to the hypothalamus of monkeys inhibited TSH
secretion from the pituitary (Belchetz et al., 1978), by apparently
inhibiting the release of TRH and/or regulating its breakdown (Jackson et
al., 1979). However, the thyroid hormones may be acting instead to
stimulate the release of neurotransmitters, including dopamine and
somatostatin, known to be involved at both TRH and TSH levels of control
(Montoya et al., 1979; Berelowitz et al., 1980; Chen & Ramirez, 1981;
Smythe et al., 1982).
TSH release is inhibited by dopamine acting directly on
thyrotrophs (Besses et al., 1975) and by somatostatin, the characteristic
inhibitor of GH (Maeda & Frohman, 1980), and is stimulated by
noradrenaline (Montoya et al., 1979). Extra-hypothalamic factors
involved are the glucocorticoids, which inhibit TSH release (Re et al.,
1976) and oestrogens which stimulate it, and have been shown to increase
the number of TRH-Rs on thyrotrophs (de Lean et al., 1977). TSH itself,
may also be involved in a 'short-loop' feedback, acting on the
hypothalamus to influence TRH release (Roti et al., 1978).
2.3.5 TRH and regulation of prolactin release
The synthesis and release of prolactin is under complex dual regulation by
the hypothlamus, involving the interaction of prolactin-inhibiting factors
(PIFs) such as dopamine and prolactin-releasing factors (PRFs) including
TRH. The mechanisms of this regulation are discussed in section 2.5.
2.3.6 TRH and endocrine disease
The characteristic response of TSH to intravenous injection of TRH (Fig.
2.5) has resulted in the use of TRH as an indicator of several thyroid-
related disorders (Snyder et al., 1974; Hershman, 1974). The TRH test is
based on the direct action of T3/T4 on the pituitary gland. If the thyroid
hormones are present in excess, TRH generally has no effect on TSH
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Fig. 2.5
Graphs showing the normal and disease responses to the TRH test. Graph (a) shows the
failure of the pituitary to respond to TRH in prolactinoma. Graph (b) shows the
paradoxical release of GH in response to TRH, which occurs in acromegaly. Graph (c)
shows the delayed TSH response to TRH in hypothalamic disease.
Chapter 2 Literature Review 15
release, since TSH would be maximally inhibited by T3/T4 (Reichlin, 1987).
The greatest value ofTRH in clinical medicine has been in the differential
diagnosis of thyrotoxicosis (primary hyperthyroidism) in borderline cases
of mild thyroid overactivity, which show no TSH response to the test
(Hershman, 1974; Burrow, 1991).
It was hoped that the test would be able to differentiate between
hypothyroidism due to a defect at the hypothalamic level (affecting TRH),
or at the pituitary level (blockade of response to TRH, perhaps due to
defective TRH-Rs) or at the thyroid level (affecting release of the thyroid
hormones). However, the TRH test has had limited use in this area due to
the wide variety of factors involved in regulating the hypothalamic-
pituitary-thyroid axis, which can affect the response ofTSH (Snyder et al.,
1974; Cobb et al., 1981).
TRH stimulates prolactin release (see section 2.5), but in patients
with prolactin-secreting pituitary adenomas (prolactinomas), a blunted
prolactin response to the TRH test generally occurs, see Fig. 2.5
(Kleinberg et al., 1977). Specific receptors for TRH were demonstrated on
the membranes of prolactinoma cells, suggesting that the blunted
response to TRH is probably due to the maximal stimulatation of
prolactin, rather than a lack of functioning TRH-Rs (le Dafniet et al.,
1983). It was hoped that the TRH test would be able to separate
prolactinomas from other causes of hyperprolactinaemia such as primary
hypothyroidism (low levels of T3/T4 reduce the inhibitory effect on
prolactin secretion). However, a blunted prolactin response can also be
found in other diseases and the test was found to lack specificity
(Kleinberg et al., 1977).
Abnormal responses to TRH have also been observed in other
forms of endocrine disease (Fig. 2.5). In normal circumstances, TRH has
no effect on GH release from somatotrophs in the anterior pituitary,
however, a paradoxical rise in GH in response to TRH has been observed
in some patients suffering from acromegaly, diabetes mellitus or primary
hypothyroidism in children (Maeda et al., 1975; Jackson, 1982; Scanlon &
Hall, 1989). TRH can also stimulate the release of ACTH from pituitary
corticotrophs in some patients with Cushing's disease and Nelson's
syndrome (Krieger & Condon, 1978).
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2.3.7 Extra-hypothalamic TRH
Once specific antibodies had been developed for detecting TRH by
immunoassay and immunohistochemistry, the peptide was found, rather
surprisingly, to exist in regions outside the classic thyrotrophic area of the
hypothalamus. TRH was identified in virtually all areas of the brain
(Jackson & Reichlin, 1974; Winokur & Utiger, 1977; Brownstein et al.,
1977) and spinal cord (Hokfelt et al., 1975; Johansson et al., 1981; Poulat,
1992), and at early stages of development is found in the pancreas
(Martino et al., 1978) and gastro-intestinal tract where it may be involved
in the regulation of gastro-intestinal secretion and motility (Morley et al.,
1977). TRH levels in these regions are high at neonatal stages of
development and decline to low levels in the adult (Morley et al., 1979;
Kawano et al., 1983). TRH is also present in the retina, where it appears
to be regulated by environmental lighting (Schaeffer et al., 1977), and in
the reproductive tissues of the male rat including testis, where it may play
an autocrine/paracrine role in the regulation of testosterone secretion and
spermatogenesis (Feng et al., 1993a) and prostate (Pekary et al., 1980).
TRH has also been localised to human placenta (Shambaugh et al., 1979),
see Chpt. 5. The recent identification of TRH-like peptides raises
questions as to whether the initial experiments on TRH localisation
identified authentic TRH or cross-reacted with TRH-like peptides (Fuse et
al., 1990; Gkonos et al., 1993).
2.3.8 TRH as a neuromodulator/neurotransmitter
The widespread distribution of TRH, especially in the CNS, argues for a
role for TRH as a neuromodulator or neurotransmitter (Sharif, 1985)
(Table 2.1). The importance of TRH in the CNS is suported by its
involvement (together with other CNS peptides) in the control of
respiration, temperature regulation, hypertension, anorexia, locomotion
and colonic motility following infusion of TRH into the CNS (Jackson,
1982; Scanlon & Hall, 1989). Evidence has indicated that TRH directly
affects the electrical activity of single neurons and also the increased
stimulation and release of neurotransmitters such as noradrenaline,
dopamine, serotonin and acetylcholine (Winokur & Beckman, 1978;
Kerwin & Pycock, 1979). TRH has been shown to co-exist with serotonin
and substance P in the neuronal projections from the medulla oblongata to
i
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Site ofAction Effect Mechanism
Pituitary
thyrotrophs
Stimulation of TSH release Releasing
hormone
lactotrophs Stimulation of PRL release
corticotrophs Paradoxical stimulation of
ACTH release (Cushing's
disease)
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Multiple functions for TRH (adapted from Scanlon & Hall, 1989; Jackson, 1982).
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the spinal cord (Johansson et al., 1981). Substance P apparently inhibits
spinal TRH-R binding while co-depletion of serotonin and TRH results in
up-regulation of spinal cord TRH-Rs (Ogawa et al., 1985). Some of the
TRH effects are acute and transient, ie. neurotransmitter-type activity,
whilst others are prolonged, suggesting a neuromodulatory role in
interactions with other peptides or transmitters.
TRH can be localised to synaptosomal preparations and can be
released from various brain regions by stimuli such as depolarisation
(Maeda & Frohman, 1980). Specific high affinity TRH-Rs have also been
found in various regions of the CNS using radio-labelled ligand-binding
techniques and in situ hybridisation (Ogawa et al., 1981; Ogawa et al.,
1985; Eymin et al., 1993; Zabavnik et al., 1993).
2.3.9 Clinical effects of TRH in the CNS
High levels of TRH have been observed in the basal ganglia of patients
affected by Huntingdon's chorea and may therefore be implicated in the
pathophysiology of this disease (Spindel et al., 1980). TRH may also be
involved in modulating excitatory processes in epilepsy (Kubek et al.,
1993).
Despite the fact that TRH crosses the blood-brain barrier poorly,
it has been shown to reverse narcotic depression induced by barbiturates
and ethanol in the rat, however the beneficial effects of TRH on such
depression is controversial (Evans et al., 1975; Jackson, 1982; Scanlon &
Hall, 1989). TRH has been shown to antagonise the hypothermic and
cataleptic effects of opiates without affecting the analgesic effects they
produce (Holaday et al., 1983; Metcalf & Dettmar, 1981). Therapeutic
effects of TRH have been observed in various forms of shock in which
opioid antagonists such as naloxone are traditionally used (Holaday &
d'Amato, 1981). TRH was found to maintain blood pressure after
haemorrhagic and endotoxic shock in the rat, and can also improve
recovery and survival after spinal trauma injury in cats (Faden et al.,
1981). TRH appears to mediate pain perception in complex interactions
with substance P, enkephalin, oxytocin, vasopressin and angiotensin, all
of which co-exist in the spinal cord.
TRH has been shown to stimulate increased locomotor activity,
possibly by stimulating the release of dopamine from the nucleus
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accumbens (Kerwin & Pycock, 1979; Collu et al., 1992) which has
encouraged research into effects of TRH on motor function in patients
suffering from spinocerebellar degeneration (Sobue et al., 1980) and
amyotrophic lateral sclerosis (Engel et al., 1983).
2.3.10 Summary
The role for TRH as a hypothalamic releasing hormone is only one aspect
of its diverse biological functions, although it is the only role that has been
extensively characterised. The distribution and neuropharmacological
effects of TRH support a neurotransmitter or neuromodulatory role for
TRH in the CNS (Table 2.1). The involvement of TRH in the gastro¬
intestinal tract, reproductive tract and retina is even less well understood
and will be the focus of much attention in the future. TRH appears to be
an almost ubiquitous transmitter engaged in complex interactions with
many other transmitters and peptides to regulate the normal functioning
of the body. Using TRH as a therapeutic agent may disturb systems other
than the particular one being treated. The detailed study of TRH-Rs in
the pituitary, CNS and other locations will help to design and develop
specific, non-degradable TRH analogues that can penetrate the blood-
brain barrier and interact with a specfic receptor in a particular location
(see Chpts. 4, 5 and 6).
2.4 Dopamine
The catecholamines, adrenaline (epinephrine), noradrenaline
(norepinephrine) and dopamine (DA) are an important class of
neurotransmitters involved in synaptic transmission in the central
nervous system and are synthesised from the amino acid phenylalanine as
shown in Fig. 2.6. Dopamine is the predominant catecholamine
neurotransmitter in the mammalian brain (Smith, 1989) and it acts as a
neurohormone in the anterior pituitary gland.
2.4.1 Dopamine as a neurotransmitter in the CNS
The dopaminergic system comprises three main neuronal pathways:- the
nigrostriatal, mesocorticolimbic and tuberoinfundibular pathways. (Fig.
2.7) The nigrostriatal pathway contains neurons of the substantia nigra




























































Synthesis of the catecholamines, dopamine, noradrenaline and adrenaline (from Smith,
1989).















Diagram showing the ascending bioaminergic tracts involved in hypothalamic-pituitary
function in the rat. Dopaminergic fibres comprise one group whose origin is in the
substantia nigra in the midbrain. An intrinsic tuberoinfundibular system is responsible
for dopamine secretion into the hypophyseal-portal system which regulates prolactin
secretion. Not shown is the mesolimbic system which innervates the visceral brain.
Ascending fibres from the locus ceruleus bring noradrenergic influences into the
hypothalamus, and fibres from the raphe nuclei carry serotonergic signals to the
hypothalamus and elsewhere. All these neurotransmitter pathways are involved in the
regulation of the anterior and posterior pituitary, in addition to other important visceral
and behavioural effects (from Reichlin, 1987).
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which synthesise DA and neurons of the striatum which respond to it.
Degeneration of these neurons results in Parkinson's disease, thus this
pathway appears to control normal movement (Lee et al., 1978). The
mesocorticolimbic pathwa}' consists of neurons of the central tegmental
area which connect with those of the limbic fore-brain and is thought to be
involved in controlling emotions. Breakdown of this system may
contribute to schizophrenia and is the site of action of neuroleptic drugs
(Seeman, 1987). The tuberoinfundibular neurons originate in the
hypothalamus and DA is secreted by these neurons (known as the TIDA
system) into the portal blood and is transported to the pituitary where its
principle action is to inhibit prolactin secretion and thus regulate lactation
and fertility (Birge et al., 1970). Dopamine also acts to inhibit TSH
secretion from the anterior pituitary (Scanlon et al., 1979; Besses et al.,
1975).
Clinical pathologies such as Parkinson's disease and
schizophrenia were the main reasons for stimulating research into the
dopaminergic system, resulting in the elucidation of the different
pathways and the family of receptors involved (Kebabian & Calne, 1979;
Civelli et al., 1991; Civelli et al., 1993).
2.4.2 Dopamine receptors in the CNS
Unlike the TRH system, where the identification and analysis of specific
receptors and receptor subtypes is just beginning, the existence of a family
of DA receptors (DA-Rs) has been known for some time. Certain criteria
were laid down for the classification of receptors for a particular
transmitter. Firstly, the endogenous ligand must be identified. Since
1966, Parkinson's patients had been treated with the amino acid L-
dihydroxyphenylalanine (L-DOPA), a precursor in the synthesis of the
catecholamines (Kebabian & Calne, 1979). This produced 'miracle cures'
and identified a role for DA in controlling normal movement via a DA-R in
the nigrostriatal region.
The discovery of antipsychotic drugs known as neuroleptics in
1952 (Seeman, 1987) stimulated extensive research into their mode of
action. These drugs were used to relieve the symptoms of schizophrenia,
but their sites of action were unknown. It was discovered that long term
treatment with neuroleptics could produce effects similar to the movement
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disorders found in Parkinson's disease, while high doses of DA (L-DOPA)
used to treat Parkinson's patients could result in psychoses (such as
hallucinations) common to schizophrenics. These observations pointed to
the involvement of dopaminergic systems in the etiology of schizophrenia
as well as Parkinson's disease, suggesting that the binding sites for
neuroleptic drugs might be DA -Rs (Seeman, 1975; Seeman, 1977). It was
also suggested that since separate neural pathways were involved in the
two disorders, the DA-Rs involved in each pathway might also be subtly
different.
2.4.3 Pharmacological classification of dopamine receptors
Once the endogenous ligand has been identified, receptors can be
classified pharmacologically, based on the action of drugs that selectively
mimic (agonists) or inhibit (antagonists) the effects of the endogenous
ligand. The receptor should respond to minute quantities of a particular
drug in a specific manner.
DA-Rs were initially characterised according to their responses to
various drugs including DA itself, and agonists like apomorphine and the
amphetamines which, in large doses, produced schizophrenic symptoms.
Neuroleptics such as the phenothiazines and butyrophenones alleviated
the symptoms of schizophrenia and were thought to block DA-Rs (Snyder
et al„ 1974).
To explain the varying potencies of the different drugs, it was
initially thought that there might be two DA-Rs located on different cell
types. Direct binding to DA-Rs in the brain was achieved with radio-
labelled ligands. [3H]DA itself, and [3H]haloperidol (a member of the
butyrophenone antagonists) were shown to bind with high affinity and
selectivity to synaptic DA-Rs in membrane preparations of the calf
caudate. The ability of various antipsychotic agents in displacing [3H]DA
and [3H]haloperidol binding correlated well with the clinical potencies of
these drugs (Creese et al., 1975; Seeman, 1975; Burt et al., 1975).
The similar regional distribution of [3H]DA and [3H]haloperidol
binding suggested that one DA-R existed in two different states with
selective high affinities for agonists and antagonists, rather than there
being two separate receptors. The demonstration that glycine receptors
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had two such binding sites, supported the possibility (Young & Snyder,
1974), although this theory was later disproved.
2.4.4 Dopamine-sensitive adenylate cyclase
The demonstration of a DA-sensitive adenylate cyclase in the superior
cervical sympathetic ganglion, substantia nigra and the retina provided
an in vitro model for studying the properties of the DA-R (Kebabian &
Greenwood, 1971; Iversen, 1975; Clement-Cormier et al., 1974, Kebabian
et al., 1972). Dopaminergic stimulation of cAMP formation in bovine
parathyroid cells led to the release of parathyroid hormone (Brown et al.,
1977), further suggesting a role for the adenylate cyclase-cAMP signal
transduction system in the propagation of a physiological response to DA.
Not all DA-Rs, however, shared the same properties, casting
doubt on the 'one receptor, two binding states' model (Kebabian & Calne,
1979). Discrepancies arose from the action of the butyrophenones which
did not correlate with their ability to inhibit the DA-sensitive adenylate
cyclase. These drugs were potent clinically, but were weak inhibitors of
adenylate cyclase (Karobath & Leitich, 1974; Roufogalis et al., 1976;
Seeman, 1977).
2.4.5 More than one dopamine receptor?
It was becoming apparent that there might be more than one DA-R,
although confusion still existed due to the overlapping dopaminergic
binding sites in the brain (Creese et al., 1975). Direct evidence for at least
two classes of DA-R came from results showing that most of the striatal
3[H]haloperidol binding sites in the rat were physically separate from the
DA-sensitive adenylate cyclase binding sites (Schwarz et al., 1978).
2.4.6 Dopamine and the hypothalamic-pituitary axis
The primary sites of DA action were thought to occur in the CNS until its
role as a neurohormone, regulating pituitary hormonal secretion, became
appreciated. Catecholamines were found to inhibit the release of prolactin
from the anterior pituitary (Steiner et al., 1970). Further studies with
selective catecholamine agonists and antagonists on rat anterior pituitary
glands suggested that DA was the major physiological inhibitor of
prolactin secretion, acting directly on the anterior pituitary gland via
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specific DA-Rs (MacLeod & Lehmeyer, 1974; Yamauchi et al., 1977), see
section 2.5.1. The presence of DA in the anterior pituitary gland
(Saavedra et al.,1975) and in the hypophyseal portal circulation (Ben-
Jonathan et al., 1977) supported this theory. DA is secreted into the
portal vessels of the pituitary gland by the neurons of the TIDA system,
whose cell bodies are located in the arcuate nucleus (Fig. 2.7). DA also
inhibits the secretion of TSH from thyrotrophs in the anterior pituitary
(Fig. 2.2). The major inhibition of TSH is due to feedback of the thyroid
hormones (section 2.3.3), but DA does seem to be involved, although in a
more modulatory role (Besses et al., 1975; Scanlon et al., 1979).
2.4.7 Dopamine binding sites in the pituitary
The use of the ergot alkaloid [3H]dihydroergocryptine (a potent DA
agonist) to study binding sites in bovine pituitary membranes indictated
that binding was associated with mammotrophs (lactotrophs) and that
these DA sites modulated prolactin secretion (Caron et al., 1978). This
represented the first direct study of DA binding sites in the anterior
pituitary and the first correlation with binding of a dopaminergic ligand to
a DA-regulated physiological process.
The use of selective radio-labelled antagonists confirmed the
presence of these regulatory DA binding sites (Calabro & MacLeod, 1978)
and suggested a difference between brain and pituitary DA-Rs. In the
anterior pituitary, apomorphine acted as a DA agonist (Caron et al., 1978),
however in tissues where DA-Rs were linked to adenylate cyclase,
apomorphine acted as a DA antagonist. Also, brain preparations
contained DA-sensitive adenylate cyclase, whilst there was no
catecholamine activation of this enzyme in the anterior pituitary (Steiner
et al., 1970).
DA was shown to inhibit basal levels of adenylate cyclase in
homogenates of human prolactin-secreting adenomas and the DA-Rs
mediating this inhibition had the same pharmacological properties as
those regulating prolactin secretion (de Camilli & Macconi, 1979). Studies
with various DA agonists and antagonists in rat anterior pituitary cells
confirmed that the pituitary DA-R involved in the inhibition of prolactin
secretion was negatively coupled to adenylate cyclase (Enjalbert &
■
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Bockbaert, 1983). The action of dopamine via the pituitary DA-R in the
anterior pituitary gland is discussed in more detail in section 2.5.1.
2.4.8 Two classes of dopamine receptor: D1 and D2
In 1979 DA-Rs were placed in two distinct categories based on the
accumulation of physiological, pharmacological and anatomical data and
were called Dl-like and D2-like receptors (Kebabian & Calne, 1979).
Briefly, Dl-like receptors were described as being linked to the
stimulation of adenylate cyclase and were not found in the anterior
pituitary, while D2-like receptors inhibited adenylate cyclase, had a high
affinity for neuroleptics, especially the butyrophenones, and a lower
affinity for DA agonists. Both D1 and D2-Rs existed in the brain, often
with overlapping distributions and both classes of receptor were found to
occur both pre-synaptically (autoreceptors) and post-synaptically in the
dopaminergic neurons (Table 2.2).
For just over a decade, this two-receptor classification has explained
most of the observed effects of DA in the different dopaminergic pathways.
The existence of other DA-Rs was guessed at (Enjalbert & Bockaert,

































D1/D2 classification of Dopamine Receptors (from Kebabian & Calne, 1979).
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2.4.9 Multiple dopamine receptor subtypes
The discovery that DA-Rs were coupled to G-proteins (Vallar & Melddesi,
1989) eventually led to their molecular characterisation. The existence of
a superfamily of similar membrane G-protein-coupled receptors (GPRs)
was used to clone new receptors by homology screening, using nucleic acid
probes based on observed sequence similiarities. Thus prior knowledge of
peptide sequence or even biological activity was unnecessary when cloning
novel receptors (Civelli et al., 1993 for review).
The rat D2-R was cloned using the hamster (3-adrenergic receptor
sequence (a member of the GPR family) as a probe for homology screening
(Bunzow et al., 1988). The cloning and characterisation of the mouse gene
for this receptor is discussed in detail in Chpt. 7. The Dl-R was cloned
from rat striatum using the polymerase chain reaction (PCR) (Zhou et al.,
1990; Monsma et al., 1990) and also by homology screening (Dearry et al.,
1990; Sunahara et al., 1990). These putative Dl-Rs were expressed in
transfected cell lines and were shown to stimulate adenylate cyclase
confirming their identity.
Since then, three other DA receptors have been cloned. The D3-R
(Sokoloff et al., 1990) and D4-R (Van Tol et al., 1991) are most closely
related to the D2 receptor, but each has a distinct pharmacological profile.
The D5-R (Sunahara et al., 1991, Grandy et al., 1991; Tiberi et al., 1991)
is similar to the Dl-R in that it stimulates adenylate cyclase, however, it
has a higher affinity for dopamine.
2.4.10 Even more dopamine receptors?
There is evidence for yet more DA-Rs. A D2-like receptor that binds
spiperone (a DA antagonist) but has a different nucleotide sequence and
which does not appear to be linked to a G-protein, has been reported (Todd
et al., 1989). Dl-like receptors have been detected in renal tissue
(Goldberg et al., 1978; Felder et al., 1989) and are linked to the activation
of phospholipase C and the phosphoinositide (PI) second messenger
pathway, rather than adenylate cyclase. The cloned Dl-R was not
expressed in renal tissue (Dearry et al., 1990; Zhou et al., 1990). A Dl-
like receptor, but of a different size, coupling to the PI pathway has also
been isolated from rat striatum mRNA (Mahan et al., 1990).
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2.4.11 Summary
Dopamine is a major neurotransmitter in the CNS where it is involved in
regulating emotion and movement. Disruptions in these dopaminergic
pathways (possibly at the receptor level in some cases) result in common
disorders such as Parkinson's disease, schizophrenia and susceptibility to
alcohol and drug abuse. DA also acts as a neurohormone in the
hypothalamus, inhibiting the release of prolactin and TSH from the
anterior pituitary. The existence of multiple DA-R subtypes has affected
preconceptions of the dopaminergic system. Overactive D2-Rs were
traditionally thought to be responsible for schizophrenia, but recent
evidence has implicated the D4-R subtype (Seeman et al., 1993; Iversen,
1993). Characterisation of the DA-R subtypes and their genes is critical
for designing selective agonists/antagonists for specific DA receptors and
this molecular information will also be useful in linking specific DA
receptors to particular disease states. Chpt. 7 reports the cloning and
characteristion of the mouse D2-R gene.
2.5 Regulation of prolactin release by dopamine and
TRH
The regulation of prolactin secretion from lactotrophs in the anterior
pituitary appears to involve complex interactions between multiple
intracellular signalling pathways linked to DA, TRH and VIP (Fig. 2.2 and
Fig. 2.8).
2.5.1 Prolactin inhibitory factors
The major regulatory role of the hypothalamus is inhibitory with respect
to prolactin secretion. It has long been known that dopamine inhibits
adenylate cyclase via a specific receptor on lactotrophs (section 2.6.9) and
that this is related to the inhibition of prolactin release (de Camilli et al.,
1979; Schettini et al., 1983). It is now clear that it is the withdrawal of
dopamine that results in the secretion of prolactin from anterior pituitary
lactotrophs (Fig. 2.11). The dissociation of DA from its lactotroph D2-R
releases adenylate cyclase which can then activate the cAMP pathway.
This process may potentiate the action of prolactin releasing factors
(PRFs) (de la Escalera & Weiner, 1992) see Fig. 2.8 and 2.11. Other















Diagrammatic representation of neuroendocrine regulation of prolactin secretion. A
variety of prolactin-inhibiting factors (PIFs) and prolactin-releasing factors (PRFs) as
well as central and peripheral modulators are depicted. Several peptides regulate
prolactin secretion within the pituitary gland by means of autocrine and paracrine
mechanisms. Peripheral hormones, particularly oestradioi and progesterone, exert their
influence through both hypothalamic and pituitary sites (Adapted from Yen, 1991).
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prolactin-inhibiting factors (PIFs) include a-melanocyte-stimulating
hormone and possibly GABA, which may act directly, but is less potent
than DA (Yen, 1991b).
2.5.2 Prolactin releasing factors
Increases in prolactin secretion without measureable decreases in
dopamine levels (Neill et al., 1981), together with an acute prolactin
release observed under maximal inhibition by dopamine (Clemens et al.,
1983) suggested the existence of one, or more, prolactin-releasing factors
(PRFs). The time-course of circulating levels of prolactin in response to
TRH, its dose-reponse characteristics and its suppressibility by T4 pre-
treatment were similar to those for TSH, suggesting that TRH might play
a role in stimulating prolactin secretion (Leong et al., 1983) (Fig. 2.8).
TRH has been shown to be a potent stimulator of prolactin release in vitro
from dispersed anterior pituitary cells in culture, and the administration
of TRH antiserum results in a decrease in both prolactin and TSH in rats
(Koch et al., 1977). Specific TRH-Rs have been found on lactotrophs
(Labrie et al., 1972; Hinkle & Tashjian, 1973) and TRH has been shown to
stimulate prolactin gene transcription within minutes, as well as
stimulating an acute release ofprolactin (Gershengorn et al., 1984) via the
Ca2+/protein kinase C pathway (see section 2.6.8 and Fig. 2.11).
Evidence against a primary role for TRH in regulating prolactin
comes from the observation that TRH antiserum did not prevent the
release of prolactin in the ewe (Fraser & McNeilly, 1982) or in the rat
(Harris et al., 1978). Circadian rhythms of prolactin and TSH are
dissociated in humans (Harris et al., 1978), further supporting only a
modulatory role for TRH. The hypothalamic hormone VIP, positively
coupled to adenylate cyclase, also stimulates the release of prolactin in an
autocrine manner (Nagy et al., 1988).
2.5.3 Modulation of prolactin secretion
The effects of TRH on prolactin secretion are known to be modulated by
various peripheral hormones and neurotransmitters. In cases of
hypothyroidism, low levels of T3/T4 stimulate prolactin release and in
hyperthyroidism, high levels of thyroid hormones inhibit prolactin release
(Snyder et al., 1973). Oestrogens are known to potentiate TRH-induced
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prolactin release by interfering with the coupling of the dopamine D2-R to
its second messenger system and by up-regulating the numbers of TRH-Rs
on lactotrophs (Raymond et al., 1978; Munemura et al., 1989). Oxytocin,
angiotensin II, serotonin, endogenous opioids, histamine and neurotensin
have also been implicated in modulating the response of prolactin to TRH
(Yen, 1991).
Since prolactin release is not regulated by feedback from its target
organ (the mammary gland), prolactin itself may regulate secretion of
PIFs and PRFs by a short-loop feedback mechanism. This is supported by
the fact that central injection of prolactin results in an increase in both
DA turnover in the median eminence and in the DA concentration in the
portal blood (Gudelsky & Porter, 1980), and by the presence of prolactin-
binding sites in the median eminence (Barton et al., 1989).
2.6 G-protein-coupled receptors
The dopamine D2-R and the TRH-R are both members of the G-protein-
coupled receptor (GPR) superfamily. The D2-R is negatively coupled to
the adenylate cyclase-cAMP second messenger pathway via the G-protein,
Gj, while the TRH-R stimulates the phospholipase C-inositol phosphate
pathway via Gq and/or Gn. This section describes general structural and
functional features common to the members of this receptor family.
The concept of molecules able to recognise specific stimuli and
transduce the signal to the intracellular environment was proposed by
Langley in 1905 to explain the action of curare on skeletal muscle
(Ahlquist, 1948). In 1906, Henry Dale suggested a receptive mechanism
for adrenaline to explain the fact that ergot alkaloids prevented only the
excitatory actions of adrenaline and had no effect on its inhibitory actions.
The adrenotropic receptors were therefore considered to belong to two
classes, those that generally resulted in excitatory functions, the alpha
receptors, and those generally responsible for inhibition of effector cells,
the beta-adrenergic receptors (Alquist, 1948; Brazier, 1959).
2.6.1 Receptors and Adenylate Cyclase
One of the early concepts of a cell-surface receptor was proposed by
Robison and coworkers (Robison et al., 1967), who suggested that a
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specific binding site might involve a single 'receptor' protein extending
from one side of the cell membrane to the other. Adenylate cyclase, an
enzyme known to reside in the cell membrane (Davoren & Sutherland,
1963) and to respond to stimulation by adrenaline (0ye & Sutherland,
1966) was suggested for the role of receptor. The enzyme was thought to
have two subunits, one regulatory and facing the extracellular fluid (the
two classes of adrenergic receptor were initially thought to be opposing
regulatory elements of the adenylate cyclase receptor), and one catalytic
and facing the cytoplasm, involved in converting ATP to adenosine 3',5'-
monophosphate (cAMP). cAMP acted as a second messenger, translating
the extra-cellular signals into a biological response within the cell.
The study of the adrenergic receptor-adenylate cyclase response
system in erythrocytes became the focus for elucidating the mechanisms of
transmembrane signalling as erythrocytes were a convenient source of
receptor and the adenylate cyclase system was well known (Hoffman &
Lefkowitz, 1980; Lefkowitz et al., 1983; Levitski, 1988).
2.6.2 Pharmacological ligand binding assays
Direct detection of receptors only became possible in the 1970s when
pharmacological binding assays were developed (Hoffman & Lefkowitz,
1980). These assays exploited the use of radio-labelled agonists and
antagonists for particular chemical transmitters and thus it was
discovered that the beta-adrenergic receptor (PAR) was an independent
unit that could be transferred from one adenylate cyclase system to
another (Orly et al., 1976). Limbird and Lefkowitz (Limbird & Lefkowitz,
1977) used the frog erythrocyte system to confirm that the functions of
pAR binding and adenylate cyclase activity were carried out by separate
molecular entities.
Binding studies, supported by biochemical data (Hoffman &
Lefkowitz, 1980; Lefkowitz et al., 1983; Levitski, 1988) confirmed the
existence of the two major classes of adrenergic receptor which had been
known since 1947 (Alquist, 1948) and allowed their further division into
subclasses termed alpha (a)i and 0C2, and Pi and P2. Both pARs stimulated
adenylate cyclase, but had different affinities for adrenaline and
noradrenaline (norepinephrine). The 0C2AR mainly inhibited adenylate
cyclase, but aiARs did not seem to be linked to the adenylate cyclase
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system. Thus the concept ofmultiple receptor subtypes for an endogenous
ligand, exerting multiple cellular responses was beginning to capture
attention.
2.6.3 Receptor purification
The development of affinity chromatography columns in the 1970s
(Lefkowtiz et al., 1983) allowed the purification of minute amounts of
receptor proteins. The (3]AR was purified from turkey erythrocytes
(Vauquelin et al., 1977; Vauquelin et al., 1979) and the muscarinic
cholinergic receptor from calf forebrain (Andre et al., 1983). The purified
receptors were shown to have all the properties of their endogenous
membrane-bound counterparts using ligand-binding assays, and
reconstitution experiments in lipid vesicles (Lefkowitz et al., 1983).
2.6.4 G-protein-coupled receptors
Many hormone/neurotransmitter receptors respond to ligand binding by
activating an enzyme such as adenylate cyclase or phospholipase C. In
1971, Martin Rodbell (Rodbell, 1980) discovered that the nucleotide,
guanine triphosphate (GTP), was essential for the activation of adenylate
cyclase and that its action was enhanced by hormones. This led to
Rodbell's 'G-protein theory' in which he suggested that a nucleotide
regulatory unit (G-protein) with site(s) for binding GTP was located at the
inner face of the plasma membrane and was responsible for mediating the
effects of GTP and hormones on adenylate cyclase, the catalytic
component of the system.
2.6.5 Heterotrimeric G-proteins
The first G-protein to be identified and sequenced was Gs, an adenylate
cyclase-stimulating GTP-binding protein, involved in mediating the effects
of adrenaline on adenylate cylcase (Gilman, 1987; Birnbaumer, 1990). Gs
consists of three tightly associated subunits, a, (3 and y in a 1:1:1 ratio and
was most similar to transducin (Stryer, 1986), a GTP-binding protein in
the visual system, coupled to the photoreceptor rhodopsin, another
member of the GPR family.
Reconstitution experiments in which the purified components of
the proposed signalling system, ie. receptor, G-protein and adenylate
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cyclase, were combined in phospholipid vesicles, established that receptors
could interact directly with GTP-binding proteins. (Lefkowitz et al, 1983).
These experiments also showed that the ligand binding and G-protein
coupling sites of a receptor existed in a single molecule (Asano et al.,
1984).
G-proteins were defined according to their sensitivity to ADP-
ribosylation of the a-subunit by pertussus toxin, or cholera toxin (Gilman,
1987; Neer & Clapham, 1988; Birnbaumer, 1990; Simon et al., 1991;
Bourne et al., 1991). Initially, the cholera toxin substrates were thought
only to stimulate adenylate cyclase, and the pertussis toxin substrates to
inhibit the enzyme, and the convention has been to name the G-protein
after its a-subunit, for example Gas and G«i respectively. The rhodopsin
G-protein, transducin, is a substrate for both toxins (Neer & Clapham,
1988). It is now known that G-proteins can also couple receptors to other
second messenger pathways, such as the PI pathway and can regulate ion-
channels (Kuo & Bean, 1993).
G-proteins, like the receptors, also belong to a large superfamily of
related nucleotide-binding proteins. More than thirty different G-protein
a-subunits have been cloned and are separated into four classes based on
amino acid similarity: Gas, Gai, Gaq and Gai2 (Simon et al., 1991).
Subunit diversity also exists amongst the (3 and y subunits (Birnbaumer,
1990).
2.6.6 The G-protein cycle
The agonist-stimulated receptor has an increased ability to bind to the
inactive Ga(3y heterotrimer (by a mechanism not yet understood) and this
interaction leads to the release of GDP bound to the a-subunit (Fig. 2.9).
GTP has a higher affinity than GDP for the 'empty' Ga subunit and the
binding of GTP mediates a conformational change in the a-subunit which
alters its affinity for binding other macromolecules, resulting in its
activation. The activated a-subunit then associates with an effector
molecule such as a phosphodiesterase, adenylate cyclase, phospholipase C,
phospholipase A2 or an ion channel (Simon et al., 1991). The a(3y complex
is transient since the binding of GTP results in the dissociation of the
GTP-a-subunit complex from the (3y dimer. The intrinsic GTPase activity








The G-protein cycle. A ligand-bound receptor (R*) catalyses the exchange of bound GDP
for GTP on the G-protein, which in turn, interacts with an effector protein to produce an
intracellular signal. The activated state of the G-protein is terminated by an intrinsic
GTPase activity, resulting in the hydrolysis of bound GTP to GDP and the dissociation of
the a-subunit from the fiy dimer.
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of the a-subunit hydrolyses bound GTP to GDP, and the GDP-a-subunit
can once again reassociate with the [3y dimer. The receptor uncouples
from the inactive a(3y protein and is ready to activate the next G-protein
(Gilman, 1987; Neer & Clapham, 1988; Birnbaumer, 1990; Simon et al.,
1991; Bourne et al., 1991). G-proteins, therefore, function as molecular
switches, being turned on by binding GTP and off by hydrolysing GTP to
GDP. Until recently, the Ga-subunit alone was thought to activate
effector molecules, but newer evidence has indicated that the (3y dimer can
also regulate effector pathways, increasing the complexity of the cell's
signalling system (Federman et ah, 1992; Clapham & Neer, 1993).
2.6.7 GPRs and signal transduction
The heterotrimeric G-proteins activate various intracellular signal
transduction pathways by their affinity for binding and activating
enzymes such as phospholipase C or adenylate cyclase (Table 2.3).
G-protein Effector
Gs, G; Adenylate cyclase regulation
Gt, G0if Sensory transduction
Gq, Gii Phospholipase activation
G0, Gs Ion channel activation
Table 2.3 G-proteins coupling to second messenger pathways.
These enzymes generate regulatory molecules or 'second messengers'
which can then effect physiological responses such as selective protein
phosphorylation, gene transcription, reorganisation of the cytoskeleton,
protein secretion and membrane depolarisation. The availability of
multiple receptor subtypes, multiple G-proteins and multiple isoforms of
the signal transduction enzymes, suggests a complex network of cellular
interactions required to co-ordinate intracellular communication (Suh et
al., 1988; Krupinski et al., 1989; Kuo & Bean, 1993). Recently, some
receptors have been shown to activate both the adenylate cyclase and
phospholipase C pathways in vitro, or to activate one and inhibit the
other, and several models for multiple signalling pathways by GPRs have
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been proposed (Fig. 2.10). It is becoming apparent, however, that the
activation of particular signalling pathways by transfected receptors
depends upon the environment provided by the particular cell-line used
(Birnbaumer, 1990; Milligan, 1993).
2.6.8 Phospholipase enzymes and signal transduction
Stimulation of cell surface receptors, eg. TRH-Rs and activation of the
appropriate G-protein (Table 2.3) results in the activation of a
phospholipase enzyme (a minor constituent of the plasma membrane)
which in turn catalyses the hydrolysis of a membrane-bound phospholipid
(Fig. 2.11). This hydrolysis produces at least two second messenger
molecules, diacylglycerol (DAG) and inositol 1,4,5-trisphosphate (IP3).
DAG remains in the plasma membrane and activates protein kinase C
(PKC), while IP3 binds to intracellular vesicles that store calcium ions
(Ca2+). Calcium is released into the cytoplasm where it may bind
calmodulin, a regulatory subunit for other enzymes such as protein
kinases. Inositol phosphates can also promote an influx of extracellular
Ca2+ through ion channels in the plasma membrane, in response to
certain agonists.
There are multiple forms of inositol phosphates regulating Ca2+
influx into the cell as well as the mobilisation of the various intracellular
Ca2+ pools. The inositol phosphate (IP) signalling system is complex and
widespread allowing a cell to distinguish between different receptors
involved in controlling short-term functions such as protein secretion in
response to a hormonal stimulus, or long-term responses such as cell
growth (Berridge & Irvine, 1989).
2.6.9 Adenylate cyclase and signal transduction
The adenylate cyclase signalling system has been the focus of attention for
many years. Its second messenger molecule, cAMP is capable of
regulating many different biochemical pathways and its discovery by
Sutherland in the 1950s resulted in the Nobel Prize for physiology and
medicine in 1971 (Bloom, 1981). Receptor stimulation of an appropriate
G-protein by VIP or DA withdrawal, for example (Table 2.3) triggers the
activation of adenylate cyclase within minutes, which catalyses the
formation of cAMP from ATP (Fig. 2.11).
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Mechanisms for signal bifurcation by G-protein-linked receptors. Model 1: One receptor
subtype interacts with one G-protein. Model 2: Different ligands activate their
respective receptors which can couple to the same G-protein. Model 3: A single receptor
interacts with a single G-protein, but signal bifurcation is achieved by regulation of
different effectors by the G-protein a- and Py-subunits. Model 4: A single receptor
activates multiple G-proteins, each of which can regulate a separate effector. Model 5:
Different G-proteins coupled to different receptor systems can activate the same effector
(Adapted from Birnbaumer, 1990 and Milligan, 1993).







Stimulation of Prolactin secretion
Fig. 2.11
Simplified diagram illustrating putative second messenger coupling pathways involved in
the regulation of prolactin secretion. The stimulatory action of TRH may be potentiated
by prior activation of the protein kinase A (PKA) pathway. Withdrawal of dopamine (DA)
from its receptor (R) activates adenylate cyclase (AC) generating the second messenger
cAMP. PKA pathway activation by the dissociation of DA from its receptor, or by the
association of VIP with its receptor (not shown), has a prolonged effect, and may
modulate the response to TRH by phosphorylating voltage-gated Ca2+ channels.
Association of TRH with its receptor activates the phospholipase C (PLC) enzyme which
generates two second messengers, diacylglycerol (DAG) activating protein kinase C
(PKC) resulting in the phosphorylation of Ca2+ channels, and inositol 1,4,5-trisphosphate
(IP3) which effects the release of Ca2+ from intracellular stores.
Chapter 2 Literature Review 40
Amplification of the original receptor stimulus is due to the slow GTP-
hydrolysis step, which allows the production of approximately a hundred
cAMP molecules before GTP decays to GDP and the ligand-receptor-G-
protein-enzyme complex is inactivated. One receptor can activate
approximately ten adenylate cyclase molecules, amplifying the original
stimulus approximately a thousand times. cAMP exerts its effects on the
intracellular environment through cAMP-dependent protein kinase A
(Levitski, 1988).
2.6.10 Cloning of G-protein-coupled receptors
While the G-protein theory was being proposed, microsequencing of
purified receptor proteins resulted in the production of oligonucleotides
used to isolate receptor genes. Rhodopsin, a GPR in the visual system was
cloned and sequenced in 1982 (Ovchinnikov, 1982) and the (3AR receptor
was cloned and sequenced in 1986 from hamster (Dixon et al., 1986).
Surprisingly, hydrophobicity analysis indicated that both receptors
appeared to have a similar structure to bacteriorhodpsin, a non-G-protein-
coupled, light-driven proton pump isolated from Halobacterium halobium.
Amino acid sequencing and electron diffraction studies had shown that
bacteriorhodopsin consisted of seven transmembrane-spanning a-helices
(Ovchinnikov, 1982).
2.6.11 A G-protein-coupled receptor superfamily
The existence of a large family of GPRs was initially based on the
structural and sequence homology of two GPRs, bovine rhodopsin and
hamster [3AR (Lefkowitz et al., 1986). It seemed reasonable to suppose
that other adenylate cyclase-coupled receptors would also have the seven
transmembrane-spanning a-helical structure. Moreover, the other
members of the opsin family (Nathans et al., 1986), the putative yeast
pheromone receptors (Nakayama et al., 1985) and the human mas
oncogene (Young et al., 1986) all exhibited a seven TM-spanning domain
structure. The GPR superfamily is growing daily as new members are
constantly being identified and cloned and so far includes receptors for
such diverse ligands as the biogenic amines, peptide hormones, the
tachykinins, arachidonic acid derivatives, light and odourants (Table 2.4).
















Hypothalamic peptides Thyrotrophin-releasing hormone
Gonadotrophin-releasing hormone
Growth hormone-releasing hormone





















Note: Several receptors have been cloned for which no ligands have as yet been
identified, these receptors are known as orphan receptors and will add to this list once
their ligands have been discovered.
Table 2.4
Ligands for GPR subfamilies (adapted from Probst et ah, 1992, Lefkowitz, 1991).
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2.6.12 Structural features of the GPR family
Alignment of the sequences for the GPRs (Strosberg, 1991; Probst et ah,
1992) has indicated several features common to most members of the
family, see Fig. 2.12 (Dixon et ah, 1986; Lefkowitz et ah, 1986; Baehr &
Appleby, 1986; Strange, 1988; Lefkowtiz, 1991; Dohlman et al., 1991;
Strosberg, 1991; Probst et ah, 1992). The general structure includes seven
hydrophobic transmembrane domains connected by three extracellular
and three cytoplasmic hydrophilic loops, an extracellular amino (NH2)
terminus of varying length and a cytoplasmic carboxy (COOH) terminal
tail, also of varying length. The gonadotrophin-releasing hormone (GnRH)
receptors however, have no C terminal tail (Tsutsumi et al., 1992; Eidne et
ah, 1992; Kakar et ah, 1992; Chi et ah, 1993).
The greatest sequence homology between different receptors
occurs in the membrane-spanning domains, whilst the widest sequence
divergence occurs in the three extracellular and three intracellular
connecting loops and the NH % terminus and COOH-terminal tails. A large
third intracellular loop, is another common characteristic.
2.6.13 Common functional properties of GPRs
The binding of a ligand to its specific receptor results in a conformational
change in receptor structure leading to the activation of a G-protein and
subsequent stimulation or inhibition of signal transduction systems such
as adenylate cyclase and/or phospholipase C. Another common feature of
GPRs is their ability to adapt to long-term stimulation by the same ligand,
known as desensitisation. Receptor phosphorylation appears to play a
critical role in this process (Gilman, 1987; Strange, 1988; Strosberg, 1991;
Probst et ah, 1992).
2.6.14 Functional domains and chimaeric receptors
The initial reconstitution experiments performed with the individual
components of the G-protein-coupled signal transduction system
(Lefkowitz et ah, 1983) were not sensitive enough for detailed analysis of
the various molecular interactions involved between receptor, G-protein
and catalytic enzyme.
Molecular biology has provided a powerful new tool for studying
these interactions. The use of chimaeric receptors formed from regions of













Schematic representation of a G-protein-coupled receptor illustrating the proposed seven
transmembrane (TM) topography with three extracellular loops (EL) and three
intracellular loops (CL) and putative functional domains, determined by site-directed
mutagenesis and chimaeric receptor analysis.
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different receptor sub-types has enabled the identification of separate
domains involved in ligand binding and G-protein coupling. Much of this
work was initially performed with the adrenergic receptors (Ward et ah,
1990). Combining different regions of the 0C2AR, which couples to Gj and
inhibits adenylate cyclase, with the P2AR, which couples to Gs and
stimulates adenylate cyclase, produced a receptor that combined features
of the two original proteins. The binding of an 0C2AR agonist to one
construct stimulated adenylate cyclase, normally a (3AR response (Kobilka
et al., 1988). This experiment enabled tentative identification of a role for
transmembrane 7 (TM7) in ligand binding and the NH^-terminal region of
TM5 to the COOH-terminal region of TM6 in G-protein coupling.
Chimaeric receptors formed from hamster f5i and P2ARS indicated
that the region around TM4 and TM5 contributed to subtype-specific
binding of receptor agonists, but could not identify any one amino acid
responsible for agonist differentiation (Dixon et ah, 1989).
Combining different domains of the tachykinin receptors,
substance P and substance K, indicated that the domains responsible for
ligand binding of any tachykinin covered TM2 to TM7, with a region
extending from TM2 to the third extracellular loop (EL3) and a minor
section of the extracellular NhG-terminal domain selecting for a particular
tachykinin (Yokota et ah, 1992).
2.6.15 Deletion and site-directed mutagenesis
Deletion and site-directed mutagenesis studies are further examples of
molecular techniques that have helped to determine more accurately,
domains, and even specific amino acids, involved in ligand-binding and G-
protein coupling (Ward et ah, 1990). Deletion mutagenesis, involving the
removal of small regions of a receptor, has indicated that the ligand-
binding domain of the [3AR does not directly involve the hydrophilic loops
of the molecule as their absence has no effect on ligand-binding (Dixon et
ah, 1987). Site-directed mutagenesis has been widely used to pinpoint
interactions between specific amino acid residues by replacing conserved
residues with other amino acids of a different size or with a different
functional side-group (Ward et ah, 1990). This type of mutation can
provide useful functional information, although the replacement amino
acids must be selected carefully, as major conformational changes in the
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receptor could mask the effects of the chosen residue. Again, much of the
original work was performed with the adrenergic receptors, but this
technique is now widely used.
The catecholamine group of ligands (DA, adrenaline and
noradrenaline) are protonated amines and it was suggested that the
ligand-binding site should contain an acidic residue to counteract the
amine group. Therefore, substitution of aspartate (Asp) and glutamate
(Glu) residues in the transmembrane domains with neutral amino acids
helped to determine their importance. Only two substitutions had any
effect, Asp79 to Ala in TM2 of the pAR resulted in a tenfold decrease in
receptor agonist affinity, but had no effect on antagonist binding. Asp113
to Ala in TM3 resulted in a dramatic decrease in the affinity of the
receptor for both agonists and antagonists. Response was measured by
the decrease of adenylate cyclase stimulation (Strader et al., 1987a;
Strader et ah, 1988). The TM3 Asp has since been found to be a conserved
residue in all catecholamine receptors, but not in receptors whose ligands
are not biogenic amines (Tota et ah, 1991; Probst et ah, 1992).
Several conserved serine residues in TM5 of the catecholamine
receptors have also been implicated in ligand binding by this approach
(Strader et ah, 1989a). Two conserved threonines in TM5 of the
acetylcholine (ACh) muscarinic receptors were positioned in the predicted
plane of ligand binding near the ligand's ester group, but were found to
face away from the predicted binding site (Wess et ah, 1991; Brann et al.,
1993).
An asparagine in TM6 of the muscarinic receptors is thought to
interact with the ester group of ACh and is not found in any other receptor
class (Hibert et ah, 1991). Recent receptor modelling by Brann et ah
(1993) has demonstrated that this TM6 Asn is ideally located in the
membrane pocket for interaction with the ester group of the ligand.
Site-directed mutagenesis has also supported the involvement of
TM7 in ligand binding (retinal is covalently bound to a lysine in TM7 of
rhodopsin). The aromatic amino acids phenylalanine (Phe290) in TM6
and/or tyrosine (Tyr326) in TM7 of the (3AR may interact with the phenyl
ring of serotoninergic and adrenergic ligands (Dixon et ah, 1989; Strader
et ah, 1989b).
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2.6.16 Ligand-binding and GPR subfamilies
The chromophore retinal lies in a hydrophilic pocket formed by the inner
surfaces of the TM domains of rhodopsin, and when stimulated by a
photon of light, produces a conformational change in the structure of the
receptor (Thomas & Stryer, 1982; Findlay & Pappin, 1986). Dixon et al.,
(1986) proposed a similar model of a binding pocket formed by the
hydrophobic TM domains encasing a hydrophilic core, for the interaction
of the catecholamines with the f)AR. This model was based on sequence
homology of the postulated transmembrane domains 5, 6 and 7 (the
retinal-binding site of rhodopsin) with the same region of the (3AR and
seems a likely model for receptors binding to small ligands such as the
peptide hormones and neurotransmitters.
Within the GPR superfamily, several interesting subfamilies exist
(Lefkowitz, 1991). The glycoprotein hormones, LH, FSH, and TSH belong
to a family with unusually long extracellular NH2-terminal domains
(Probst et al., 1992), the TSH receptor NH2-terminus is 398 amino acids
long (Parmentier et al., 1989). These hormones are large, heterodimeric
proteins unlikely to 'fit' into a transmembrane binding pocket. The
extracellular NH2-terminal domains are rich in cysteine residues that may
form disulphide bonds to stabilise the tertiary structure of this putative
ligand-recognition domain (Xie et al., 1990; Nagayama et al., 1991).
Another proposed sub-family, based on ligand-binding
characteristics, is the tachykinin group (substance P, substance K and
neuromedin receptors). These peptides are intermediate in size between
the neurotransmitters and glycoproteins, and Yokota et al. (1992) have
proposed an intermediate ligand-binding mechanism with the
transmembrane domains TM2, TM3 and TM4 together with part of the
extracellular NH2-terminus involved in recognition and binding (Yokota et
al., 1992).
A further variation on ligand-binding has been illustrated by the
cloning of the thrombin receptor (Vu et al., 1991). This receptor was also
found to have a large, extracellular NH2-terminal domain, but contained
an unusual extra feature. Thrombin, a platelet aggregation factor, was
shown to cleave the NH2-terminus of the receptor, creating a new NH2-
terminus that acted as a 'tethered' ligand and could activate the receptor.
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2.6.17 Molecular modelling of the ligand binding domain
Bacteriorhodopsin is the only seven transmembrane domain protein that
has been crystallised so far (Henderson et al., 1990) and three-
dimensional models for the GPR ligand-binding pocket are generally
based on its structure. Helical wheel models of receptors (Baldwin, 1993)
see Fig. 2.13, can be used to study the binding pocket in which conserved
residues can be arranged so that their side-chains face into the 'pocket'
with most of the non-conserved residues facing into the lipid bilayer.
Analysis of wheel models demonstrated that the seven transmembrane
domains can be arranged to form a pocket with a hydrophilic centre into
which the ligand may fit (Hulme et al., 1990). This information can be
used for each receptor to further the study of ligand-receptor interactions.
Recently, computer modelling has been developed to facilitate the work
(Findlay & Eliopoulos, 1990; Brann et al., 1993).
Although site-directed mutagenesis studies have tried to define
amino acids involved in ligand binding that are common to receptors of a
particular group, it is becoming apparent that each ligand may define its
own particular binding site depending on the precise interactions between
each functional group of the ligand and the amino acid residues of the
domains with which the ligand binds.
2.6.18 Cytoplasmic domains and G-protein coupling
The methods used to study the ligand binding domain have also been used
to identify the determinants for G-protein coupling. Receptor-G-protein
interactions are presumed to occur at the inner surface of the plasma
membrane and accordingly the intracellular loops and/or COOH-terminal
tail were predicted to be involved in G-protein coupling. Initial
experiments involving proteolytic cleavage of the large third cytoplasmic
loop (CL3) of rhodopsin abolished coupling with the G-protein transducin,
supporting this assumption (Findlay & Pappin, 1986).
Deletion mutagenesis studies with the [3AR extended the theory
and showed that the important domains for G-protein coupling and
adenylate cyclase activation were the regions of CL3 adjacent to the
plasma membrane, see Fig. 2.12 (Dixon et al., 1987). The critical residues
for activation of adenylate cyclase were eight amino acids forming the
junction between TM5 and the NH2-terminus of CL3 (Strader et al.,
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Symbols used:
^ Polar residue conserved in more than 10% of GPRs
W Residue conserved in more than 85% of GPRs
0 Size of circle indicates depth of residue within the membrane
Bar indicates non-conserved residues
— Internal bar indicates residue conserved in more than 65% of GPRs
Fig. 2.13
Helical wheel model showing the positions of the seven helices of a G-protein-coupled
receptor according to the model of Baldwin (1993). The helices are generally shown as
three layers, viewed from the inside of the cell. This diagram shows only one layer.
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1987b) and twelve amino acids at the COOH-terminus of CL3 (Dixon et
al., 1987).
The muscarinic ml receptor is coupled to a G-protein that
stimulates phospholipase C and the m2 receptor is linked to the adenylate
cyclase system via an inhibitory G-protein. Chimaeric receptor
experiments involving the interchange of CL3 and seven amino acids from
the COOH-terminus of TM5 between the ml and m2 muscarinic receptors,
altered the coupling specificity without changing the pharmacology
(Hulme et al., 1990). More recently, the NH2-terminal seventeen amino
acids of CL3 of the m3 muscarinic receptor have been defined as an
important domain for coupling to the PI pathway (Brann et al., 1993).
This region shows the greatest sequence divergence between the
muscarinic receptors linked to the PI pathway (ml, m2 and m3 subtypes)
and those linked to the adenylate cyclase pathway (m2 and m4) (Hulme et
al., 1990).
Site-directed mutation of a conserved proline to a threonine in
CL2 of the (1AJR, did not affect agonist binding, but did cause a reduction in
adenylate cyclase stimulation (O'Dowd et al., 1988) while mutation of the
highly conserved Asp130 in the COOH-terminal region of CL2 of the (3AB,
produced a receptor displaying a partial agonist phenotype that was
uncoupled from its G-protein (Dixon et al., 1988; Fraser et al., 1988).
2.6.19 Transmembrane domains and G-protein coupling
The Asp79 in TM2 of the (3AR, conserved in most GPRs appears to be
necessary for G-protein activation as well as ligand binding. It is involved
in the Na+ and H+ modulation of receptor coupling in the DA-Rs (Neve,
1991) and the 0C2AR (Horstman et al., 1990). A conserved Cys residue in
TM6 has also been implicated in P AR-activated signal transduction
(Fraser, 1989).
2.6.20 Peptide competition studies and G-protein coupling
Synthetic peptides corresponding to sections of the hydrophilic loops have
been used to map regions of the GPRs that may physically contact G-
proteins. These peptides have helped to determine whether loss of
function due to a particular receptor mutation has been due to loss of
contact with a G-protein, or an alteration in the receptor's tertiary
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structure. Peptides derived from the membrane-proximal regions of CL1,
CL2 and CL3 and the COOH-terminal tail of receptors have implicated
these regions in contact with G-proteins (Dalman & Neubig, 1991; Palm et
al., 1990).
Mastoparan, an amphipathic helix-forming peptide derived from
wasp venom is able to directly activate the G-protein G0 (Higashijima et
al., 1990). The membrane-proximal regions of CL3 are also predicted to
form amphipathic helices (Strader et al., 1987; Higashijima et al., 1990)
and ligand binding may produce a conformational change in the receptor,
exposing the amphipathic helices to the G-protein (Strader et al., 1989b).
This may explain why receptors with little sequence identity, even in the
suspected G-protein coupling domains, can activate the same G-protein
(Segrest et al., 1990). Recent experiments with the dopamine Dl, D2 and
(3]ARs, however, has suggested that an amphipathic helical structure does
not represent the main structural determinant for interaction with G-
proteins (Voss et al., 1993).
To date, all of the intracellular, cytoplasmic domains as well as
certain amino acids in the transmembrane domains have been linked to
G-protein coupling and activation of signal transduction pathways, and so
far there does not seem to be a specific domain conserved in all receptors
for G-protein coupling. However, in spite of the evidence presented by
Voss et al. (1993), it seems likely that secondary structure does play an
important role in G-protein interactions.
2.6.21 Covalent modifications to GPRs
As well as the primary structural features of GPRs, post-translational
covalent modifications at particular conserved amino acid residues may
play an integral role in the processes of ligand binding and signal
transduction. Such modifications include N-linked glycosylation,
palmitoylation, disulphide bond formation and phosphorylation.
2.6.22 N-linked glycosylation
N-linked glycosylation involves the addition of carbohydrate residues to
the amino side-chains of asparagine (Asn) residues and is known to be
important in molecular and cellular interactions of plasma membrane
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proteins. Potential glycosylation sites (Asn-X-Ser/Thr) are generally found
in the extra-cellular NH2-terminal domain of GPRs, and may be involved
in the correct expression of the receptor within the membrane (Kornfeld &
Kornfeld, 1985; Herron & Schimerlik, 1983). Tunicamicin, a glycosylation
inhibitor, caused depletion of cell-surface muscarinic receptors and
decreased the expression of the (3AR, but had no effect on ligand binding
(Dixon et al., 1987; Liles & Nathanson, 1986). The glycoprotein hormones
have large extracellular NH2-terminal domains, particularly rich in
glycosylation sites (Parmentier et al., 1989; McFarland et al., 1989;
Sprengel et al., 1990) which may be involved in ligand interactions or the
correct expression of the receptor in the membrane (Liles & Nathanson,
1986).
2.6.23 Disulphide bond formation
A pair of cysteine residues in the extracellular loops ELI and EL2, is a
striking feature of most GPRs, with the exception of the human mas
oncogene which binds angiotensin, and the orphan receptors, human
endothelial cell GPR and human thoracic aorta GPR (Probst et al., 1992).
There is evidence from experiments with disulphide reducing agents that
these two residues form a disulphide bond and stabilise the correct
conformation of receptors. At least two such bonds have been implicated
in the normal ligand binding and cell surface expression of the fLAR
(Scattergood et al., 1987; Fraser, 1989; Dohlman et al., 1990).
2.6.24 Palmitoylation
Another conserved feature of many GPRs is the presence of several
conserved Cys residues in the COOH-terminal tail. These residues are
generally located in the membrane-proximal regions of the cytoplasmic
tail, and in both the (3AR and rhodopsin, are covalently modified by
palmitoylation (Mouillac et al., 1992; Ovchinnikov et al., 1988). The
addition of palmitate, a fatty acid, to newly synthesised proteins occurs
after exit from the endoplasmic reticulum and it has been suggested that
membrane-binding of a palmitic acid residue could create an extra loop in
the COOH-terminal tail, which may anchor the receptor in the membrane
(Findlay & Eliopoulos, 1990; O'Dowd et al., 1989) see Fig. 2.12.
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2.6.25 Phosphorylation and receptor desensitisation
After prolonged exposure to a particular stimulus, signal transduction
pathways often exhibit a reduced response. This ability to adapt or
desensitise may occur at the level of the receptor and the observed
desensitisation of systems to certain drugs is a limiting factor in the use of
GPR agonists as therapeutic agents.
Receptor desensitisation involves at least three agonist-induced
alterations in the properties of a receptor (Sibley & Lefkowitz, 1985;
Strader et al., 1989b; Dohlman et al., 1991). Prolonged exposure to
agonist results in down-regulation of receptors, and reflects the
internalisation of receptors away from the plasma membrane. This is a
slow process occuring over a number of hours and does not account for the
rapid loss of intracellular response. The agonist also triggers a faster
(within minutes) sequestration of receptor into a cellular compartment
distinct from the plasma membrane from where it is quickly recycled to its
active form. Finally, the agonist also induces a rapid modification of the
receptor such that it functionally uncouples from the G-protein. This
uncoupling may be mediated by receptor phosphorylation (Strader et al.,
1987b; Bouvier et al., 1988; Hausdorff et al., 1989; Dohlman et al., 1991).
2.6.26 Long-term desensitisation
Down-regulation of receptor numbers on the cell surface occurs over a
number of hours. Receptors do not have to be phosphorylated or
sequestered to be down-regulated (Hausdorff et al., 1991). Both cAMP-
dependent and independent mechanisms have been implicated in receptor
down-regulation and may include alterations in mRNA stability as well as
in regulating rates of gene transcription, protein synthesis and receptor
degradation (Chuang, 1984; Hadcock & Malbon, 1988; Collins et al., 1989).
Mutations of the human P2AR that interfered with G-protein coupling also
interfered with receptor down-regulation but not sequestration (Campbell
et al., 1991).
2.6.27 Sequestration of receptors
Sequestration is another process involved in the negative regulation of
receptors, occuring within minutes of exposure to agonist stimulation. It
may involve the removal of the receptor from the cell-surface to an
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unknown site within the cell (Wang et ah, 1989). Upon removal of agonist
stimulation, sequestered receptors are rapidly recycled to the cell surface
in a fully functional state (Hertel et al., 1983).
Ligand-bound TRH-Rs appear to be sequestered while still
coupled to the G-protein-phospholipase C complex (Nussenzveig et al.,
1993a), with two domains in the COOH tail affecting this process
(Nussenzveig et al., 1993b). This is in contrast to adenylate cyclase-
coupled receptors which are believed to uncouple from the G-protein
before internalisation (Birnbaumer et al., 1990). Receptor sequestration
can be blocked without affecting desensitisation (Hertel et al., 1985) thus
there appears to be no correlation between phosphorylation and
sequestration (Strader et al., 1987c).
2.6.28 Short-term desensitisation
Exposure of cells expressing the (3AR to low concentrations of agonist (nM)
reduces the sensitivity of cells to the agonist without changing the
maximal responsiveness. Low concentrations of agonist appear to activate
only an agonist-independent kinase such as the cAMP-dependent protein
kinase A (PKA) (Hausdorff et al., 1989; Clark et al., 1989). PKA has been
shown to phosphorylate the (3AR at ArgArgSerSer residues in CL3 and the
membrane-proximal region of the COOH tail (Hausdorff et al., 1989).
Site-directed mutagenesis of these sites resulted in reduced receptor
phosphorylation and impaired desensitisation, but did not affect coupling
of the (32^AR to Gs (Hausdorff et al., 1991; Clark et al., 1989). Protein
kinase C (PKC), coupled to the PI/Ca2+-calmodulin pathway also acts in
an agonist-independent manner to phosphorylate receptors (Richardson &
Hosey, 1990; Bouvier et al., 1991).
Exposure of cells expressing the (3AR to high concentrations of
agonist (|iM) decreases both the sensitivity and maximal responsiveness
and activates an agonist-dependent kinase known as [3 ARK (Benovic et
al., 1986) which phosphorylates the (3AR at Ser/Thr residues at the distal
end of the COOH tail (Bouvier et al., 1988; Benovic et al., 1989). (3ARK
phosphorylation is thought to facilitate the binding of the cytosolic protein
(3-arrestin (Lohse et al., 1990) to the receptor, which seems to further
disrupt G-protein coupling. (3ARK can also phosphorylate receptors other
than the [3AR, and may be ubiquitous (Richardson et al., 1993; Kwatra et
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al. 1993). Thus there appears to be two independent pathways involved in
desensitisation of receptors.
2.6.29 Homologous and heterologous desensitisation
Short-term desensitisation can be further separated into homologous and
heterologous responses (Sibley & Lefkowitz, 1985; Dohlman et al., 1991).
Homologous desensitisation describes the reduced responsiveness to the
original stimulus, while heterologous desensitisation involves the
incubation of receptor with one agonist attenuating the response to other
agonists operating through distinct receptors. Heterologous
desensitisation of the (3AR appears to involve the cAMP-dependent PKA
and follows any stimulus that raises cAMP levels in the cell (Dohlman et
al., 1991).
2.6.30 GPRs and disease
GPRs mediate a wide variety of physiological actions (Table 2.4) including
hormonal stimulation and neurotransmission, olfaction and vision via
ubiquitous intracellular signalling pathways. It is possible, therefore, that
defects in these receptors might be responsible for certain pathologies.
Recently two reports have described spontaneous mutations that result in
the constitutive activation of GPRs and human disease. Permanantly
activated TSH-Rs result from somatic mutations in the membrane-
proximal region of the third cytoplasmic loop, and are found only in tissue
from hyperfunctioning thyroid adenomas (Parma et al., 1993). Male
precocious puberty is due to a mutation in TM5, which constitutively
activates the LH-R resulting in Leydig cell hyperplasia and production of
testosterone in the testis (Shenker et al., 1993). A mutation in TM7 which
prevents binding of retinal to rhodopsin leads to constitutive activation of
the receptor and retinal degeneration (Robinson et al., 1992). In mice,
point mutations in CL1 and TM2 result in constitutive activation of the
melanocyte-stimulating hormone receptor leading to hyper-pigmentation
(Robbins et al., 1993).
Interestingly, the mutations in the TSH-R occur in the same
positions as mutations produced in the aig-AR in vitro (Allen et al., 1991)
which induced focus formation in transformed fibroblasts without agonist
stimulation of the receptor. Similar mutations in the P2-AR (Samama et
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al., 1993) and the 0C2-AR (Ren et al., 1993) also resulted in constitutive
receptor activation. It appears, therefore, that certain amino acid residues
must be responsible for preventing receptors from coupling to G-proteins
until stimulated by an agonist. When these residues are mutated, the
receptor conformation somehow changes to a permanantly activated state
(Lefkowitz, 1993a,b).
Over-expression of wild-type serotonin (a neurotransmitter)
receptors in non-neural cell lines results in transformation when
stimulated by agonist (Julius et ah, 1989) suggesting that ectopic
expression of receptors might cause them to act as oncogenes. One
example of a potential transforming GPR is the human mas oncogene
which binds angiotensin, a peptide responsible for regulating blood
pressure (Young et ah, 1986; Jackson et ah, 1988). Recently three GPR
homologues have been identified within the coding region of the human
cytomegalovirus (HCMV) (Chee et ah, 1990). HCMV is a herpes virus, but
can cause congenital and neonatal disease, and is a dangerous pathogen in
individuals with a deficient immune system.
The study of GPR-activating mutations as well as wild-type
receptors that act as oncogenes will be useful in determining the causes of,
and possible therapies for, receptor-related diseases. These mutations will
also be helpful in elucidating the structural basis for agonist-stimulated
receptor activation in wild-type receptors.
2.6.31 Evolution of GPRs
Comparison of GPR sequences with those of bacteriorhodopsin, which has
seven transmembrane domains, but is not G-protein-coupled, has revealed
fairly low sequence homology. This is not surprising, as GPRs must have
diverged from bacteriorhodopsin approximately 1.5 billion years ago when
prokaryotes and eukaryotes diverged. The observation by Pardo et ah,
(1992) that TM7 of bacteriorhodpsin is most homologous to TM3 of GPRs
led them to propose that exon shuffling occured during the evolution of the
GPRs with the result that the TM helices would require a different folding
pattern. Taylor & Agarwal (1993) suggested that the GPRs may instead
have evolved by a gene duplication event from bacteriorhodopsin such that
TM5 to TM7 arose as duplicates of TM1 to TM3, which also explains why
TM3 of the GPRs is similar to TM7 of bacteriorhodopsin. Since most of
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the three-dimensional work on GPRs has been based on the structure of
bacteriorhodopsin, this question needs to be resolved.
Comparison of GPR genes that contain introns has shown that
introns are often in similar positions, even in genes of different GPR
families, and generally occur outside the transmembrane domains (Probst
et al., 1992, Strosberg, 1991) supporting the idea that members of the
GPR family may have evolved from a common ancestor. The yeast
pheromone receptors are also seven transmembrane domain GPRs with
structural and functional, if not sequence, similarity to the rest of the GPR
superfamily (Blumer et al., 1988), implying an ancient origin for the GPR
genes.
2.6.32 Multiple subtypes for GPRs
The first GPR genes to be cloned, the (3AR and muscarinic receptors, were
intronless (Dixon et al., 1986; Hulme et al., 1990), however introns have
been described in GPR genes such as the dopamine D2, D3 and D4
subtypes (Civelli et al., 1993), the tachykinins (Gerard et al., 1990; Gerard
et al., 1991), the thyrotrophin-releasing hormone receptor (Duthie et
al.,1993b), the opsins (Nathan & Hogness, 1984, Nathans et al., 1986), the
prostaglandin PGE2 EP3 receptor (Namba et al., 1993) and the pituitary
adenylyl cyclase-activating polypeptide (PACAP) type I receptor (Spengler
et al., 1993).
In addition to multiple receptor subtypes for a particular ligand,
GPR genes containing introns are capable of even greater structural and
functional diversity by a process known as alternative splicing. The first
example of an alternatively spliced GPR was the dopamine D2 receptor
which has a 29 amino acid insert within the third cytoplasmic loop (see
Chpt. 7 for further discussion). Another instance of a functional role for
alternative splicing has been clearly demonstrated for the PACAP
receptor (Spengler et al., 1993). Five splice variants of this receptor have
been identified with insertions at the COOH-terminal end ofCL3, a region
implicated in G-protein coupling. These inserts are created by the
presence, or absence, of one or two, 84 nucleotide casettes termed 'hip' and
'hop'. Expression studies showed that these splice variants have
individual patterns of adenylate cyclase and phospholipase C stimulation.
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Alternative splicing of the prostaglandin PGE2 EP3 receptor
produces different COOH-terminal tails resulting in differential G-protein
coupling (Namba et al., 1993) and it is possible that the various forms of
the TRH-R (Straub et al., 1990, Zhao et ah, 1992, de la Pena et ah,
1992a,b; Sellar et ah, 1993; Duthie et ah, 1993a,b; Matre et ah, 1993,
Yamda et ah, 1993) may be able to couple to different G-proteins or be
differentially regulated due to the variation in the length of their COOH
tails. The genomic structure of the TRH-R will be discussed in more detail
in Chpt. 6.
2.7 Summary
The molecular cloning of increasing numbers of GPR cDNAs and their
genes has greatly accelerated the analysis of GPR ligand-binding, G-
protein-coupling and regulatory mechanisms. Site-directed mutagenesis
and the use of chimaeric receptors have helped to determine domains
involved in specific functional events, including ligand binding, G-protein-
coupling and receptor phosphorylation. Three-dimensional modelling
techniques have aided the study of receptor-ligand binding domains,
whilst the expression of mutant receptors in mammalian cell lines has
furthered the study of receptor activation of intracellular signal
transduction systems.
3 General Materials and Methods
The techniques described in this chapter are general methods used for the
isolation and characterisation of cloned DNA sequences from commercially
prepared libraries. Specific information is given in the relevant chapters.
A detailed list of buffers is included in Appendix I and a list of chemical
and equipment suppliers in Appendix II.
3.1 Introduction
To determine the sequence of a DNA molecule, it must first be cloned in
order to make millions of copies of one molecule. DNA from the required
source (genomic DNA or complementary DNA (cDNA), a stretch of DNA
which faithfully copies a stretch of RNA) is ligated into an appropriate
vector, such as a plasmid or bacteriophage. The vector and DNA is known
as recombinant since the foreign DNA is cut with enzymes called
restriction endonucleases, and recombined into a compatible site in the
vector. A single molecule of recombinant DNA is then introduced into a
host bacterium. Plasmids are transformed into bacteria by mechanically
permeabilising the host cell walls, while bacteriophage have the ability to
infect their hosts. An E.coli bacterium will divide approximately every
twenty minutes, and as each bacterium may contain several hundred
copies of the recombinant molecule, millions of identical recombinant
molecules can be produced in a short time.
Over the last twenty years, progressively simpler, but more
powerful, techniques for cloning genes have been developed. Improved
host bacterial strains and vectors have been produced, together with a
greater understanding of mammalian cell culture, synthetic
oligonucleotide synthesis and enzymes that operate on DNA and RNA.
The recent development of the polymerase chain reaction (PCR) in the
mid-1980's (Saiki et al., 1985, Mullis et al., 1986, Mullis and Faloona,
1987) with its ability to detect very rare DNA sequences and amplify them
without resorting to cloning, has brought about a technical revolution in
molecular biology.
Once the desired gene has been cloned, determination of its
nucleotide sequence enables the primary structure of the resultant protein
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or polypeptide to be elucidated. The amino acid sequence can then be
used to predict the conformational structure and the functional domains of
the molecule. For a G-protein-coupled receptor, embedded in the cell
membrane, the distribution of the hydrophobic and hydrophilic residues
allows its arrangement in the lipid bilayer to be predicted (Kyte &
Doolittle, 1982).
3.2 Library Screening - general principles
Homology screening of both genomic and cDNA libraries was performed
using similar methods based on those described by Benton & Davis, 1977.
3.2.1 Preparation of host plating cells
A master plate was prepared by streaking 5pl of the appropriate E.coli
host strain (in 50% glycerol, Clontech) on to a magnesium-free LB agar
plate containing the required media additives, and incubating overnight
at 37°C. A single, isolated colony was streaked on to a second LB agar
plate and incubated overnight. A 10ml overnight culture was set up by
innoculating 10ml of LB broth with 0.2% w/v maltose, lOmM MgSCU
(Appendix I) with a single colony of E.coli and incubating with shaking
overnight at 37°C. A control culture excluding E.coli was also set up to
ensure that growth was due to the host bacteria and not contamination.
Cells were spun down for lOmin. at 2000rpm, the media decanted off, and
the cell pellet carefully resuspended in 4ml of lOmM MgS04..
3.2.2 Screening Procedure
A total of 6xl05 plaques were screened for each library on two 23cm2
culture plates (Nunc). Host plating cells (400pil) were inoculated with
3xl05 pfu of the phage library, for each primary plate, and incubated at
37°C for 20min. to allow the phage to adsorb to the host cells. Molten LB
top agar (50ml) was added to the inoculant, mixed well and spread evenly
on to a 23cm2 culture plate containing LB bottom agar. The plates were
incubated at 37°C overnight until plaques were visible.
The culture plates were refrigerated for an hour at 4°C to prevent
the top agar from sticking to the nylon filters. Replica plaque lifts, with
Biodyne A nylon filters (Pall, UK) were performed according to the
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manufacturer's instructions. Each plate was overlaid with a nylon filter
cut to size and the plaques allowed to adsorb to the filter for lmin. The
filter was orientated using needle marks pricked through the filter on to
the agar. It was then carefully removed and placed, plaque side up, on
Whatman 3MM filter paper, saturated with high salt denaturing solution
(Appendix I), for 5min., and on filter paper saturated with neutralising
solution (Appendix I), for 5min. and left to air-dry on dry Whatman filter
paper. A second filter was laid on to the culture plate for 3min.,
orientated with the same needle marks and treated in the same way as
the first filter. A diagram of the method is shown in Fig. 3.1. The DNA
was fixed to the filter by baking at 80°C for 30min. and/or cross-linking
using the optimal cross-link setting on a Spectrolinker XL-1000 u/v
crosslinker. Before cross-linking, the filters were wrapped in cling-film to
protect the surface of the membrane. The primary culture plates were
stored at 4°C for use after screening.
3.2.3 Prehybridisation
There are many methods available to hybridise radioactive probes to
nucleic acids immobilised on solid supports such as nylon filters. The
method used here was based on guidelines set by Sambrook et al. (1989).
The dried, cross-linked filters were incubated in a small volume (just
enough to cover the filter) of 15% formamide cDNA hybridisation buffer
(see Appendix I) in a heat-sealed plastic bag at 65°C for a minimum of 2
hours.
3.2.4 Hybridisation
A radio-labelled, double-stranded rat cDNA probe (prepared as described
in section 3.5) was denatured by boiling for lOmin. and then placed
immediately on ice. Following prehybridisation, the hybridisation buffer
was decanted and replaced with buffer containing approximately lxlO6
counts/ml of the denatured probe. The filters were incubated overnight at
65°C in heat-sealed bags.
3.2.5 Washes
After hybridisation, the probe-containing buffer was carefully discarded
and the filters washed firstly at low stringency (3XSSC, 0.1% w/v SDS) at
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pick phage plaque and isolate phage DNR
Fig. 3.1
Library screening. Several thousand phage plaques are overlaid with duplicate nylon
membranes. Phage adhere to the membranes creating a precise replica of the plaque
pattern. Membranes are incubated with a radio-labelled probe which binds to
complementary sequences in the phage plaques. Membranes are washed to reduce non¬
specific binding. Positive clones appear as dark spots when membranes are exposed to x-
ray film. Film is aligned with the master plate and positive plaques isolated.
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room temperature for a total of 30min., changing wash buffer frequently
and monitoring the level of radioactivity. The filters were then washed at
higher stringency (1XSSC, 0.1% w/v SDS) at 65°C for 1 to 5min.
Once the background radiation had been reduced to between 5
and 10 counts per second, the filters were blotted quickly on Whatman
3MM paper, and making sure they were still damp, placed in heat-sealed
plastic bags as filters cannot be reprobed once they have dried.
3.2.6 Autoradiography
The plastic-enclosed filters were placed in cassettes with two intensifying
screens, overlaid with two X-OMAT™ AR scientific imaging films (Kodak)
and exposed overnight at -70°C. The top film was developed with LX 24
X-ray developer (Kodak), fixed with FX-40 X-ray liquid fixer (Kodak)
according to manufacturer's instructions and left to dry. If positive
signals were visible, the second film was also developed, if not, it was left
for a longer exposure time at -70°C.
3.2.7 Secondary screening
Films from replica filters were aligned using the needle orientation marks.
Putative clones were identified as dark spots appearing in the same
position on both films. Film was matched to the primary culture plate and
positive areas marked. A square of agar was removed from the
appropriate area and placed in 3ml SM buffer (Appendix I) at 4°C
overnight to allow the phage to diffuse out of the agar into the buffer.
The phage-containing SM buffer was diluted, and titered on
150mm LB agar plates so that each plate contained approximately 500
plaques. Following overnight incubation, replica lifts, hybridisation and
autoradiography was performed for each secondary plate as described
previously. Individual positive plaques were identified and placed in
500pl of SM buffer with a drop of chloroform, at 4°C overnight.
3.3 Isolation and purification of bacteriophage DNA
3.3.1 Plate lysate preparation (small scale)
Approximately 105 pfu (1/20 of a resuspended plaque) was mixed with
0.1ml plating cells and incubated at 37°C. After 20min., 15ml molten LB
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top agar was added, and the inoculum poured on to 150mm LB bottom
agar plates. Plates were incubated overnight at 37°C. SM buffer (8ml)
was added and the plates stored at 4°C for several hours with intermittent
shaking. The SM buffer was harvested with a pasteur pipette and placed
in a 50ml polypropylene tube (Falcon). Fresh SM buffer (2ml) was added
to the plate, which was stored in a tilted position for 15min. The
remaining SM buffer was harvested, combined with the first harvest and
the plate discarded. To lyse any remaining intact plating cells, chloroform
was added to 5% total volume to the pooled SM buffer, vortexed and
centrifuged at 4000rpm for lOmin. at 4°C. The supernatant was
recovered, a drop of chloroform added, and stored as a stock lysate at 4°C.
3.3.2 Phage stock preparation
TM buffer (5ml) and DNAse 1 (150U) was added to 5ml of the stock lysate,
mixed by gentle inversion and incubated for 15min. at room temperature
to digest any bacterial DNA. To promote dissociation of bacteriophage
particles from host cell debris, the lysate was incubated on ice with 1ml of
5M NaCl and l.lg of PEG 6000 (ensuring that the PEG was completely
dissolved) for 15min. The bacteriophage suspension was centrifuged at
8000rpm (in a Beckman centrifuge, Model J2-21, fixed angle rotor JA-
20.1) for 15min at 4°C. The supernatant was poured off, the precipitated
bacteriophage pellet resuspended in 150p.l ofTM buffer and transferred to
an eppendorf tube. The PEG and cell debris was extracted from the
bacteriophage suspension by vortexing with 150pl chloroform. After
centrifuging for 5min. the upper aqueous layer was removed to a new tube
and the chloroform extraction repeated.
NaCl was added to a final concentration of 0.5M together with
25mM EDTA, pH 8.0 and 175pl of stock-solution phenol (Appendix I) to
remove the protein coat from the bacteriophage. This was vortexed and
centrifuged for 5min. The upper aqueous layer was removed to a new
tube and 175pl of chloroform added. After vortexing well, and
centrifuging for 5min. the upper phase was again removed to a new tube.
To precipitate the DNA, 0.1 volume sodium acetate, pH 5.2 and 2.5
volumes of absolute ethanol was added, mixed by gentle inversion and the
tube placed on wet ice for lOmin. The DNA was centrifuged at 4°C for
lOmin. at 14000rpm. The supernatant was carefully decanted off the
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DNA pellet, and discarded. The pellet was washed with 75pl of 70%
ethanol and centrifuged again at 4°C for lOmin. The supernatant was
discarded, the pellet dried under vacuum and resuspended in an
appropriate volume (50pl) of TE buffer. The DNA was stored at -20°C
prior to restriction digestion or polymerase chain reaction analysis (PCR).
3.3.3 Large scale liquid lysate preparation
This method was based on a procedure described by Malik et al. (1990)
utilising double nuclease digestion and PEG precipitation.
Host plating cells (10ml, prepared as described previously) were
inoculated with approximately 5xl07 pfu of phage for every 1010 plating
cells and incubated at 37°C for 20min, shaking occasionally. A sterile
growth flask containing 500ml of LB broth and lOmM MgSCL was
inoculated with the infected plating cells, plugged with cotton wool and
shaken overnight at 37°C.
Once the supernatant cleared, indicating lysis of the culture, 10ml
of chloroform was added and the culture shaken for an additional lOmin.
at 37°C. The culture was cooled to room temperature, DNAse I and
RNAse A each added to a final concentration of lpg/ml and left to stand
for 30min. These enzymes digested nucleic acids liberated from the lysed
bacteria, which would otherwise trap phage particles.
NaCl (1M final concentration) was added to promote dissociation
of phage from bacterial debris and for efficient precipitation of phage
particles from PEG. The culture was left to stand for 1 hour at 4°C.
Bacterial debris was removed by centrifugation at 8000rpm for lOmin. at
4°C (in a Beckman JA-10 fixed angle rotor) in 250ml polypropylene
bottles.
Final concentrations of 10% (w/v) PEG 8000 and lOmM MgS04
were added to the aqueous supernatant. The PEG was dissolved slowly at
room temperature and then left to precipitate for 1 hour at 4°C. Phage
was collected by centrifugation at 8000rpm for 20min., at 4°C, the
supernatant discarded, and the pellet drained carefully of excess liquid.
The pellet was resuspended in 7.5ml TM buffer for each 250ml bottle and
transferred to a 50ml polypropylene tube (Falcon).
The PEG was extracted from the phage suspension by adding
equal volumes of chloroform, vortexing well and centrifuging for 15min. at
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3100rpm, 4°C in a swing out rotor (Omnispin R centrifuge, Sorvall
Instruments). The upper aqueous phase containing the phage particles
was collected, being careful not to disturb the PEG interface, and the
chloroform extraction repeated.
Second nuclease digestion: DNAse I and RNAse A were each added to
a final concentration of O.lmg/ml and the phage suspension incubated at
37°C for 30min. Following digestion, the phage particles were lysed to
release the DNA by incubating with 0.2% SDS and lOmg/ml proteinase K
for 1 hour at 37°C.
The phage DNA was phenol/chloroform extracted and ethanol
precipitated as described for the small scale preparation. DNA could also
be further purified from proteins, salts etc. using the Promega Magic™
DNA Clean-Up System kit according to manufacturer's instructions.
3.4 Subcloning DNA into a plasmid vector
The TA Cloning™ System (Invitrogen) utilises the single deoxyadenosines
added to the 3' ends of all PCR products by Taq polymerase, which allow a
PCR product to be inserted into a specially designed plasmid vector,
pCR™II, containing single 3' T-overhangs at the insertion site (Fig. 3.2).
A 1:1 and 1:3 molar ratio of vector to PCR insert was used in the
ligation reactions which were performed according to manufacturer's
instructions. The TA Cloning™ One Shot Cells (INVaF' cells) provided
were transformed with lgl of the ligation mix and transformants were
selected on LB agar medium containing 50|ig/ml ampicillin (Amp) and
50|il X-Gal (20(ig/ml).
Insertion of the PCR product into the vector disrupts the Ecoli
lacZ gene resulting in the appearance of white colonies. Blue colonies are
the result of self-ligation of the vector and normal functioning of the lacZ
gene which produces the enzyme (3-galactosidase in the presence of an
inducer such as the chromogenic substrate X-Gal (Sambrook et al, 1989).
Positive white colonies were picked and restreaked onto LB agar
plates containing Amp and X-Gal, incubated overnight at 37°C and stored
at 4°C as stock plates. The colonies were also subjected to plasmid lysis
PCR as described in the next section.
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M13 Reverse Primer Sp6 Promoter
CAG GAA ACA GCT ATG AC C ATG ATT ACG CCA AGC T AT TTA GGT GAC ACT ATA
GTC CTT TGT CGA TAC TG G TAC TAA TGC GGT TCG A TA AAT CCA CTG TGA TAT
Nsil Hindlll Kpnl Sacl BamH I Spel
TAC TCA AGC TAT GCA TCA AGC TTG GTA CCG AGC TCG GAT CCA CTA GTA ACG GCC
ATG AGT TCG ATA CGT AGT TCG AAC CAT GGC TCG AGC CTA GGT GAT CAT TGC CGG
BstXI EcoRI
GCC AGT GTG CTG GAA TTC GGC TT
CGG TCA CAC GAC CTT AAG CCG
EcoRI EcoRV
A GCC GAA TTC TGC AGA TAT
TT CGG CTT AAG ACG TCT ATA
Aval
PaeR7l
BstXI Notl Xhol Nsil Xbal Apal
CCA TCA CAC TGG CGG CCG CTC GAG CAT GCA TCT AGA GGG CCC AAT TCG




AGT GAG TCG TAT TA
TCA CTC AGC ATA AT
C AAT TCA
GTTA AGT
Ml3 (-20) Forward Primer
CTG GCC GTC GET TTA dAA CG
GAC CGG CAG CAA AAT G TT GC
M13(-40) Forward Primer
T CGT GAC TGG GAA AAC
A GCA CTG ACC CTT TTG
Fig. 3.2
TA cloning vector pCR™II (Invitrogen) used in subcloning polymerase chain reaction
(PCR) products amplified from genomic or cDNA clones.
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3.5 Plasmid lysis PCR
Positive colonies (see above) were picked from the agar plate with a sterile
cocktail stick. Each colony was inoculated into 50pl of plasmid lysis buffer
(Appendix I) in a 0.5ml Eppendorf tube. The lysis buffer/colony was
heated to 95°C for 5min. and spun for 30sec. to pellet cell debris. The
supernatant (5pl) was used as the template in a PCR reaction (see section
3.9). Appropriate oligonucleotide vector primers (SP6 and T7) were used
to amplify subcloned DNA. This method was used to screen large
numbers of colonies for the presence and size of the DNA insert without
having to grow up and purify large amounts of plasmid DNA for
restriction digestion analysis.
3.6 Purification of plasmid DNA
A culture of E.coli was prepared by inoculating 10ml LB broth
(supplemented with appropriate antibiotics) with a single bacterial colony,
infected with the required plasmid (section 3.4). The culture was
incubated at 37°C overnight with shaking. DNA was purified with the
Promega Magic Mini-Preps™ DNA Purification System according to
manufacturer's instructions. This method involved the resuspension,
lysis, and neutralisation of 3ml aliquots of the culture and produced
approximately lOgg of plasmid DNA starting from a 1 to 3ml culture of
E.coli. For larger amounts of DNA, a 10ml starter culture of E.coli was
prepared and used to inoculate 500ml LB broth (supplemented with
appropriate antibiotics). The Promega Magic Maxi-Prep™ kit yielded
approximately 600pg of DNA from a 500ml starting culture ofE.coli.
3.7 Analysis of purified DNA
3.7.1 Restriction enzyme digestion
In order to determine the size of isolated positive clones, the insert was
released from the lambda vector by digestion with the appropriate
restriction enzyme (see relevant chapters for details). Restriction enzymes
were generally obtained from Boehringer Mannheim or Pharmacia
(Appendix II). Restriction digests of purified DNA were carried out in IX
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restriction enzyme buffer in a total volume of 20]il and incubated for a
minimum of 1 hour at 37°C.
3.7.2 RNAse treatment
To remove contaminating RNA, the purified, digested DNA was treated
with DNAse-free RNAse A at a final concentration of lOOpg/ml and
incubated at 37°C for 30min. The digested DNA fragments were then
separated on an agarose gel.
3.7.3 Agarose gel electrophoresis
An agarose gel of the appropriate percentage was chosen according to the
expected size of DNA fragments to be separated (Table 3.1). For example
a 0.7% w/v agarose gel (SeaKem) in 1XTBE, containing 0.3pg/ml EtBr was
run at a constant voltage of 50V for several hours in 1XTBE














Range of separation in gels containing different amounts of agarose (Sambrook et al.,
1989).
Electrophoresis loading buffer was added to 10pl of each sample in order
to estimate the position of the DNA in the gel. DNA markers (lambda -
Hind III/Eco Rl, and pGEM® - Promega) were also included to ascertain
the size of digested DNA fragments. Following electrophoresis the
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separated DNA fragments were viewed under ultraviolet light using a u/v
transilluminator (Vilber Lourmat).
3.7.4 Southern blotting (alkali blotting procedure)
Apparatus was set up as depicted in Fig. 3.3. Two pieces of Whatman
3MM filter paper were cut and soaked in alkali transfer buffer (0.4M
NaOH). Each wick was laid over the glass plate and bubbles rolled out
with a glass rod. The gel was placed on top of the wicks and bubbles
rolled out as before. (Gels containing DNA fragments of greater than
lOkb were first placed in 1M HC1 until the loading buffer dyes turned
yellow, left for an additional lOmin., and rinsed in distilled water). Cut
autoradiograph film was inserted between the gel and the wicks to ensure
that the buffer soaked up through the gel. Hybond N+ nylon membrane
(Amersham), cut to size, was placed on top of the gel and bubbles removed.
Four pieces of Whatman 3MM paper were placed on top of the Hybond
membrane, the first sheet having been soaked in transfer buffer. Paper
towels were laid on top of the Whatman paper and a heavy weight placed
on top. The blot was left overnight to ensure good transfer of DNA to the
membrane.
After blotting, the apparatus was dismantled and the positions of
the wells on the membrane marked with a needle. The membrane was
peeled away and the top left hand corner cut for orientation. Finally the
membrane was washed in 2XSSC for 15min. to remove the alkaline buffer
before hybridising with a radio-labelled cDNA or oligonucleotide probe.
3.8 Preparation of radio-labelled probes
3.8.1 Isolation of cDNA insert from plasmid vector
Approximately l(ig of plasmid DNA was digested with an appropriate
restriction enzyme in order to release the cDNA insert. Following RNAse
A treatment, the cDNA was separated from the plasmid on a 0.8% low
melting point (LMP) agarose gel. The gel was poured into a mini-
submarine gel tray at 4°C and allowed to set for 30min. The gel was run
in 1XTBE buffer at 4°C and a low voltage (30-50V) to prevent the LMP gel
melting and to ensure good resolution of DNA fragments. The gel was















Capillary transfer of DNA from agarose gel to solid nylon membrane. Transfer buffer is
drawn from the reservoir through the gel, via the wick, and into a stack of paper towels.
The DNA is eluted from the gel by the moving stream ofbuffer and is deposited on to the
nylon membrane. The weight applied to the top of the paper towels ensures a tight
connection between the layers ofmaterial used in the transfer system.
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viewed under u/v light to visualise the insert which was cut out of the gel
with a scalpel and placed in a 1.5ml eppendorf tube.
3.8.2 Purification of cDNA insert
The DNA was isolated from the gel slice using Bio-Rad's 'Prep-a-Gene
DNA purification matrix' according to manufacturer's instructions.
3.8.3 Random-primer labelling of double-stranded cDNA probes
The cDNA insert was labelled with alpha 32P dCTP (Amersham) by the
random primer method based on the method developed by Feinberg and
Vogelstein, (1983, 1984), using the Random Primed DNA Labelling Kit
(Boehringer) according to manufacturer's instructions. Generally, 50ng of
DNA was boiled to denature the double-stranded probe and placed on ice
to prevent re-annealing. Label mix containing ljil each of dGTP, dATP
and dTTP dinucleotides and 2|il of reaction mix was prepared and added
to the denatured probe, together with 50pCi of radio-isotope and 2jll1 of
Klenow enzyme to a total volume of 20jil. The probe was incubated at
37°C for an hour and then briefly centrifuged to collect reagents at the
bottom of the tube. A NucTrap™ Push Column (Stratagene) was used to
separate the probe from unincorporated nucleotides. The specific activity
of the labelled probe was measured using in a 1209 Rackbeta liquid
scintillation counter (LKB Wallac).
Before adding the probe to hybridisation buffer, it was denatured
by boiling for 10 min. and placed on ice. Approximately lxlO6 counts/ml of
labelled cDNA was used in each hybridisation.
3.8.4 Oligonucleotide Synthesis
Synthetic oligonucleotides (generally 18 to 24mers) were synthesised on
an Applied Biosystems PCR Mate Synthesiser, removed from the columns
with 1ml of ice-cold ammonia and deprotected overnight at 55°C. The
deprotected oligonucleotides were stored at -20°C and purified by ethanol
precipitation as required. The concentration of a 1/100 dilution of a
purified oligonucleotide was determined by measuring the optical density
(OD) of the sample at 260nm in a Kontron Analytical spectrophotometer.
An OD260 of 1.0 = 20(i.g/ml DNA. Purified oligonuclotides were aliquoted
and stored at -20°C.
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3.8.5 End-labelling of oligonucleotide probes
Fresh gamma 32P-dATP (Amersham) of high specific activity (10|iCi/|il)
gave the best results when labelling oligonucleotides. Synthetic
oligonucleotides are synthesised without a phosphate group at their 5'
termini, and can therefore be easily labelled by transfer of the gamma 32P
from [gamma 32P]ATP using the enzyme bacteriophage T4 polynucleotide
kinase. The reaction was performed with T4 polynucleotide kinase and IX
kinase buffer in a total volume of 20|il, and incubated at 37°C for 30min.
The reaction was terminated by adding lpl of 0.25M EDTA (pH 8.0).
Unincorporated radionucleotides were removed by passing the labelling
reaction through a NucTrap™ column according to the manufacturer's
instructions. The specific activity of the probe was measured as for cDNA
probes. Approximately 5xl05 counts/ml of labelled oligonucleotide were
used in each hybridisation.
3.9 Polymerase chain reaction
Specific regions from clones of interest were amplified using PCR. PCR
allows amplification of DNA segments in vitro by a succession of
incubation steps at different temperatures (Saiki et ah, 1985, Mullis et al.,
1986, Mullis and Faloona, 1987).
The double stranded DNA is initially denatured (94°C, 3 to 5min.,
1 cycle), the DNA is then melted (94°C, 30s.) and two oligonucleotide
primers complementary to the 5' and 3' boundaries of the target sequence
are annealed at low temperature (Tm -5°C, lmin.) and then extended at
an intermediate temperature (72°C, lmin.). These 3 steps are repeated
for 30 cycles with a final extension at 72°C for lOmin. Programs were
designed according to guidelines laid out in 'PCR Protocols' (Innis et al.,
1990) and Perkin Elmer Cetus (GeneAmp® PCR Reagent Kit). This
process can generally amplify DNA sequences by at least 105 fold.
PCR was performed using Taq polymerase (Promega), sense and
antisense synthetic oligonucleotide primers synthesized as described in
Section 3.8.4 and a programmable heating block (Perkin Elmer Cetus
DNA Thermal Cycler).
Reactions were carried out in a total volume of 100pl, which
included the following: 200pM of each of the deoxynucleoside
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triphosphates dATP, dCTP, dTTP, dGTP, IX reaction buffer (lOmM
Tris-HCl pH8.3, 50mM KC1, 1.5mM MgCl2, 0.001% (w/v) gelatin), lpM
each of the sense and antisense PCR primers, 2.5U Taq polymerase, lng
DNA template and sterile water. The reactions were overlaid with lOOpl
of mineral oil to reduce evaporation. PCR amplification products were
visualised under u/v following electrophoresis on 1% (w/v) agarose gels.
3.9.1 Purification of PCR products
PCR amplification products were purified through CHROMA SPIN™
columns (Clontech) according to manufacturer's instructions.
3.10 DNA Sequencing
3.10.1 Manual sequencing - preparation of labelling reactions
Sequencing of genomic DNA, cDNA and PCR fragments was performed
according to the dideoxynucleotide chain termination method of Sanger et
al. (1977) using the commercially available Sequenase® sequencing kit
(U.S.B.). The annealing mix included ~500ng of DNA, 2pl 5X reaction
buffer and ~1220ng of oligonucleotide primer. This was boiled for 2min.
and placed on ice. Each of the 4 dideoxynucleotides (2.5pl each of ddATP,
ddCTP, ddGTP, ddTTP) were prewarmed to 37°C. The labelling mix (l|il)
was diluted with 13.5jil of water, and ljil of the Sequenase™ enzyme was
diluted in 7pi of ice-cold enzyme dilution buffer. (10% (v/v) DMSO was
added to each of the ddNTPs and to the labelling mix for sequencing of
purified PCR fragments).
The labelling reaction was carried out by adding lpl DTT (0.1M),
2pl diluted labelling mix, 0.5pl 35S dATP (Amersham) and 1.5pl diluted
Sequenase™ enzyme to the reaction mix followed by 5min. incubation at
room temperature. Reactions were terminated by adding 3.2pl of the
sequencing reaction to each of the prewarmed ddNTPs, 4pl of formamide
stop dye and incubating at 37°C for 5min. Terminated reaction products
were stored on ice.
3.10.2 Manual sequencing - preparation of sequencing gel
Sequencing reaction products were run on Bio-Rad Sequi-Gen™
Sequencing Gel Apparatus. The gel base (27.8g urea, 12ml 30% (w/v)
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Acrylamide [19:1] Bisacrylamide Solution (NBL), 15ml 10XTBE, 6ml
water) was heated in a microwave to melt the urea, and 150|il of
ammonium persulphate (Bio-Rad - O.lg in 400|il water) and 150|il TEMED
(Bio-Rad) added. The gel base was poured immediately into the casting
tray to seal the bottom of the gel apparatus. The sequencing gel was made
up of top mix (27.6g urea, 12ml acrylamide, 6ml 10XTBE, 20ml water) and
bottom mix (9.2g urea, 4ml acrylamide, 5ml 10XTBE, 2ml water), with
60pl each of TEMED and ammonium persulphate added to top mix and
20gl each to bottom mix, once the urea had been melted. A 25ml pipette
was used to draw up 7.5ml top mix followed by 6.5ml bottom mix to form
the base of the gel. The rest of the top mix was poured down the middle of
the gel apparatus and left to polymerise with the gel comb placed upside
down. Once polymerised, the comb was removed and the top of the gel
washed with 1XTBE.
Gels were run using a Bio-Rad Computer Controlled
Electrophoresis Power Supply (Model 3000Xi), in 1XTBE buffer at 1800
volts for 30min. to prewarm. The comb was inserted with the teeth just
entering the gel and the wells washed again with 1XTBE. Samples were
preheated at 70°C for 2min., loaded and run for 2 to 3 hours at 1800 volts,
or overnight at 600 volts. The gel was transferred to Whatman 3MM filter
paper, covered with cling-film and dried under vacuum at 80°C for 2 hours
on a Savant SGD4050 gel drier (Stratech Scientific). The cling film was
removed from the dried gel which was exposed to X-OMAT™ AR Kodak
diagnostic film (20cmx25m roll) overnight. The film was developed as
described in section 3.2.6.
3.10.3 Automated sequencing
Automated sequencing was performed using an Applied Biosystems 373A
DNA sequencer according to the manufacturer's instructions. The Taq
DyeDeoxy™ Terminator Cycle Sequencing Kit uses four ABI dye-labelled
dideoxynucleotides: G, A, T and C DyeDeoxy™ Terminators which allow
the incorporation of a dye-label, or fluorochrome, into the DNA together
with the terminating base. Thermal cycling of the sequencing reactions in
a Perkin Elmer Cetus Thermal Cycler increases signal intensity and thus
decreases sensitivity to reaction conditions. All four reactions are
performed in one tube as different dyes are used which emit light at
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different wavelengths when excited by a laser. The emission peaks
overlap and have to be resolved by computer analysis.
3.10.4 Sequence Analysis
Sequence analysis was performed using the computer program,
GeneJockey, produced by P. L. Taylor, distributed by Biosoft and run on
Apple Macintosh computers.




Thyrotrophin-releasing hormone (TRH), a hypothalamic tripeptide
releasing factor, is involved in stimulating the release of thyrotrophin
(TSH) from thyrotrophs and prolactin from lactotrophs in the anterior
pituitary (Jacobs et ah, 1971; Vale et al., 1977; le Dafniet et al., 1983;
Gershengorn, 1985). TRH also has several effects in the central nervous
system (CNS) including reversal of the narcosis induced by some CNS
depressants, the modification of neuronal firing rate and the stimulation
of locomotor activity, for reviews see Jackson (1982), Sharif (1985) and
Scanlon & Hall (1989). The diverse functions of TRH have been discussed
in Chpt. 2.3 (see Table 2.1).
The use of TRH as a potential therapeutic agent in neuronal and
endocrine disease prompted the study of its receptor. The design of TRH
analogues specific to a particular neuronal pathway, or cell type, in the
anterior pituitary would be greatly facilitated by a knowledge of the ligand
binding site and an understanding of TRH/receptor interactions and
methods of intracellular signalling. It is also particularly important to
determine the sequences of G-protein-coupled receptors (GPRs) as
mutations in GPRs have been implicated in disease pathologies such as
the constitutive^ activating mutations mentioned in Chpt. 2.6.30. Thus it
is vital to be able to compare the sequence and structure of a receptor
implicated in a particular pathology with that of the wild-type receptor.
The cloning of the mouse TRH-R (Straub et al., 1990) and rat
TRH-R (Sellar et al., 1993) indicated species differences at the carboxy
(COOIi) tail, a domain implicated in GPR desensitisation and
downregulation (Chpt. 2.6.25-29). One of the major problems in clinical
medicine involves the desensitisation of GPRs following prolonged
exposure to certain drugs and, as a result, much attention has been
focused on this GPR domain. The aim of this project was to determine
whether the human TRH-R differed from the mouse and rat receptors at
the COOH tail and to examine the possibility of the existence ofmultiple
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TRH-R subtypes. The chromosomal localisation of the human TRH-R
gene was also undertaken to determine whether the TRH-R gene was
linked to any chromosomal abnormalities.
Early studies with the TRH-R in the brain and pituitary indicated
similar ligand binding and biochemical properties (Burt & Taylor, 1980).
However, the development of synthetic TRH analogues, specific for the
behavioural CNS effects of TRH, but lacking TSH-releasing activity
(Szirtes et al., 1984), suggested differences in TRH-Rs from these tissues.
Johnson et al., (1989) then undertook a comparison of the molecular
properties of TRH-Rs in brain and pituitary. Some variation in charge
characteristics between solubilised brain and pituitary receptors was
observed, possibly reflecting amino acid differences, or variation in post-
translational modifications, such as glycosylation or phosphorylation.
They also presented evidence that TRH-Rs in the amygdala, septum and
hippocampus mediated reduction in narcosis, whereas those in the
nucleus accumbens enhanced dopamine release and locomotor activity.
Taken collectively, these studies suggested that different TRH-R subtypes
might exist.
The transmembrane signalling systems activated by TRH have
been intensively studied in the pituitary. TRH has been shown to act via
the inositol phospholipid-calcium-protein kinase C pathway (Gershengorn,
1985, 1986) by coupling to a G-protein that activates the second
messenger, phospholipase C (see Chpt. 2.6.7-9). Thus the TRH-R was
thought to belong to the superfamily of seven transmembrane, GPRs (see
Chpt. 2.6). Some controversy exists over the potential involvement of
cAMP in TRH signal transduction and, in general, evidence has suggested
that cAMP plays a secondary role in transducing the effects of TRH
(Denef, 1988). Recently, however, it has been reported that TRH-Rs can
couple to both adenylate cyclase (Paulssen et al., 1992) via Gs and
phospholipase C via Gq/Gn (Hsieh & Martin, 1992) in pituitary GH3 cells,
providing further hints that multiple TRH-R subtypes might exist.
Although the pharmacology of TRH binding sites and the
biochemistry of its signalling systems has been studied, little was known
about the molecular nature of the receptor. Purification of the receptor
and the cloning of the TRH-R gene(s) was needed to further the
understanding of these processes. The receptor had not been purified, but
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rapid advances in recombinant DNA technology since the mid-1980s have
resulted in the isolation of cDNAs encoding TRH-Rs from several species.
The first TRH-R to be cloned was a mouse pituitary TRH-R cDNA
isolated from thyrotrophic TtT tumour cells using the Xenopus oocyte
expression system (Straub et ah, 1990). Structural characterisation
indicated a single polypeptide of 393 amino acids with the predicted
similarity to other members of the GPR superfamily (Probst et al., 1992
for review). Following the identification of the mouse TRH-R, several rat
TRH-R subtypes were rapidly cloned and characterised. One rat subtype
was identified both from a mammotroph-derived GH^C] cell line (Zhao et
ah, 1992) and from a mammotroph/somatotroph GH3 tumour cell line (de
la Pena et ah, 1992a). The rat TRH-R had high sequence homology to the
mouse receptor, but encoded 412 amino acids (TRH-R412) due to an extra
19 amino acids at the 3' end of the carboxy (COOH) tail. Other forms of
the rat TRH-R were then identified, including a receptor of 387 residues,
TRH-R337 (de la Peha et ah, 1992b) and one of 411 residues, TRH-R411
(Sellar et ah, 1993). The amino acid variation in both of these subtypes
occurred at the COOH terminus. TRH-R387 had a 52bp deletion, due to
the presence of a retained intron (Breitbart et ah, 1987) in the coding
sequence of the receptor. Splicing of this 'intron1 resulted in a frame-shift
that produced 12 variant COOH amino acids. The TRH-R41 \ subtype had
a deletion of 3 nucleotides, resulting in the loss of a single amino acid at
position 393.
This chapter reports the isolation of a functional human pituitary
TRH-R (Duthie et ah, 1993a) displaying high sequence homology with the
mouse and rat TRH-R sequences, but with amino acid variation at the
COOH tail, and discusses the potential significance of this finding in
relation to other TRH-R subtypes isolated.
4.2 Materials and methods
This section provides only a brief outline of the methods used to isolate
and sequence the human TRH-R. A detailed description of the procedure
involved in isolating genes from commercially prepared DNA libraries has
been described in Chapter 3. Specific information relevant to the
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subcloning, functional analysis and chromosomal localisation studies of
the human TRH-R cDNA is included here.
4.2.1 Screening a human XgtlO cDNA library
C600 hfl (high frequency of lysogeny) Ecoli host plating cells (Clontech)
were innoculated with approximately lxlO6 pfu of a ?igtlO human
pituitary 5' stretch cDNA library (Clontech). The library was probed with
a 2.5kb rat TRH-R cDNA fragment (Sellar et al., 1993) labelled with 32P
by random primer labelling as described in Chpt. 3.
Positive plaques were isolated following a secondary screening,
and the bacteriophage DNA was purified (Chpt. 3.3) and digested with
EcoRl to release the insert (Chpt. 3.7). The size of the insert was also
determined by PCR analysis (Chpt. 3.9) using commercially available
vector primers (Clontech) designed to amplify the A-gtlO insert.
EcoRl digests of putative clones were Southern blotted (Chpt.
3.7.4) following separation of the restriction fragments by electrophoresis
on agarose gels. The blots were again probed with the 32P-labelled 2.5kb
rat TRH-R cDNA, to confirm that the isolated plaques hybridised
positively to the TRH-R sequence.
4.2.2 Sequencing of positive clones
Sequencing of the purified bacteriophage DNA was carried out several
times in both orientations using the automated ABI DNA sequencer
(Chpt. 3.10). Initial sequencing primers used were the 5' and 3' vector
primers T7 and SP6. Subsequently, oligonucleotides were designed to
internal sequence and used as sequencing primers. Sequence analysis
was performed using the program GeneJockey on Apple Macintosh
computers.
4.2.3 Subcloning the human TRH-R cDNA into pCR™II
The human TRH-R XgtlO clone had an EcoRl site in the 5'UTR, so the
2.3kb insert could not be released as a single fragment from the vector's
EcoRl cloning site. It was decided therefore, to subclone a PCR-amplified
fragment of the receptor into a plasmid vector which could be more easily
manipulated than a X vector. The coding region of the TRH-R from -18bp
to 1238bp was first amplified by PCR using the following oligonucleotide
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primers (sense primer 5'Ti [nucleotides -18 to +4]
5'dAGCTTCAATCCACTGAAGATGG3' and antisense primer 3'Tp
[nucleotides 1217 to 1238] 5'dTTCTCAATTTCTTTGTCATCC3') were
based on sequence analysis of the human TRH-R clone as described in
section 4.2.2. The 1.2kb PCR product was subcloned directly into the TA
cloning vector pCR™II (Invitrogen) as described in Chpt. 3.4.
Several positive colonies were picked and analysed by plasmid
lysis PCR (Chpt. 3.5) and each colony was also grown up overnight in
10ml LB broth, supplemented with Amp (50pg/ml), in a 37°C shaking
incubator. Colonies that contained the correct size of insert (1.2kb), as
detected by plasmid lysis PCR, were purified from the overnight cultures
using the Promega Magic Mini-Prep kit (Chpt. 3.6). Purified plasmid
DNA was also sequenced to confirm that the pCR™II vector did contain
the human TRH-R insert and that no mismatches had been introduced
into the subclone as a result of PCR amplification of the original A-gtlO
human clone.
4.2.4 Chromosomal localisation of the human TRH-R gene
The chromosomal localisation for the human TRH-R gene was achieved by
fluorescence in situ hybridisation (F.I.S.H.) using the human TRH-R
cDNA as a probe. Both the )igtl0 human TRH-R cDNA clone (2.3kb) and
the 1.2kb human TRH-R subclone in pCR™II were biotinylated and
hybridised to metaphase chromosome spreads obtained from normal
human males. Hybridisation was detected by incubation with avidin-
fluorescein isothiocyanate and the signal amplified twice by two further
incubations with biotinylated anti-avidin. Chromosomes were
counterstained and examined under a fluorescence microscope. This
experiment was conducted in collaboration with Professor J M Connor's
group at the Duncan Guthrie Institute of Medical Genetics in Glasgow
and a detailed description of the method is provided in Appendix III.
4.2.5 Subcloning the human TRH-R into pcDNA-1
Functional analysis of the human clone required expression of the cDNA
in a mammalian cell line. To achieve this, the human TRH-R cDNA in
pCR™II was subcloned into the EcoRl site of the mammalian expression
vector pcDNA-1 (Invitrogen) in front of the cytomegalovirus promo tor
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(CMV) see Fig. 4.1. The following protocol was derived from Sambrook et
al., (1989). The human TRH-R pCR™II subclone was digested with EcoRl
to release the 1.2kb insert. The vector and insert were separated by
electrophoresis on a 1% LMP agarose gel and the insert was purified from
the LMP gel (Chpt. 3.8.2) and concentrated to ~50ng/pl by ethanol
precipitation.
A total of 5|ig of pcDNA-1, which has both Tet and Amp resistance
genes, was also digested with EcoRl in 5 x lpg aliquots. A sample of each
digest was electrophoresed on a 1% mini-agarose gel to ensure that the
plasmid had been completely linearised. Once digestion was complete, the
samples were pooled, making up a total volume of lOOpl,
phenol/chloroform extracted, precipitated for 15min. at -20°C and
resuspended in lOmM Tris/HCl pH8.3.
Vector dephosporylation: To prevent the plasmid from self-ligating,
the 5' phosphate groups were removed by digestion with calf intestinal
alkaline phosphatase (CIAP) (Promega) for 30min. at 37°C in a total
volume of lOOpl:- 60|il linearised pcDNA-1, lpl CIAP (lU/lOOpM 5'
terminal phosphate residues), 10(il 10X CIAP buffer, 29gl water. After
dephosphorylation, the enzyme was denatured with 0.5% SDS and 5mM
EDTA and proteinase K added to a final concentration of 100|ig/ml. The
reaction mix was incubated at 56°C for 30min. and cooled to room
temperature. It was then extracted once with phenol and once with
chloroform before ethanol precipitation with 3M sodium acetate, pH7
(EDTA precipitates out of solution at acid pH) for 15min. The pellet was
washed in 70% ethanol and resuspended at a concentration of lOOpg/ml in
TE buffer
Ligation reactions: The following ligations were set up and incubated
at 16°C overnight: A - vector + insert (1:1 molar ratio); B - vector + insert
(1:3 molar ratio); C - vector only; D - insert only; E - no DNA. The ligation
reactions were performed in a total volume of 30|il with 3gl T4 DNA ligase
(3U/(il) (Clontech, Union-DNA ligation kit), 3|il 10X ligation buffer, and
3(il rATP (lOmM).
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High efficiency electro-transformation of E.coli: MC1061/P3
electrocompetent cells (Invitrogen) were transformed with the ligated
DNA using a Bio-Rad Gene Pulser set at 25pF and 2.5kV with the Pulse
Controller at 200 Ohms. Aliquots of electrocompetent cells (40|il) were
thawed carefully on ice. Between lpl and 2|il of ligation mix was added to
each 40|il cell suspension, mixed gently and incubated on ice for lmin.
before being transferred to a cold 0.2cm sterile electroporation cuvette
(Bio-Rad) and pulsed for 15 seconds. An aliquot of the MC1061/P3 cells
was also transformed with lOng of supercoiled pcDNA-1 as a positive
control. The transformed cells were immediately resuspended in 1ml SOC
medium (Appendix I) and incubated at 37°C with vigorous shaking. After
1 hour's incubation, colonies were selected by plating lOOpl of the SOC
mixture onto LB agar plates containing Tet (12.5pg/ml) and Amp
(50pg/ml) and incubated overnight at 37°C.
Colonies that grew on Amp/Tet plates were picked and subjected
to plasmid lysis PCR and were also grown up as overnight cultures in
10ml LB broth (50pg/ml Amp) and purified using the Promega Magic
Mini-Prep kit. To determine the orientation of the TRH-R insert within
the vector, an internal PCR oligonucleotide primer (5'Tx [nucleotides 829
to 849] 5'dCTTTTATGGATGCCCTACAGG3') was used in conjunction
with the vector primer SP6 to amplify a small region of the insert.
Subclones were sequenced to confirm the orientation of the TRH-R insert.
4.2.6 Transient transfection of COS-1 cells
Tissue culture work was performed in a sterile Class II hood with all
media and solutions prewarmed to 37°C in a water bath. Monolayer
cultures of COS-1 cells (5x10s cells/lOOmm dish) were plated out in 5ml of
DMEM medium (Appendix I) in 100mm dishes and allowed to attach
overnight at 37°C in a humidified atmosphere of 5% (v/v) CO2 in air.
Transient transfections were performed using lipofectin®
Reagent (Gibco-BRL). lipofectin is a formulation of cationic lipids which,
when mixed with negatively charged DNA, forms a neutral lipid-DNA
micelle complex (Feigner et al., 1987). Micelles fuse with the cell
membrane and discharge their contents into the cell.
For each transfection, human TRH-R in pcDNA-1 (3pg) and
lipofectin Reagent (50pg) were each pre-diluted in 1.5ml serum-free
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DMEM medium in sterile polystyrene jars (Greiner). Antibiotics and
serum inhibit the action of LIPOFECTIN. Diluted DNA and LIPOFECTIN
Reagent were combined, mixed gently, and incubated at room
temperature for 15min. This predilution step should prevent any
precipitate forming.
Monolayer cultures of COS-1 cells (60 to 70% confluent) were
washed (X2) with 5ml of serum-free medium. The diluted DNA/LIPOFECTIN
mix (3ml) was added to each dish and incubated for 4hrs at 37°C in a
humidified atmosphere of 5% (v/v) CO2 in air. The DNA-containing
medium was then replaced with 10ml of complete DMEM medium and the
cells left overnight to recover from the transfection procedure.
Transfected cells were assayed for the presence and activity of receptors
72hrs post transfection.
4.2.7 Inositol phosphate (IP) production assay
COS-1 cells were trypsinised 24 hours after transient transfection with
the human TRH-R pcDNA-1 subclones and transferred to 12-well plates.
Cells were labelled to isotopic equilibrium with 2uCi/ml mvo-3[H|inositol
(Amersham) in inositol-free DMEM medium (Appendix I).
This medium was removed 72hrs post-transfection and 270jil
Buffer A (Appendix I) containing LiCl (lOmM) was added to each well and
incubated at 37°C for 15min., (LiCl inhibits IP1 phosphatase, an enzyme
involved in the degradation of IPl to inositol). TRH concentration (30pl of
10~5M) was added to the wells in triplicate and the cells returned to the
incubator for 45min.
The drug-containing medium was removed and the reaction
terminated by adding 500(ll 0.5M perchloric acid (PCA) solution
containing 5mM EDTA (PCA/EDTA stop solution) to the cells, followed by
50pl phytic acid (1.8mg/ml) and incubating for lOmin. at 4°C. The
reaction mixture was transferred to numbered test tubes, and neutralised
with 0.5mM potassium hydroxide/60mM Hepes, containing Universal pH
indicator, producing a 'mid-green' colour (pH 7-7.5).
Cell extracts were centrifuged for 15min. at 3000rpm and 900pl of
the resulting supernatant was removed and added to test tubes containing
500pl Dowex resin (Analytical grade anion exchange AGKE) 1-X8 Resin,
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100-200 mesh, Bio-Rad), gently mixed with a whirlimixer, allowed to
settle and the supernatant removed by aspiration. Inositol, glyceroinositol
phosphates and total inositol phosphates (containing IP1, IP2 and IP3)
fractions were eluted from the resin by washing sequentially with 1ml
H2O, 60mM ammonium formate/5mM sodium tetraborate and 1M
ammonium formate/0.1M formic acid respectively. An aliquot (800pl) of
the total IP fraction was added to 5ml Optiphase HP (Pharmacia) liquid
scintillant and the radioactivity measured in an LKB Rackbeta liquid
scintillation counter.
4.2.8 Measurement of total cell radioactivity
Total cell radioactivity was measured to compensate for differences in cell
number between wells. Wells were washed twice with 500pl of the
PCA/EDTA stop solution and solubilised with 500pl 0.1M NaOH solution.
The resultant solution was transferred to scintillation vials and
neutralised with 260pl 0.66% acetic acid. Scintillation fluid (4ml) was
added to each vial and the radioactivity measured as described previously.
4.2.9 Receptor binding assay
Monolayer cultures of transfected COS-1 cells (section 4.2.6) were washed
twice with phosphate buffered saline (PBS) (Flow Laboratories), a further
2ml PBS added and manually harvested by scraping with a cell-scraper
(Costar). Whole cell suspensions were transferred to sterile universals
(15ml) and centrifuged at 3000rpm for lOmin. to obtain cell pellets. The
supernatant was carefully poured off, the cell pellet resuspended in 2ml of
ice-cold Assa}' Buffer (Appendix I) and allowed to stand for lOmin. on ice
to lyse the cells. Cell suspensions were then homogenised with coarse and
then fine pestles in a Teflon homogeniser. Using a pasteur pipette,
homogenates were transferred to 2ml Eppendorf tubes and centrifuged at
llOOOrpm at 4°C for 30min. The supernatant was decanted and the
prepared cell membranes stored at -70°C until use.
Ice-cold Assay Buffer was added to thawed cell membranes on ice.
An even membrane suspension was obtained by aspirating the
membranes through a 19 gauge needle. Ligand binding assays were
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carried out using the TRH agonist, 3H[3-Me-His2]TRH (Peninsula). The
radiolabel was diluted (10-3) in Assay Buffer and 50|i.l added to each tube.
Cold peptide [3-Me-His2]TRH (50gl) was added at varying concentrations
ranging from 10 10M to 10"8M, and the reactions performed in triplicate.
Finally, 400|il of the cell membranes was added to each tube resulting in a
final assay volume of 500pl. In addition, maximal binding (B0) was
measured by replacing the cold peptide with assay buffer, and non-specific
binding was then measured by adding a saturating dose (10"5M) of 3H[3-
Me-His2]TRH.
Following incubation on ice for 60min., the membranes were
filtered using a Brandel Cell Harvester (semat). Filter paper (GF/B
Whatman) was soaked in Assay Buffer containing 1% polyethylene glycol
(Sigma), a detergent that prevents the radiolabel from sticking to the
apparatus. The filters were washed three times in rapid succession, with
Assay Buffer, to separate the free ligand from ligand bound to the cell
membranes. Numbered scintillation vials were placed on a tray, a dried
filter circle placed in each vial and 4.5ml scintillation fluid added. The
vials were placed on a shaker overnight to allow the radioactivity to leach
out of the filters, before counting on a Rackbeta liquid scintillation
counter.
4.2.10 Calcium imaging
This experiment was performed in collaboration with Dr Lorraine
Anderson and a detailed description of the method used can be found in
Appendix III. COS-1 cells, transiently transfected with the human TRH-R
were loaded with the fluorescent calcium dye, fura-2 AM (4|iM).
Intracellular calcium ([Ca2+]i) was then measured in single cells
stimulated with 10"6M TRH, using dual wavelength fluorescence
microscopy combined with dynamic video-imaging.
4.3 Results
4.3.1 Human TRH-R cDNA: cloning and structural analysis
One positive clone was isolated from the ).gtl0 pituitary cDNA library.
This clone contained an insert of approximately 2.3kb. Sequencing of the
positive clone indicated the largest open reading frame (ORF) as being
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1194bp, and the ATG initiation codon was identified by comparison with
the mouse and rat TRH-R sequences. The nucleotide and deduced amino
acid sequences for the human receptor are shown in Fig. 4.2. The human
TRH-R encoded a putative GPR protein of 398 amino acids (Fig. 4.3), as
compared to 393 for the mouse TRH-R (Straub et ah, 1990), and 412 (Zhao
et al., 1992; de la Pena et ah, 1992a), 387 (de la Pena et al., 1992b) and
411 amino acids (Sellar et ah, 1993) for the rat TRH-Rs.
The deduced amino acid sequence has several possible consensus
sites for modification of the receptor protein, including sites for potential
N-linked glycosylation (Asn-X-Ser/Thr) (Kornfeld & Kornfeld, 1985) and
phosphorylation (Ser and Thr residues in varying consensus motifs,
depending on the kinase) (Kemp & Pearson, 1990, Kennelly & Krebs,
1991) as indicated in Fig. 4.2. The human clone contained approximately
lkb of 5' untranslated region (UTR), mostly unsequenced and only 130bp
of 3'UTR. There was no polyadenylation signal present.
Comparison of the human, mouse and rat TRH-R sequences
indicated very high homology between the species. The only major
sequence variation occurred at the same site in each receptor (residue 392)
at the 3' end of the COOH tail (Fig. 4.4). Following residue 392, the
human receptor had 6 variant amino acids, the mouse had 1 amino acid
and the long forms of the rat receptor had 20 (TRH-R412) and 19 (TRH-
R411) residues respectively. The short form of the rat receptor (TRH-R387)
had a 52bp deletion in this region which produced a frame-shift and
resulted in 12 variant amino acids at the COOH tail.
4.3.2 Chromosomal localisation of the TRH-R gene
Forty-one metaphases from two normal human males were scored
following hybridisation to the 2.3kb ^gtlO TRH-R probe, and the position
of 73 signals recorded. Of these, a highly significant (p<0.005) 15 signals
(20.5%) were located on chromosome 8 with 13 (17.8%) comprising a signal
peak at 8q23.
Forty-four metaphases from two normal males were scored
following hybridisation to the 1.2kb pCR™II TRH-R probe, and the
position of 186 hybridisation signals recorded as shown in Fig. 4.5. Of
these, a highly significant (p<0.005) 35 signals (18.8%) were located on
chromosome 8 with 26 (14%) comprising a signal peak at 8q23. These
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TAGCTTCAAGCCACTGAAG
Met Glu Asn Glu Thr Val Ser Glu Leu Asn Gin Thr Gin Leu Gin P ro Arg Ala Val Val Ala Leu 22
1 ATG GAA AAC GAG ACA GTC AGT GAA CTG AAC CAA ACA CAG CTT CAG CCA CGA GCA GTG GTG GCC TTA
Glu Tyr Gin Val Val Thr He Leu Leu Val Leu lie lie Cys Gly Leu Gly lie Val Gly Asn He 44
67 GAA TAC CAG GTG GTC ACC ATC TTA CTT GTA CTC ATT ATT TGT GGC CTG GGC ATT GTA GGC AAC ATC
Met Val Val Leu Val Val Met Arg Thr Lys His Met Arg Thr Pro
o
Thr Asn Cys Tyr Leu Val Ser 66
133 ATG GTA GTC CTG GTT GTC ATG AGA ACC AAG CAC ATG AGG ACC CCC ACA AAC TGC TAC CTG GTG AGC
Leu Ala Val Ala Asp Leu Met Val Leu Val Ala Ala Gly Leu Pro Asn lie Thr Asp Ser lie Tyr 88
199 CTG GCA GTA GCT GAT CTC ATG GTC TTG GTG GCC GCA GGC CTC CCC AAC ATA ACA GAC AGT ATC TAC
Gly Ser Trp Val Tyr Gly Tyr Val Gly Cys Leu Cys lie Thr Tyr Leu Gin Tyr Leu Gly lie Asn 110
265 GGT TCC TGG GTC TAT GGC TAT GTT GGA TGC CTC TGC ATT ACT TAC CTC CAG TAT TTG GGA ATT AAT
Ala Ser Ser Cys Ser lie Thr Ala Phe Thr lie Glu Arg Tyr lie Ala lie Cys His Pro lie Lys 132
331 GCA TCC TCT TGT TCA ATA ACA GCC TTT ACC ATT GAG AGG TAC ATA GCA ATC TGT CAC CCC ATC AAA
Ala Gin Phe Leu Cys Thr Phe
0
Ser Arg Ala Lys Lys lie lie lie Phe Val Trp Ala Phe Thr Ser 154
397 GCC CAG TTT CTC TGC ACA TTT TCC AGA GCC AAA AAG ATT ATC ATC TTT GTC TGG GCT TTC ACA TCT
Leu Tyr Cys Met Leu Trp Phe Phe Leu Leu Asp Leu Asn lie Ser Thr Tyr Lys Asp Ala lie Val 176
463 CTT TAC TGT ATG CTC TGG TTC TTC TTG CTG GAT CTC AAT ATT AGC ACC TAC AAA GAT GCT ATT GTG
He Ser Cys Gly Tyr Lys lie
o
Ser Arg Asn Tyr Tyr Ser Pro lie Tyr Leu Met Asp Phe Gly Val 198
529 ATA TCC TGT GGC TAC AAG ATC TCC AGG AAT TAC TAC TCA CCT ATT TAC CTA ATG GAC TTT GGT GTC
Phe Tyr Val Val Pro Met lie Leu Ala Thr Val Leu Tyr Gly Phe lie Ala Arg lie Leu Phe Leu 220
595 TTT TAT GTT GTG CCA ATG ATC CTG GCT ACC GTC CTC TAT GGA TTC ATA GCT AGA ATC CTT TTC TTA
Asn Pro lie Pro Ser Asp Pro Lys Glu Asn Ser Lys Thr Trp Lys
V
Asn Asp Ser Thr His Gin Asn 242
661 AAT CCC ATT CCT TCA GAT CCT AAA GAA AAC TCT AAG ACA TGG AAA AAT GAT TCA ACC CAT CAG AAC
Thr Asn Leu Asn Val
V
Asn Thr Ser Asn Arg Cys Phe Asn Ser Thr Val Ser
o
Ser Arg Lys Gin Val 264
727 ACA AAT CTG AAT GTA AAT ACC TCT AAT AGA TGT TTC AAC AGC ACA GTA TCT TCA AGG AAG CAG GTC
Thr Lys Met Leu Ala Val Val Val lie Leu Phe Ala Leu Leu Trp Met Pro Tyr Arg Thr Leu Val 286
793 ACC AAG ATG CTG GCA GTG GTT GTA ATT CTG TTT GCC CTT TTA TGG ATG CCC TAC AGG ACT CTA GTG
Val Val Asn Ser Phe Leu Ser Ser Pro Phe Gin Glu Asn Trp Phe Leu Leu Phe Cys Arg lie Cys 308
859 GTT GTC AAC TCA TTT CTC TCC AGT CCT TTC CAA GAA AAT TGG TTT TTG CTC TTT TGC AGA ATT TGC
lie Tyr Leu Asn Ser Ala lie Asn Pro Val lie Tyr Asn Leu Met Ser Gin Lys Phe Arg Ala Ala 330
925 ATT TAT CTC AAC AGT GCC ATC AAC CCG GTG ATT TAC AAT CTC ATG TCC CAG AAA TTC CGT GCA GCC
Phe Arg Lys Leu Cys Asn Cys Lys Gin Lys Pro
o
Thr Glu Lys Pro Ala
V
Asn Tyr Ser Val Ala Leu 352
991 TTC AGA AAG CTC TGC AAC TGC AAG CAG AAG CCA ACA GAG AAA CCT GCT AAC TAC AGT GTG GCC CTA
V
Asn Tyr Ser Val lie Lys Glu
o
Ser Asp His Phe Ser Thr Glu Leu Asp Asp lie Thr Val Thr Asp 374
1057 AAT TAC AGC GTC ATC AAG GAG TCA GAC CAT TTC AGC ACA GAG CTT GAT GAT ATC ACT GTC ACT GAC
Thr Tyr Leu Ser Ala Thr Lys Val Ser Phe Asp Asp Thr Cys Leu Ala Ser Glu Val Ser Phe Ser 396







Gin Ser Stop 398
118 9 CAA AGT TGA ATGGAAAACGAGACAGTCAGTGAACTGAACCAAACACAGCTTCAGCCACGAGCAGTGGTGGCCTTAGAATACCAG
1273 GTGGTCACCATCTTACTTGTACTCATTATTTGTGGCCTGGGCATTGTAGGCAACATC
Fig. 4.2
Nucleotide and deduced amino acid sequences of the TRH-R clone isolated from human
pituitary gland. The putative transmembrane domains I to VII are underlined and are
assigned on the basis of a Kyte and Doolittle hydrophobicity plot (1982). Potential N-
linked glycosylation sites are indicated by (A) and phosphorylation sites by (°).
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Schematic representation of the proposed seven transmembrane-spanning domains and
deduced amino acid sequence for the human TRH-R. Putative di-sulphide bridges
between cysteine residues are highlighted in yellow. The alternative COOH tail encoded
by the human TRH-R is also highlighted in yellow. Potential N-linked glycosylation sites
are indicated by (A ) and phosphorylation sites by (°).
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10 20 30 40 50 60
Human ( 398 ) MENETVSELNQTQLQPRAVVALEYQVVTILLVLIICGLGIVGNIMVVLVVMRTKHMRTPTNCYLVSLAV
Mouse (393) D M E Q-A V
Rat (412) P--V W A
Rat (411) P--V W A
Rat (387) P--V W A
III
70 80 90 100 110 120 130






140 150 160 170 180 190 200
Human (398) FSRAKK11IFVWAFTSLYCMLWFFLLPLNISTYKPAIVISCGYKISRNYYSPIYLMPFGVFYWPMILA
Mouse (393) I N-V-V -
Rat (412) 1 M
Rat (411) 1 M
Rat (387) 1 M
VI
210 220 230 240 250 260 270
Human (398) TVLYGFIARILFLNPIPSPPKENSKTWKNPSTHQNTNLNVNTSNRCFNSTVSSRKQVTKMLAVWILFA









Rat (411) ' A
Rat (387) A
350 360 370 380 390 400 410
Human (398) ANYSVALNYSVIKESPHFSTELPPITVTPTYLSATKVSFPPTCLASEVSFSQS•
Mouse (393) R E V-T N#
Rat ( 412 ) -R V-T KNGPSSCTYGYSLTAKQEK X*
Rat (411) R V-T NGPSSCTYGYSLTAKQEKI#
Rat (387) R RMDPVLVHMDIL#
Fig. 4.4
Alignment of the amino acid sequences of human, mouse and rat TRH-Rs. Numbers in
brackets after each species name indicates the number of amino acids encoded by each
subtype. The amino acid sequence is shown in one-letter code. Homology between the
sequences is indicated by dashes. Variant amino acids are indicated in red. Red dots
indicate deleted amino acids. Stop codons are indicated by (•), and the putative
transmembrane domains are underlined. Aligned sequences are: human (398), mouse
(393) Straub et al. [1990]; Rat (412) Zhao et al. [1992], de la Pena et al. [1992a]; rat (411)
Sellar et al. [1993]; rat (387) de la Pena et al. [1992b].
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a
Fig. 4.5
Chromosomal localisation of the human TRH-R gene to chromosome 8q23. Fig. 4.4a
illustrates a normal human male partial metaphase spread, hybridisation signals show
up as yellow spots. Fig. 4.4b shows signal distribution over 44 normal human male
metaphases following hybridisation to the 1.2kb human TRH-R pCR™II probe. (*)
represents 5 signals.
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experiments support the assignment of the gene for the human TRH-R to
chromosome 8q23 (Morrison et ah, in press).
4.3.3 Human TRH-R expression and functionality
The human TRH-R clone was subcloned into the mammalian expression
vector, pcDNA-1, to determine whether it encoded a functional OPR. The
binding of TRH to its receptor results in the rapid activation of the
stimulatory G-proteins, Gq/Gn (Hsieh & Martin, 1992) and subsequently,
the activation of the enzyme phospholipase C and the PI second
messenger pathway as described in Chpt. 2.6.8.
COS-1 cells were transiently transfected with the human TRH-R
in the correct orientation, and following exposure to TRH (HHM), total IP
production was measured and was found to increase approximately
twofold. In untransfected cells TRH had no effect (Fig. 4.6). Receptor-
ligand binding assays were performed for the human TRH-R in the correct
orientation. Scatchard analysis (Fig. 4.7) indicated a single high affinity
binding site with an estimated (equilibrium dissociation constant) of
4.28nM and a Bmax (receptor numbers expressed in pmol/mg protein) of
41,8pM/mg.
Functionality of the human clone was further confirmed using
calcium image analysis. Activation of the intracellular PI pathway results
in the release of intracellular calcium |Ca2+]j from Ca2+ stores within the
cell (see Fig. 2.11 in Chpt. 2.6). TRH (ICHM) produced a rapid elevation of
|Ca2+|j in fura-2-labelled, single COS-1 cells expressing the human TRH-
R. [Ca2+j j rose from a resting level of 27nM to a peak of 177nM with levels
returning to control values approximately 1.6min. after addition of TRH
(Fig. 4.8). In this experiment, onty two cells in a field often single cells
responded to TRH. This was probably due to the low transfection
efficiency generally found in transiently transfected, as opposed to stably
transfected cells.
The ability of TRH to produce both a rise in total IP production
and lCa2+]; confirms that the human TRH-R clone, in the direct
orientation, behaves as a functional G-protein-coupled receptor with a
single high affinity binding site for TRH.














TRH-induced IP production in COS-1 cells transiently transfected with the 1.2kb human
TRH-R in pcDNA-1. Twenty four hours after transfection, cells were trypsinised and
labelled with myo-[3H]inositol (2pCi/ml for 48 hours) and IP production measured after
exposure to TRH (10~6M, 30min.). Results are expressed as the mean ± SEM, n = 3.














0.00e+0 1.00e-11 2.00e-11 3.00e-11 4.00e-11
Bound
Fig. 4.7
Scatchard plot showing TRH-R binding. Binding studies in COS-1 cells transiently
transfected with the 1.2kb human TRH-R pcDNA-1 clone showed the existence of a
single-high affinity binding site with a of 4.28nM.
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Fig. 4.8
The effect of TRH (10~6M, t = 210sec., n = 2) on intracellular calcium [Ca^+Jj in COS-1
cells transiently transfected with the 1.2kb human TRH-R pcDNA-1 clone.
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4.4 Discussion
This chapter has described the isolation and sequencing of a cDNA
encoding a human pituitary TRH-R. Evidence that the cDNA encoded a
functional, G-protein-coupled TRH-R was obtained from COS-1 cells
transiently transfected with the human TRH-R. The binding of a
radiolabeled TRH analogue to membranes of transfected COS-1 cells was
demonstrated, and the ability of TRH to induce inositol phosphate
formation, and the subsequent mobilisation of [Ca2+]i further confirmed
the functionality of the human clone. Finally, sequence comparison of the
isolated human clone with the previously reported mouse (Straub et al.,
1990) and rat TRH-Rs (Zhao et al., 1992; de la Pena et ah, 1992a,b; Sellar
et ah, 1993) indicated high sequence homology within the coding region of
all three species, with major variation occurring only at the distal end of
the cytoplasmic COOH tail. The more recently isolated human brain
TRH-R (Matre et ah, 19931) is identical to the pituitary receptor, but was
formed by splicing together two different clones with overlapping sequence
homology from TM3 to TM6. An identical human TRH-R was also isolated
from a pituitary cDNA library by Yamada et al, (19931). The TRH-R gene
structure and the possibilities of alternative splicing are more fully
discussed in Chpt. 6.
Primary sequence analysis: The amino acids of the 7 transmembrane
(TM) domains were highly conserved between the human, rat and mouse
TRH-Rs. Aside from the COOH tail variation, most amino acid changes
occurred in the extracellular amino (NH2) terminus and the third
cytoplasmic loop (CL3) when compared to the rat and mouse sequences
(Fig. 4.4).
Several residues thought to be of functional importance in GPRs
were found to be similarly conserved in the TRH-Rs from all three species.
For example, the human TRH-R has two putative consensus sites (Asn-X-
Ser/Thr) for N-linked glycosylation (Kornfeld & Kornfeld, 1985) in the
NH2 domain, two in CL3, and two in the COOH tail (Fig.4.2). N-linked
1
The paper by Duthie et al., was accepted for publication by Molecular and Cellular Endocrinology
on June 30, 1993. The paper by Matre et al., appeared in BBRC on August 31, 1993 and the paper
by Yamada et al., appeared in BBRC on September 15, 1993.
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glycosylation is thought to be important for correct insertion of the
receptor in the plasma membrane (Chpt. 2.6.22). Disulphide bonds are
known to form between Cys residues in the extracellular loops of the P-
adrenergic receptor (pAR), thereby stabilising its tertiary structure
(Dohlman et al., 1990). A disulphide bond may also occur between
similar conserved Cys residues in the extracellular loops (EL) ELI (Cys98)
and EL2 (Cys179) of the TRH-R (Fig. 4.3) as a reduction in TRH-R density
occurred when disulphide bonds were disrupted by dithiothreitol (DTT)
(Sharif & Burt, 1984). A conserved Cys residue, present in the COOH tail
ofmany GPRs (Cys337 in the TRH-R) may be palmitoylated, enabling the
formation of a fourth cytoplasmic loop (O'Dowd et al., 1989; Mouillac et al.,
1992).
The TRH-R also encodes the highly conserved Asn in TM1 (Asn43)
and Asp61 in TM2 (Fig. 4.3). These residues are present in nearly all
GPRs (Probst et al., 1992) and, therefore, are likely to be involved in the
correct folding of the protein for expression in the membrane, which in
turn promotes ligand binding and second messenger activation. Indeed,
mutation of the rat TRH-R TM2 Asp to Ala (Perlman et al., 1992) resulted
in a decrease in ligand binding affinity and abolished TRH-induced
stimulation of inositol phosphates, supporting this theory.
An Asp residue found in TM3 of all receptors that couple to
cationic ligands, (Strader et al., 1988) is not conserved in the TRH-R,
neither are the Ser residues in TM5 which are thought to bond with
aromatic hydroxyl groups of catecholaminergic ligands (Strader et al.,
1989a; Probst et al., 1992 for GPR sequence alignment). TRH contains a
His residue that can be protonated, and it was initially thought that TRH
may bind to its receptor via ionic interactions, however, experiments by
Perlman et al. (1992) demonstrated reduced TRH binding efficiency at low
pH. They also mutated Asp residues in TM2, TM4, TM5 and EL2 that
were possible residues for ionic interactions with TRH, and only the Asp
in TM2 had any effect on ligand binding, as mentioned previously. Thus it
was suggested that TRH binds in an unprotonated, or neutral form, to its
receptor and does not involve ionic interactions.
The TRH-R activates the PI pathway by coupling to the G-
protein(s) Gq/Gn (Hsieh & Martin, 1992) which stimulate the enzyme
phospholipase C (PLC). In certain systems, TRH has also been shown to
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stimulate the adenylate cyclase pathway via Gs (Paulssen et al., 1992).
Important regions in coupling of GPRs to G-proteins include the
membrane proximal regions of CL3 and the membrane proximal region of
the COOH tail (Dohlman et al., 1991; Strosberg et al., 1991; Probst et al.,
1992). These regions are proposed to form amphipathic helical secondary
structures (Segrest et al., 1990) which may directly contact and activate
G-proteins. The amino acid variation found at the COOH tail of the
mouse, rat and human TRH-Rs could be involved in TRH-R coupling to
different second messenger pathways as was found for the prostaglandin
PGE2 EP3 receptor subtypes (Namba et al., 1993).
Other conserved GPR features found in the TRH-R include the
D(E)RY sequence in the membrane proximal region of CL2 and conserved
prolines in TM5, TM6 and TM7 (Fig. 4.3). Pro residues are believed to
introduce 'kinks' or bends into the transmembrane domains for correct
formation of the ligand binding pocket (Hibert et al., 1993).
Continued exposure of receptors to agonist can eventually result
in a reduced response, known as desensitisation. Phosphorylation of
receptors at Ser/Thr residues may contribute to receptor downregulation
and, therefore, desensitisation (discussed in Chpt. 2.6.25-29). The TRH-R,
coupled to the PLC pathway, does desensitise and does have potential
phosphorylation sites (Fig.4.2), but work by Perlman and Gershengorn
(1991) suggested that protein kinase C (PKC), a kinase activated by
diacylglycerol (DAG), as part of the PLC second messenger pathway
stimulated by TRH, does not appear to be involved. Stimulation of
receptors by TRH also results in elevated [Ca2+]i, which might activate a
Ca2+/calmodulin-dependent protein kinase. Elevated calcium, however,
does not seem to be responsible for desensitisation either, at least in GH3
cells (Perlman & Gershengorn, 1991). Other PKC isozymes in other cell
types may produce different results.
The human TRH-R has 4 more Thr residues than the mouse TRH-
R and the rat TRH-Rs have 3 more Thr residues than the mouse in the
central region of CL3 (Fig. 4.4). These amino acid differences may reflect
variation in phosphorylation of TRH-Rs between thyrotrophs and
lactotrophs, or differences in G-protein-coupling between TRH-Rs in
different cell-types.
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The variant COOH tails might also be involved in differential
TRH-R regulation by phosphorylation. The human and rat (412/411)
TRH-Rs encode three extra Ser residues than the mouse TRH-R, and the
long form of the rat TRH-R has two extra Thr residues than the human
receptor at the COOH tail. Interestingly, the rat TRH-R387 has lost six
serines and five threonines due to the 52bp deletion and frame-shift. Both
the long and short forms of the rat TRH-R have been shown to co-exist in
GH3 cells (de la Pena et al., 1992b) and Paulssen et al. (1992) have
demonstrated activation of both the PI and adenylate cyclase pathways by
the TRH-R in GH3 cells. Thus the rat TRH-R COOH tail differences
might allow differential receptor regulation, or activation of multi¬
functional signalling pathways by TRH via different receptors within the
same cell (Milligan, 1993) as was found for the prostaglandin EP3
receptors (Namba et al., 1993).
Internalisation of receptors is thought to occur following ligand-
binding and activation of the second messenger pathway (Chpt. 2.6.26).
No consensus signalling sequences for this process have yet been found,
although the region encoded by the COOH tail has been implicated (Chpt
2.6.18-20). Two distinct domains that affect agonist-induced receptor
internalisation have been characterised in the mouse TRH-R
(Nussenzveig et al., 1993a). These include a domain between residues 335
and 368, and the need for a proximal Cys residue(s), either Cys335 or
Cys337. The Cys337 may be palmitoylated, so perhaps post-translational
modifications are involved in internalisation. Nussenzveig et al. (1993b)
have also reported that coupling to G-protein and PLC increases TRH-R
internalisation. This supports the theory that a quaternary complex of
ligand-receptor-G-protein-effector is internalised, unlike (3ARs, which are
thought to dissociate from their adenylate cyclase-coupled G-proteins
before internalisation (Lefkowitz & Hausdorff, 1991; Yu et al., 1993). It
will be interesting to define the domains involved in desensitisation and
internalisation of the human TRH-R, with respect to the COOH tail
variation.
Chromosomal localisation of the human TRH-R gene
The localisation of the human TRH-R to the long arm of chromosome 8
(8q23) will prove useful if chromosomal abnormalities such as
Chapter 4 Human TRH receptor cDNA 100
translocations or deletions are discovered in this region of the genome. A
search of the 10th edition of McKusick (1992) has so far revealed no
chromosome alterations at 8q23 relevant to the TRH-R. An autosomal
recessive phenotype, termed 'TRH deficiency: hypothalamic
hypothyroidism', may possibly be caused by a TRH-R genetic defect,
although this is only speculation (Foresti & Ferrari, 1985). Genetic
defects at the level of point mutations as well as larger chromosomal
abnormalities can also cause serious disease (Chpt. 2.6.30), and knowledge
of the human TRH-R sequence will be helpful in determining whether the
TRH-R is implicated in any clinical pathologies.
4.5 Summary
In conclusion, this chapter has reported the cloning of a cDNA encoding
the human pituitary TRH-R protein with a predicted sequence of 398
amino acid residues. Comparison of the amino acid sequence of the
human TRH-R with the previously published rodent TRH-Rs showed that
all the TRH-R subtypes are highly homologous, except that each subtype
encodes variant amino acids at the 3' end of the COOH . The human
TRH-R belongs to the family of 7 transmembrane domain, G-protein-
coupled receptors and it is believed that the COOH terminal region of this
family of receptors may play an important role in receptor
downregulation/internalisation, and possibly G-protein coupling. COS-1
cells expressing the human TRH-R showed high affinity receptor binding.
Stimulation of these cells with TRH produced a typical phosphinositide
response and mobilisation of intracellular calcium. The human pituitary
TRH-R appears to be identical to a sequence obtained from human brain
(Matre et al., 1993), but there may be multiple subtypes of the human
TRH-R as yet undetected in brain and pituitary, as has been found for the
rat TRH-R (de la Peha et al., 1992b). These possibilities are discussed
further in Chpt. 6.
5 Tissue localisation studies of TRH-R
messenger RNA in human
5.1 Introduction
The initial characterisation of the TRH-R utilised receptor radio-ligand
binding studies using membrane homogenates from various mammalian
species, and high affinity TRH analogues such as [3H](3-Me-His2)TRH.
High affinity binding sites have been characterised in the anterior
pituitary (Wilber & Seibel, 1973; Labrie et al., 1972; Gautvik & Lystad,
1981) and are widely distributed throughout the brain (Burt & Snyder,
1975; Burt & Taylor, 1980; Ogawa et ah, 1981; Pazos et ah, 1985) using
these methods. By 1984, Johnson and colleagues (Johnson et ah, 1984)
had succeeded in solubilising TRH-Rs from rat brain, and their results
suggested the existence of high and low affinity binding sites related to a
single macromolecular complex. TRH-Rs have also been described in
medullary neurons projecting to the spinal cord where they have been
proposed to coexist with substance P and serotonin (Ogawa et ah, 1985;
Johansson et ah, 1981).
Recent advances in molecular technology have resulted in the
cloning of several TRH-Rs from mouse pituitary (Straub et ah, 1990), rat
pituitary (Zhao et ah, 1992; de la Pena et ah, 1992a,b; Sellar et al., 1993),
human pituitary (Duthie et ah, 1993a; Yamada et ah, 1993) and human
brain (Matre et ah, 1993). The use of these TRH-R sequences as
hybridisation probes has enabled techniques such as Northern blot
analysis and in situ hybridisation (Whitman, 1991) to be used in studying
the distribution of the TRH-R in different tissues. These methods are
capable of determining receptor gene expression by hybridising DNA or
RNA probes to the receptor messenger RNA (mRNA) as it is expressed in
a particular tissue. A detailed study by Zabavnik et ah (1993)
demonstrated the distribution of the TRH-R expression in rat pituitary,
and in various regions of the rat brain, by in situ hybridisation.
TRH and TRH-like peptides have been localised to several tissues
outside the CNS, including the retina (Schaeffer et ah, 1977), gastro¬
intestinal system (Morley et ah, 1977; Martino et ah, 1978; Morley et ah,
1979; Kawano et ah, 1983), placenta (Shambaugh et ah, 1977), and the
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male reproductive system (Pekary et al., 1980; Feng et al., 1993a),
prompting the search for TRH binding sites in these tissues. Localisation
of TRH-Rs to particular tissues will help to determine possibles roles for
TRH other than as a pituitary releasing hormone. TRH in the retina
appears to be regulated by environmental lighting (Schaeffer et al., 1977)
and this, together with the identification of TRH-R mRNA in the rat
retina (Satoh et al., 1993), suggests some function for TRH in this tissue.
A biological role for TRH in the male reproductive tract also appears
likely, as TRH (Pekary et al., 1980; Feng et al., 1993a) and TRH-Rs have
been co-localised to the rat testis by Northern analysis, membrane-binding
studies and in situ hybridisation (Feng et al., 1993b). It is speculated that
TRH may be an autocrine regulator of testosterone production and a
paracrine regulator of spermatogenesis (Feng et al., 1993b).
TRH and TRH-like peptides have also been localised to the
prostate (Pekary et al., 1980; Pekary et al., 1989; Fuse et al., 1990; Del
RioGarcia & Smyth, 1990; Bilek et al., 1992; Gkonos et al., 1993). This
raises the question of whether TRH binding sites are also expressed in the
prostate. Having established the structure of the human TRH-R (Chpt 4)
it now becomes possible to examine this question using molecular
techniques such as Northern blotting and in situ hybridisation. Thus the
aim of this study was to further the understanding of extra-pituitary
functions for TRH by studying the distribution of TRH-R mRNA in
various human tissues.
5.2 Materials and methods
Buffers and solutions used are described in Appendix I. All glassware was
washed and baked before use to inhibit RNAse enzymes that destroy the
RNA. Gloves were worn at all times.
5.2.1 Slide and tissue preparation for in situ hybridisation
The distribution of the human TRH-R mRNA in human pituitary,
prostate, ovary and placenta was studied using in situ hybridisation (rat
pituitary was used as a positive control). A normal human pituitary,
obtained following post-mortem, was donated by Dr J Bevan, Aberdeen
Royal Infirmary. The pituitary had been frozen at -70°C, eleven hours
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after death. Ovarian tissue (in early follicular phase with a 6mm follicle,
day 4 of the menstrual cycle) was obtained at surgery by Dr P Illingworth.
Placental tissue was obtained by Dr S Cooper, immediately following
routine delivery, from the Edinburgh Royal Infirmary. Prostatic tumour
tissue (benign and malignant) was kindly donated by Dr J Waxman of the
Hammersmith Hospital, London. The ovary, placenta and prostatic tissue
was frozen immediately and stored in liquid nitrogen until use.
Frozen tissue was sectioned (10pm) in a Frigocut cryostat and
thaw-mounted on to microscope slides (previously washed and baked)
coated with 2% aminopropyltriethoxy-silane (APES). Sections were stored
at -70°C prior to hybridisation.
5.2.2 Riboprobe preparation
The human TRH-R cDNA clone was amplified by PCR to produce a 410bp
fragment of DNA encoding nucleotides 938 to 1347 of the TRH-R coding
region. Transcripts ofbetween 200bp and 800bp are thought to be optimal
for tissue penetration (Whitman, 1991). Larger probes have to be
hydrolysed, which is difficult to control and results in the loss of much of
the probe's activity. The PCR product was purified as described in Chpt.
3.9.1 and subcloned into the TA cloning vector pCR™II (Chpt. 3.4). At
least lpg of this recombinant plasmid was linearised with the restriction
enzymes Notl and Sacl, which cut the vector on either side of the inserted
PCR fragment. The linearised plasmid was extracted once with
phenol/chloroform, and once with chloroform/IAA (24:1) and precipitated
for an hour at -20°C. The plasmid was pelleted by microfuging at
13,000rpm for lOmin. at 4°C, washed in 70% ethanol, air-dried and
resuspended in 9pl double-distilled water. A sample (l|il) of the plasmid
was electrophoresed on an agarose gel to determine the extent of
linearisation.
The linearised plasmid was in vitro transcribed from either the
SP6 promotor (Notl-cut plasmid) or the T7 promotor (Sacl-cut plasmid)
with SP6 and T7 polymerases (Promega) respectively. The antisense
strand was transcribed from the T7 promotor and represented the
experiment, while the sense strand was transcribed from the SP6
promotor and represented the control. The transcription reaction mix
contained 5XTSC buffer (Promega), lpg DNA template, lOmM each of
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rATP, rGTP and rCTP and 0.2mM rUTP, 50pCi [33P]rUTP (Amersham),
20U RNA polymerase, 40U RNAse blocker (RNAsin, Promega) and
double-distilled water to a total volume of 25|il. After 45min. incubation
at 37°C, a further lpl of the appropriate RNA polymerase was added to
ensure a full-length transcript was obtained, and transcription continued
for a further 45min. Following transcription, 2pl tRNA (lOmg/ml) was
added as a carrier molecule and the DNA template was degraded with
DNAse I (10U, Boehringer) for lOmin. at 37°C. The riboprobes were
extracted once with phenol/chloroform and once with chloroform/IAA
(24:1) and precipitated for at least an hour at -20°C. The riboprobes were
pelleted by microfuging at 13,000rpm for 15min. at 4°C, washed with 70%
ethanol, centrifuged, air-dried and resuspended in 20pl double-distilled
water. Incorporation of 33P was determined by adding lgl of riboprobe to
lml scintillation fluid and counting on a Rackbeta counter. Riboprobes
were stored at -20°C until use.
4.2.3 In situ hybridisation
The method used was adapted from that described previously (Peters et
al., 1991). Frozen tissue sections were dried rapidly with a hair-dryer and
fixed in fresh 4% paraformaldehyde (5min.). Fixed sections were washed
twice in 0.1M phosphate buffer (5min. each) and once in double-distilled
water with shaking. Sections were washed in TEA buffer for 2min. and
treated with TEA buffer (containing 0.25% acetic anhydride) for lOmin.
with shaking to reduce non-specific binding of the negatively charged
probe to the positively-charged APES used to coat the slides. The melting
temperature (Tm) for hybridisation was determined using the following
equation Tm = 81.5 + 16.6(log[M]) + 0.41(%G+C) - 0.65(F) - 820/1, where M
= salt concentration of buffer, G+C = %G:C content of the riboprobe, F =
formamide concentration of buffer and 1 = length of the riboprobe (Chan et
al., 1989). The sections were rinsed in 2XSSC, blotted and prehybridised
with a few drops of prehybridisation buffer at 42°C (Tm -15°C to -25°C) for
an hour in a Hybaid oven. Prehybridisation was performed to reduced
non-specific binding of the riboprobe.
During the prehybridisation step, the sense (SP6) and antisense
(T7) riboprobes were diluted in hybridisation buffer (lxlO6 counts in 40|il
hybridsation buffer for each slide), heated to 60°C for 3min. and placed
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directly on ice until required. Following the prehybridisation step, slides
were blotted and placed in sterile dishes. Diluted riboprobe (40pl) was
added to each section and covered with FMC Gelbond film (hydrophilic
side up). Vials of sterile water were also placed in the dishes to prevent
the sections from drying out. Tissue sections were incubated at 42°C (Tm
-15°C to -25°C) overnight.
5.2.4 Washing of hybridised tissue sections
Following hybridisation, the sections were washed in 4XSSC to remove
the coverslips. Tissue sections were then incubated with prewarmed
RNAse buffer containing 20|ig/ml RNAse A at 37°C for 30min. to remove
non-specific riboprobe, and rinsed once with RNAse A buffer for a further
30min. Washing was performed at low stringency in 2XSSC for 30min. at
room temperature, with shaking, followed by 1XSSC and then 0.5XSSC
both for 30min. at room temperature. The tissue sections were
dehydrated through an ascending series of industrial methylated spirit
[IMS], (50%, 85%, 100%) containing 300mM ammonium acetate for 3min.
each, and air-dried.
5.2.5 Autoradiography of hybridised tissue sections
Slides with washed and dried hybridised tissue sections were prewarmed
on a hot-plate at 45°C. Coating of slides with prewarmed (45°C) Kodak
NTB2 autoradiography emulsion was performed in a dark-room. Once
coated, the slides were placed in a rack in a sealed plastic box lined with
damp tissue and left at room temperature for 4 hours in a light-proof
container. The slides were transferred to black polyacetyl boxes
(Raymond A. Lamb) containing a perforated vial of silica gel and double-
wrapped in tinfoil. Sections were exposed to the emulsion at 4°C for 10 to
21 days.
Before developing, slides were prewarmed to ~15°C. The
developer (Kodak), stop solution (water), and fixative (Kodak UNIFIX,
diluted 1/5) were cooled to ~15°C on ice before use. In the darkroom the
slides were processed through each solution as follows: developer (4min.),
stop solution (20 seconds), fixative (5 to lOmin.) and washed in distilled
water for 10 to 15min. The slides were rinsed in running water for 15min.
before staining with haemotoxylin (stains nuclei purple) for 1 to 5min.
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Excess haemotoxylin was removed with 1% (v/v) acid alcohol for 20
seconds and the slides placed in Scott's tap water. After each of these
treatments, the slides were rinsed in fresh, running tap water. The tissue
sections were examined to determine the extent of staining, and the
process repeated ifnecessary.
The counterstained sections were dehydrated through an
ascending series of ethanol (70%, 80%, 100%) and placed in Histoclear
(National Diagnostics) for 5min. before transferring to Xylene (BDH) in a
fume-hood. Sections were mounted in Eukitt (O. Kindler GmBH & Co.)
under a coverslip and viewed under dark-field microscopy to determine
the localisation of the radioactive probe, revealed by the distribution of
silver grains in the photographic emulsion.
5.2.6 RNA extraction
Total RNA was extracted from 293 human embryonic kidney fibroblast
cells stably expressing a 3.5kb rat TRH-R cDNA clone (293-E2 cell line,
established by Jelka Zabavnik), as a positive control, and from
untransfected 293 cells (negative control). Prostate mRNA (poly A+) was
obtained from Clontech. The method used was essentially that of
Chomczynski & Sacchi (1987). Cultured monolayers of 293 cells were
placed on ice, the culture media removed and the cells washed with ice-
cold phosphate buffered saline (PBS). Solution D (1ml to 2ml, Appendix I)
was added to the monolayer to lyse the cells, and the viscous solution
removed to polypropylene tubes. The dish was washed with a further 1ml
to 2ml (depending on the size of the culture) of solution D and pooled with
the previous extract.
After cell lysis, the following solutions were added sequentially
(per 1ml solution D), with shaking after each addition; 0.1ml 2M sodium
acetate (pH 4.0), 1ml water-saturated phenol and 0.2ml
chloroform/isoamyl alcohol (49:1). The final mixture was shaken
vigorously for 10 seconds and cooled on ice for 15min. Samples were
centrifuged for 20min. at 10,000g and 4°C in a pre-cooled Beckman fixed-
angle rotor (JA 20.1). The aqueous phase, containing the RNA, was
carefully removed to a sterile tube, ensuring no contamination from
proteins at the interphase, and mixed with an equal volume of cold
isopropanol. The RNA was left to precipitate at -20°C for at least an hour,
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and centrifuged as described above. The supernatant was discarded, and
the translucent RNA pellet redissolved in 0.3ml to 1ml solution D. The
solution was transferred to a sterile 1.5ml Eppendorf tube before adding
an equal volume of cold isopropanol, inverting to mix, and precipitating at
-20°C for at least an hour. RNA was pelleted by microcentrifuging at
13,000rpm for lOmin. at 4°C. The supernatant was discarded carefully,
and the pellet resuspended in cold 75% ethanol, microcentrifuged for
2min. and the supernatant again discarded. At this point, the pellet was
either freeze-dried and resuspended in 50(il to 200gl of sterile water by
heating at 65°C for lOmin., or it was resuspended in fresh 75% ethanol.
Both were stored at -70°C.
To determine the concentration and purity of the extracted RNA,
a sample was thawed gently on ice, and then diluted (Kb2) in double-
distilled water. The absorbance of the sample was determined at an
optical density (OD) of 260nm and 280nm. The ratio of the readings
(260/280) determined the purity of the sample - a ratio of 2.0 denoted pure
RNA. An OD260 of 1.0 = 40gg/ml RNA.
5.2.7 Separation of RNA using formaldehyde gels
Total RNA (20|ig) extracted from 293-E2 cells (expressing the rat TRH-R)
and 293 cells (untransfected), 2pg polyA+ prostate mRNA (Clontech) and
3|ig RNA markers (Promega) were electrophoresed on 1.5% formaldehyde
gels. Molecular biology grade agarose (1.5g, SeaKem) was dissolved in
85ml double-distilled water in a baked conical flask. The gel was cooled to
~60°C and placed in a fume-hood where 5.4ml formaldehyde (37%
solution) was added and the gel poured immediately, leaving to set for
30min. The required volume of RNA was placed in a sterile Eppendorf
tube, the volume adjusted to 4.4pl with sterile water and 15.6pl sample
buffer (Appendix I) added. Samples were heated at 60°C for 5min. and 8pl
dye solution (Appendix I) added, mixed well and the RNA samples loaded
on to the prepared gel. Gels were run overnight at 35V in IX
MOPS/EDTA running buffer (Appendix I) and the RNA visualised and
photographed under u/v light.
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5.2.8 Northern blot analysis of RNA
RNA was transferred to Hybond N nylon membrane (Amersham)
overnight, using 20XSSC running buffer (Appendix I). The apparatus was
set up as described for Southern blotting in Chpt. 3.7.4. Following
transfer, the RNA was fixed to the membrane by u/v cross-linking, as
described in Chpt. 3.2.2 and was stored in a sealed bag at 4°C until use.
RNA gels were also photographed under u/v light after blotting to
determine the efficiency of transfer. The RNA was hybridised to a 581bp
human TRH-R cDNA PCR product (nucleotides 227 to 808), random-
primer labelled with 32P dCTP (Chpt. 3.8.3).
A multiple tissue Northern (MTN) blot (Clontech) was hybridised
with the same probe, according to manufacturer's instructions. This
Northern blot was obtained commercially owing to the difficulty in
obtaining certain human tissue for RNA extraction. The blot contained
2pg of pure poly A+ mRNA in each lane, from human heart, brain,
placenta, lung, liver, skeletal muscle, kidney and pancreas. The blot was
washed at low stringency (2XSSC, 0.1% SDS at room temperature for
several washes, and then at 50°C with 1XSSC, 0.1%SDS) to allow for
variation in TRH-R transcripts in different tissues.
5.3 Results
5.3.1 Localisation of TRH-R mRNA by in situ hybridisation
The human pituitary tissue available was poorly preserved and the RNA
appeared to have degraded, necessitating the use of rat pituitary as a
positive control. Positive hybridisation to the antisense human TRH-R
riboprobe was obtained in the anterior and neurointermediate lobes of rat
pituitary, but not the posterior lobe (Fig. 5.1A). The negative controls
(sense probe) had high background, but the signal appeared to be evenly
distributed over the whole tissue, with no specific hybridisation (Fig.
5.IB). The high background was attributed to labelling the riboprobes
with 33P (a high energy radio-isotope) and also to the long exposure time
used (19 days). Slides developed after only one week had lower backgound
levels (data not shown). Neither the ovary nor the placenta gave clear
results.
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The results presented for the prostate tumour tissue were
obtained following several trial runs with a small sample number (n=2) to
establish optimal conditions. Results from 9 benign and 8 malignant
tumours are presented in Table 5.1. Strong hybridisation to the antisense
probe (T7) was visualised in the glandular epithelium (GE) of 3/8 benign
tumours, 5/8 also showed positive hybridisation to stromal tissue. In one
benign tumour (patient 6) no clear hybridisation above background levels
was determined (ND).
The malignant tumour tissue gave similar results, with 3/6
showing strong hybridisation to glandular epithelium, 3/6 showing strong
stromal signal and 2 not determined (ND). There were no obvious
differences observed between hybridisation signals for the two types of
tissue. The sense (SP6) riboprobe seemed to 'shadow' the antisense probe
in some tumours (Fig. 5.2B), but at a much lower level of hybridisation.
This shadowing is probably an artifact as it did not occur when the slides
were developed after only 7 days incubation (data not shown). At this
stage, positive hybridisation to the antisense probe was very faint but
clearly visible. Figs. 5.2 to 5.4 show some of the results obtained with the
human TRH-R riboprobe hybridising to prostatic tumour tissue.
5.3.2 Northern blot analysis of the TRH-R
The human prostate polyA+ mRNA showed a clear hybridisation signal at
approximately 4.7kb with a second transcript at approximately 2.7kb, and
possibly a third at 1.6kb (Fig. 5.5). Washing the blot more stringently
revealed the smaller transcripts more clearly (data not shown). The
human TRH-R probe hybridised to a transcript of ~6.4kb in 293-E2 cells,
with a second, less abundant transcript at ~4.9kb. No hybridisation
signal was visible in the RNA from untransfected 293 cells (negative
control).
The Northern blot obtained from Clontech (Fig. 5.6) proved
difficult to analyse. Multiple transcripts were observed in all tissues
(Table 5.2), except the brain which had no clear hybridisation signals.
The TRH-R does exist in the brain, however, as it has recently been
isolated from a human brain cDNA library (Matre et al., 1993). Liver gave
a very strong signal which could not be resolved at low stringency.
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Tissue type Patient Probe Hybridisation
signal
Comments
Rat pituitary T7 +++++ AP and NIL only
SP6 ++
Human pituitary T7 + ND
(male) SP6 +
Human ovary T7 +++ ND
SP6 +++
Human placenta T7 +++ ND
SP6 +++
Benign prostatic 1 T7 +++++ GE only
hyperplasia SP6 ++
(BPH) 2 T7 +++++ GE only
SP6 ++ Slight 'shadowing'
3 T7 +++++ Stroma
SP6 +
4 T7 ++++ GE and stroma
SP6 ++ Slight 'shadowing'
5 T7 ++++ 'Edge effect' in
stroma
SP6 +++ Strong shadowing
6 T7 ++ ND
SP6 ++
7 T7 ++++ Signal in some GE
SP6 +++ Shadowing, poor
tissue preservation
8 T7 ++++ Stroma
SP6 ++
9 T7 ++++ GE & stroma
SP6 +++
Prostatic 10 T7 ++++ Stroma
Carcinoma SP6 +
(Malignant) 11 T7 +++++ Stroma
SP6 ++++
12 T7 +++++ GE
SP6 +
13 T7 +++++ GE, some stroma
SP6 +
14 TY +++++ Stroma
SP6 +
15 T7 ++ ND
SP6 +
16 T7 +++ ND
SP6 +++
17 T7 +++++ Some GE
SP6 +
Table 5.1
In situ hybridisation results obtained with human TRH-R riboprobe. Anterior pituitary
(AP), neurointermediate lobe (NIL). Antisense (T7), sense (SP6); strong hybridisation
signal (+++++), weak signal (+); Glandular epithelium (GE); Not determined (ND).






Photomicrographs of rat pituitary gland. Light-field photomicrographs (A) and (B)
illustrating the anterior lobe (a), neurointermediate lobe (ni) and posterior lobe (p). The
sections were hybridised with the 33P-labelled antisense human TRH-R riboprobe (C) or
sense riboprobe (D). No expression was found in D. Arrows indicate edge of tissue.
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Fig. 5.2
Photomicrographs (X10 objective) illustrating human prostate tumour tissue (benign) -
Patient 7, hybridised to the antisense (A) or sense (B) 33P-labelled human TRH-R
riboprobe. The sense probe (B) shows slight shadowing' of the antisense probe (A).
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Fig. 5.3
Photomicrographs (X4 objective) illustrating human prostate tumour tissue (benign) -
Patient 4, hybridised to the antisense (A) 33P-labelled human TRH-R riboprobe. (B)
light-field photomicrograph illustrating glandular epithelium (ge). Arrows indicate edge
of tissue.
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Fig. 5.4
Photomicrographs (X10 objective) illustrating human prostate tumour tissue (malignant)
- Patient 12, hybridised to the antisense (A) 33P-labelled human TRH-R riboprobe. (B)
light-field photomicrograph illustrating glandular epithelium (ge) and surrounding
stroma (s).
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Fig. 5.5
Northern blot analysis of poly A+ mRNA from human prostate and total RNA from 293
cells hybridised to a human TRH-R PCR fragment. Poly A+ mRNA (2|ig) from human
prostate (Clontech) and total RNA (20pg) extracted from 293-E2 cells transfected with
the rat 3.5kb TRH-R cDNA, and from untransfected 293 cells was subjected to Northern
blot analysis and hybridised to a 581bp human TRH-R PCR fragment probe as described
in section 5.2.7-8.







Northern blot analysis of poly A+ mRNA from a range of human tissues. The multiple
tissue blot (Clontech) contained 2pg poly A+ mRNA in each lane and was hybridised to a
581bp human TRH-R PCR fragment probe as described in section 5.2.7-8.
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Tissue ~Trancript sizes (kb)
293-E2 cells
(rat TRH-R)
- 6.2 4.9 - - -
Prostate - - 4.7 2.7 1.6 -
Heart - - 4.4 - 1.6 0.8
Brain - - - - (1.6) -
Placenta (8.0) - 4.4 - 1.6 0.8
Lung - - 4.4 - (1.6) -
Liver (7.5) - (4.4) (2.4) 1.6 0.8
Skeletal
muscle
7.5 5.9 4.2 2.4 1.6 0.8
Kidney - - 4.2 2.4 1.6 0.8
Pancreas - - - - 1.6 0.8
Table 5.2
RNA transcript sizes obtained from Northern analysis of the multiple human tissue in
human tissue Northern blot (Clontech) hybridised to the 581bp human TRH-R PCR
fragment probe. Figures in brackets represent transcripts that were not clearly visible.
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Washing at higher stringency suggested that the signal consisted of two
transcripts of ~7.5kb and 4.4kb, although the results were still not very
clear (data not shown). The low molecular weight transcripts appeared to
be the most abundant, while transcripts of a size expected of the TRH-R
(3.5kb in GH3 cells |de la Peha et al., 1992a; Zhao et al., 1992]; 3.8kb in
rat testis [Feng et ah, 1993b] and 3.8kb in rat retina [Satoh et ah, 1993])
were barely visible. Skeletal muscle expressed 4, or possibly 5 transcripts
ranging from ~7.5kb to 0.8kb, while the only the two smaller transcripts of
1.6 and 0.8kb were visible in the pancreas. No transcript corresponding to
~4kb was visible in the pancreas.
5.4 Discussion
In situ hybridisation analysis of extra-pituitary tissues using the human
TRH-R probe provided some interesting results. Rat pituitary acted as a
positive control in the absence of fresh human tissue, and gave a positive
hybridisation signal to the human probe (Fig. 5.1). The fact that no clear
results were obtained in placenta and ovary does not necessarily mean
that the TRH-R is not expressed in these tissues, especially in the
placenta, to which TRH itself has been localised (Shambaugh et ah, 1977).
Different receptor subtypes may be present that would not hybridise to
this particular region of the TRH-R (nucleotides 938 to 1347), or receptor
expression may be developmentally regulated. Northern blot analysis of
prostate poly A+ mRNA suggested the presence of TRH-R-like transcripts
and is discussed below.
Putative TRH-Rs in the prostate
In situ hybridisation studies using the human TRH-R isolated as
described in Chpt. 4, gave strong, positive results in human prostate
tissue, both benign and malignant. In some sections, the signal was
clearly localised to the glandular epithelium, whilst in others, positive
hybridistion was found in the surrounding stromal tissue (Figs. 5.2 to 5.4).
In certain tissue sections, some of the glandular epithelium showed
positive hybridisation to the TRH-R probe, whilst some did not. The
results revealed no obvious differences between benign and malignant
tissue.
The prostate gland is an accessory organ ofmale reproduction and
its growth and differentiation is regulated predominantly by androgen
secretion, as well as by oestrogens, prolactin, insulin and possibly other
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The prostate gland is an accessory organ of male reproduction and
its growth and differentiation is regulated predominantly by androgen
secretion, as well as by oestrogens, prolactin, insulin and possibly other
growth factors (Meikle, 1989). The weight of the gland increases with age
and the tissue often becomes hyperplastic in men at around age 45. This
hyperplasia is related to androgen secretion as men castrated before
puberty do not develop benign prostatic hyperplasia (BPH) (Meikle, 1989).
The glandular epithelium is strongly influenced by stromal growth factors
stimulated by androgens, and receptors for peptide hormones including
prolactin (Aragona et al., 1977) and GnRH (Qayum, 1990; Waxman, 1991)
have been reported in the prostate. BPH is successfully treated with
surgery, although endocrine therapy that could act to prevent the disease
would be highly desirable.
Cancer of the prostate is the second most common form of
malignancy in adult males and more than 60% of cases occur in men over
70 years of age (Lippman, 1989). Both BPH and prostate carcinoma may
respond to anti-androgens, but there are differences between the two
diseases, including the site of origin within the gland. BPH occurs
centrally, whereas carcinoma is usually peripheral (Lippman, 1989).
GnRH agonist administration has been found to reduce tumour growth by
creating a paradoxical decrease in LH and FSH from the pituitary and
subsequent reduction in gonadal steroids (Waxman, 1991). Such agonists
may also down-regulate GnRH-Rs in the prostate (Qayum et al., 1990).
GnRH agonists avoid the psychological effects of castration, however,
potentially non-reversible testicular damage has been reported as a result
of this type of therapy (Decensi et al., 1993).
Levels of TRH/TRH-like peptides in the normal prostate decrease
with age and their decreased expression in prostate cancer has also been
reported (Gkonos et al., 1993). The discovery ofputative prostatic TRH-Rs
both by in situ hybridisation and Northern analysis reported in this
chapter, implies a biological role for TRH in this tissue. Gordeladze at al.
(1988) reported that TRH stimulated adenylate cyclase in both normal,
hyperplastic and cancerous prostate, supporting the existence of TRH
binding sites in this tissue. They also reported that TRH stimulation of
adenylate cyclase was lower in hyperplastic tissue, and even lower in
prostate carcinoma. It is tempting to speculate that the observed age-
i
Chapter 5 TRH-R tissue localisation studies 120
related reduction in TRH levels in normal prostate, and in prostate
carcinoma, may somehow be related to the onset of this disease.
Northern blot analysis
Multiple transcripts hybridising to the 581bp TRH-R probe appeared in all
the human tissues analysed by Northern blotting, and were strongest in
the liver and weakest in the brain. TRH-R binding has been reported in
the liver (Burt & Snyder, 1975) and a TRH-R has recently been isolated
from a brain cDNA library (Matre et al., 1993). The blot was washed at
low stringency and thus the transcripts may represent other genes with
some homology to the TRH-R. The transcripts could also represent
alternatively spliced versions of the TRH-R gene. This possibility is
discussed in Chpt. 6. Another prospect is that these are aberrant
transcripts which are transcribed from the same gene, but are not
translated into peptides, due to truncation, or extension of the mRNA at
either the 5' or 3' terminus (Ivell, 1992). Several examples of this type of
aberrant transcription have recently been reported for genes that are
transcribed in both brain and testis, such as the pro-opiomelanocortin
gene (Jeannotte et al., 1987; Lacaze-Masmonteil et al., 1987). Aberrant
transcripts tend to occur in greater abundance than the normal-length
functional transcripts, can appear in different cell types from the
functional variants, and also show a high degree of species specificity
(Ivell, 1992).
A faintly hybridising band of ~4kb was observed in heart, lung,
skeletal muscle, kidney, prostate and possibly placenta and liver (Table
2.2). This may represent a low abundance, functional TRH-R transcript,
since it roughly corresponds to the range of TRH-R transcript sizes from
3.5kb to 4kb observed in GH3 cells (de la Pena et al., 1992a; Zhao et al.,
1992) and the rat testis (Feng et al., 1993). The LH-R gene (a member of
the GPR family) is expressed as multiple transcripts of varying sizes in
the testis, depending on the species (Loosfelt et al., 1989; Tsai-Morris et
al., 1991; Wang et al., 1991). Some of these transcripts are larger than the
open-reading-frame, and some are smaller, as was found for the human
TRH-R (Table 2.2). Multiple transcripts were also found for the GnRH-R
in sheep (Illing et al., 1993; Brooks et al., 1993).
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Ivell (1992) suggested that non-functional transcripts may arise
from 'leaky transcription'. In this case, particular combinations of
transcriptional elements may initiate, or terminate transcription at sites
other than the correct initiation/termination consensus sequences. This
effect could also explain the unusually large transcripts observed in the
293-E2, positive control RNA. Although the transfected rat TRH-R cDNA
was only 3.5kb, its insertion site into the genome of the 293 cell line might
affect its termination signals and interactions with the transcription
machinery of the cell.
These results provide interesting preliminary data and open up
several possibilities for future work. The TRH-R appears to be highly
expressed in the glandular epithelium and, to a lesser extent, in the
stroma of human prostate tumour tissue (benign and malignant). Similar
studies with animal models would be helpful in investigating the
expression of the TRH-R in relation to the development of the animal and
in relating the expression of the receptor to its peptide. It would also be
interesting to clone and sequence the TRH-R from a human prostate
cDNA library to confirm these findings and to compare the prostatic TRH-
R with the pituitary and brain TRH-Rs, as no human TRH-R isoforms
have yet been cloned. Ligand binding studies on prostatic tissue would
also help to characterise the nature of these putative TRH binding sites.
The results from the Northern blot analysis emphasise the importance of
providing functional data for observed gene transcripts. Time constraints
prevented further studies on this project.
5.5 Summary
This chapter reports the localisation of putative TRH-R mRNA transcripts
to a variety of human tissues. Significant positive hybridisation to a
410bp human TRH-R riboprobe was observed in human prostate tumour
tissue (benign and malignant) and was supported by Northern analysis of
prostate poly A+ mRNA, which revealed transcripts of ~4.7kb, 2.7kb and
1.6kb. Multiple transcripts were also observed in a variety of human
tissues and may represent homologous genes, aberrant TRH-R transcripts
or alternatively spliced versions of the gene (Ivell, 1992). Further work is
needed to establish a biological role for TRH in the prostate.
6 Structural analysis of the mouse TRH
receptor gene.
6.1 Introduction
Unlike prokaryotic genes, eukaryotic genes are very often encoded by
discontinuous DNA segments or exons, separated from each other by
intervening sequences known as introns. Introns generally do not form
part of the mature mRNA and are removed by a precise excision, or
splicing mechanism. Splice sites are recognised by consensus sequences
at the 5' and 3' boundaries of the introns, and splicing is performed by the
interaction of small nuclear RNA molecules (snRNAs) with these
sequences. In most genes studied so far, each exon is incorporated into
the mature mRNA transcript through the invariant ligation of pairs of
consecutive splice junctions. In some cases, however, non-consecutive
exons can be joined together by utilising alternative splice sites. This
process of alternative splicing allows a particular gene to produce more
than one protein from a single coding sequence, and the choice of splice
sites may be developmentally regulated or cell-type specific (Breitbart et
al., 1987).
Alternative splicing does occur in some G-protein-coupled receptor
(GPR) genes and has recently been shown to produce receptor isoforms
capable of activating different second messenger pathways (Chpt. 2.6.31).
The discovery of TRH-R subtypes with variant COOH tails (Chpt. 4) has
raised the question of alternative splicing in the TRH-R gene, particularly
as the sequence variation in each subtype has amino acid 392 as a
common point of sequence divergence. The mouse TRH-R393 isolated from
the mouse TtT thyrotroph cell line (Straub et al., 1990) encodes only one
residue after amino acid 392. Several rat TRH-R isoforms have been
isolated, including a TRH-R412 (Zhao et al., 1992; de la Pena et al., 1992a)
from rat anterior pituitary GH4C1/GH3 tumour cell lines and a rat TRH-
R411, isolated from a pituitary cDNA library (Sellar et al., 1993). These
receptors encode 20 and 19 amino acids respectively, after the breakpoint
at residue 392. TRH-R411 has a deletion of 3 nucleotides resulting in the
loss of one amino acid, residue 393 (Sellar et al., 1993).
122
Chapter 6 The mouse TRH-R gene 123
There are several other methods of generating protein diversity
from a single gene. In some cases, intronic sequence is actually 'retained'
in the mRNA, in-frame with the rest of the coding region, resulting in the
translation of a longer protein. In this case, the splice sites exist within
the coding region (Breitbart et al., 1987; Smith et al., 1989). Most
interestingly, another rat receptor subtype, TRH-R387 (de la Pena et al.,
1992b) has been cloned from GH3 cells and appears to undergo this form
of alternative splicing. This receptor contains a 52bp deletion in the
COOH terminus, which causes a frame-shift in the coding sequence and
results in 12 variant residues at the COOH terminus. PCR analysis was
used to demonstrate that the nucleotides encoding this stretch of sequence
are not contained on a separate exon and can be spliced in (TRH-R412) or
out (TRH-R387) of the mRNA to produce two receptor proteins from one
gene. The 3' splice junction of this retained intron occurs at residue 392.
It was also shown that both the long and short form of the rat TRH-R can
be coexpressed in GH3 cells (de la Pena et al., 1992b).
The mechanisms by which specific exons can be spliced in and out
of genes is not currently understood, although it has been proposed that
the presence, or absence, of particular splicing factors in a cell directs the
preferential use of a particular set of exons (Smith et al., 1989 - Review;
Lees-Miller et al., 1990). This does not explain the ability of a cell to
produce more than one form of the same gene at the same time, as was
found for the long and short forms of the rat TRH-R (de la Pena et al.,
1992b).
Yet another TRH-R subtype has been isolated from a human
pituitary cDNA library (Duthie et al., 1993a - Chpt. 4, Yamada et al.,
1993) and human brain cDNA library (Matre et al., 1993). The human
pituitary and brain receptors are identical and share high sequence
homology with the rat and mouse TRH-Rs except at the 3' end of the
COOH tail. The human TRH-R also has residue 392 as a point of
sequence divergence, encoding 6 variant amino acids after this point.
The observation that the COOH tails of the rodent TRH-R subtypes
showed sequence variation at the same site (see Fig. 4.4 in Chpt. 4),
suggested that an alternative splicing mechanism may be responsible,
perhaps the variant COOH tails were encoded on separarate exons? The
obvious step was to clone a TRH-R gene to answer this question. The
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mouse gene was chosen rather than the rat or human genes since the long
term aim of the project was to study the gene in vivo using transgenic
animal models, and the mouse is generally the species of choice in
transgenic experiments. This chapter reports the cloning and
characterisation of a mouse TRH-R gene, and focuses on the region of
interest at the COOH tail.
6.2 Materials and methods
As for Chpt. 4, the general methods for isolating genes from commercially
prepared libraries has been described in Chpt. 3. This section deals,
therefore, only with specific information relevant to the cloning and
characterisation of the mouse TRH-R gene.
6.2.1 Screening an EMBL3 mouse genomic library
Mouse genomic DNA, (Mouse BALB/c Liver, Adult) digested with Sau3A
and cloned into the Bam HI site of the X vector EMBL3 SP6/T7 (Clontech)
was used to infect the Ecoli host strain NM538 (Clontech). Approximately
6xl05 plaques were screened by hybridisation with a 32P-labelled 2.5kb
fragment of a rat TRH-R cDNA clone (Sellar et al., 1993) as described in
Chpt. 3.2. Positive plaques were isolated following secondary screening
and bacteriophage DNA was purified as previously described (Chpt. 3.3).
6.2.2 Restriction digestion of putative clones
The X vector EMBL3 can accommodate inserts of between 8 to 22kb and to
determine the size of putative TRH-R clones, each one was digested with
Sacl, Xhol or Sfil and electrophoresed on a 0.7% agarose gel. Molecular
weight markers [A. digested with EcoRl/Hind III and pGEM (Promega),
Raoul™ and kBstEII (Appligene)], with fragments ranging from 48.5kb to
36bp were run alongside the genomic digests. The approximate size of the
insert was determined from the sum of the individual restriction
fragments, using a standard curve (determined by measuring the distance
run from the wells and the sizes of the marker fragments). Southern blots
of digested genomic clones were probed with 32P-end-labelled
oligonucleotide probes (Chpt. 3.7.4) corresponding to different regions of
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the mouse TRH-R cDNA to orientate the genomic clones with respect to
the cDNA sequence.
6.2.3 PCR analysis
To identify any intronic sequences, the putative TRH-R clones were
amplified by PCR (Chpt. 3.9) using sense and antisense oligonucleotides
based on the published mouse cDNA sequence (Straub et al., 1990). The
following PCR oligonucleotide primers were used: sense primer T1
(nucleotides -155 to -138) 5'dAACTTGGACCTATTAGCA3' and antisense
primer T2 (nucleotides 473 to 490) 5'dAGCAGGAAGAACCAGAGC3';
sense primer T3 (nucleotides 1030 to 1047)
5'dCTGCTAACTACAGTGTGG3' and antisense primer T4 (nucleotides
1255 to 1273) 5'dTGCCTGAAGACATCTGTTGC3'; sense primer T5
(nucleotides 1303 to 1322) 5'dAAGATTTTCAGCAACTTACG3' and
antisense primer T6 (nucleotides 1478 to 1495)
5'dCCAGTTCAAGATGTTCTT3'; sense primer T7 (nucleotides 208 to 229)
5'dGCTGATCTCATGGTCTTGGTGG3' and antisense primer T8
(nucleotides 767 to 789) 5'dGTGCTTCCTTGAAGATACTGTGC; sense
primer T9 (616 to 635) 5'dCTGGCCACTGTGCTTTATGG3' and antisense
primer T10 (nucleotides 858 to 878) 5'dGAGACAAATGAGTTGACAACC3';
sense primer Til (nucleotides 873 to 892)
5'dTCTCTCCAGCCCTTTCCAGG3' and antisense primer T12 (nucleotides
1148 to 1165) 5'dAGCAGGTGTCATCAAAGG3'; sense primer T13
(nucleotides 1477 to 1494) 5'dAAGAACATCTTGAACTGG3' and the
lambda vector (right arm) primer 5'dGGCCTCAAGGCCATTTAGG3'.
Sizes of the amplified PCR products were compared to the rat cDNA
sequence, amplified with the same primers as positive controls. Negative
controls contained no DNA. Mouse, rat and human genomic DNA
(Novagen) was also included, in some cases, to verify results.
6.2.4 Subcloning genomic DNA
The extremely large sizes of the genomic inserts and the X vector arms
(~20kb and ~8kb) made restriction digest and sequence analysis difficult.
In some instances, smaller sections of genomic DNA such as the 3'UTR,
were amplified by PCR and subcloned into the plasmid vector pCR™II
(Chpt. 3.4) to facilitate analysis.
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6.2.5 Genomic sequence analysis
To confirm that the isolated clones did encode the gene for the TRH-R, the
clones were sequenced both manually and using the ABI automated
sequencer (Chpt. 3.10). Sequencing of individual clones from the X vector
was performed manually, while sequencing of purified PCR products and
subcloned genomic fragments was performed on the ABI sequencer. The
computer program GeneJockey was used to analyse the sequence data.
6.2.6 The TRH-R gene in other species
Analysis of the TRH-R gene in other species was undertaken using a
commercially prepared 'ZOO-BLOT' (Clontech), a Southern blot containing a
panel of genomic DNAs (8pg DNA per lane) from nine eukaryotic species.
The DNA had been digested with the restriction enzyme EcoRl, run on a
0.7% agarose gel and transferred to a charge-modified nylon membrane by
Southern blotting. DNA was obtained from human, Rhesus monkey,
Spraque-Dawley rat, mouse (BALB/c), dog, cow, rabbit, chicken and yeast
(Saccharomyces cereuisiae ). All DNA had been isolated from the kidney
apart from the human, which was obtained from placenta.
The "ZOO-BLOT' was probed according to the manufacturer's
instructions, with a 32P random-primer labelled 1.2kb human TRH-R
cDNA purified PCR fragment (5Ti/3Tp), encompassing the coding region of
the TRH-R from nucleotides -18 to 1238 (see Chpt. 4.2.3).
6.3 Results
6.3.1 Isolation and restriction analysis of the mouse TRH-R gene
Several putative primary clones were initially isolated from a total of
6xl05 plaques screened. Restriction digestion with Sacl revealed that
clones 1, 2 and 10 were not single clones (Fig. 6.1). Following Southern
blotting the digests were probed with the rat 2.5kb TRH-R cDNA (data not
shown). Clones la, 2 and 10b failed to hybridise and were abandoned.
Clones lb and Id were identical, but had a different restriction pattern
from clone lc (Fig. 6.1), although all three hybridised positively to the rat
cDNA probe. Clones 9 (see Fig. 6.2), 4, 10a, and 12 all had different
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Fig. 6.1
Ethidium bromide-stained agarose gel showing Sacl restriction digests of putative TRH-
R genomic clones. (*) indicates those clones which subsequently hybridised to the rat
TRH-R 2.5kb cDNA probe following Southern blotting of the agarose gel. The numbers to
the left indicate standard DNA size markers (lane 1) in kilobases.
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Ethidium bromide-stained agarose gel showing restriction digestion analysis of clone 9.
The first three and last three lanes contain molecular weight markers. The numbers to
right and left represent the DNA size markers in kilobases.
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restriction patterns and all hybridised positively to the rat TRH-R (data
not shown).
Restriction digestion with Sacl estimated the size of clone 9 as
~19kb (Fig. 6.2) with the remaining 5 clones ranging from 14kb to 17kb,
[clone lb/Id (~14kb), clone lc (~15.5kb), clone 4 (~14kb), clone 10a
(~17kb), clone 12 (~16kb)], see Fig. 6.1. Southern blotting and
hybridisation with oligonucleotide probes representing different regions of
the mouse cDNA (Fig. 6.3) indicated that clone 9 contained ~18.5kb of
5'UTR and the coding region as far as a Sau3A restriction site at
nucleotide position 492 in the fourth transmembrane (TM) domain. The
remaining 5 clones spanned the 3' portion of the coding region and the
3'UTR. Hybridisation with oligonucleotides representing the coding
region from TM4 to TM6 gave confusing results and two further clones,
Clone 3 and Clone 7, were eventually isolated from the mouse genomic
library using a 52mer oligonucleotide, spanning nucleotides 528 to 569 of
the coding region (data not shown).
6.3.2 PCR analysis of the mouse TRH-R gene
To identify intronic sequences in the mouse gene, the entire coding region
of the gene was amplified by pairs of PCR primers and the sizes of the
amplified genomic fragments compared to amplified rat TRH-R cDNA
(Fig. 6.4). To ensure that there were no PCR or cloning artifacts,
particularly between TM4 and TM6, mouse, rat and human genomic DNA
was included in the PCR analysis (Fig. 6.5). An intron of approximately
645bp was detected in the 5'UTR between nucleotides -155 and +490 with
primers T1 and T2. A second intron of ~1800bp was identified between
nucleotides 1030 and 1273 with the PCR primers T3 and T4, and a third
intron of ~350bp was disovered between nucleotides 1303 and 1495 using
primers T5 and T6 (Fig. 6.4).
6.3.3 Sequence analysis of the mouse TRH-R gene
Sequence analysis of the 5'UTR region of the gene identified a consensus
splice site (Ohshima & Gotoh, 1987) at position -95, separating an
untranslated exon (putative Exon 1), from the coding region of the mouse
gene. Just over 440bp upstream from the ATG initiation codon were
manually sequenced, but no consensus promotor elements such as CAT
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Fig. 6.3
Southern blot analysis of TRH-R genomic clones digested with BamHl using
oligonucleotide probes based on the published mouse TRH-R cDNA sequence (Straub et
al., 1990). Fig. 6.3A: Ethidium bromide-stained agarose gel of BamHl-digested clones.
The rat TRH-R cDNA in lane 2 acted as the positive control. Fig. 6.3B: Southern blot of
gel in A, probed with an oligonucleotide representing nucleotides -155 to -138. Fig. 6.3C:
Southern blot of gel in A, probed with an oligonucleotide representing nucleotides 368 to
384. Fig. 6.3D: Southern blot of gel in A, probed with an oligonucleotide representing
nucleotides 1449 to 1466. The numbers to the left are standard DNA size markers in
kilobases.
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Fig. 6.4
(On following page)
Polymerase chain reaction (PCR) analysis of the mouse TRH-R gene indicating the
presence of introns. Fig. 6.4A: Diagram indicating the positions of the PCR primers
(indicated by arrows) relative to the mouse TRH-R cDNA sequence (Straub et al., 1993)
used to amplify the TRH-R genomic clones. The mouse TRH-R cDNA is indicated by a
thick line, PCR primers are represented by arrows, and genomic clones are represented
by thin lines. The dashed lines indicate unknown sequence. Fig. 6.4B: Ethidium
bromide-stained agarose gel of the PCR products amplified by the pairs of oligonucleotide
primers indicated in A. Lanes 2, 5, 7, 10, 14, 17, 20 and 23 show mouse genomic clone
template. Positive controls were performed using rat or human TRH-R cDNA clones as
the template (lanes 3, 8, 15, 18 and 21). Negative controls (lanes 4, 6, 9, 11, 16, 19, 22
and 24) had no DNA added to the reaction. Lanes 1, 12, and 13 contain molecular size
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Fig. 6.5
(On following page)
Polymerase chain reaction (PCR) analysis of the central region of the mouse TRH-R gene.
Fig. 6.5A: Diagram indicating the structure of the mouse TRH-R gene as deduced from
PCR analysis of genomic clones in Fig. 6.4. Exons are represented by boxes, the dotted
line represents the region of the gene between nucleotides 208 and 878 (transmembrane
domain 2 to transmembrane domain 6) amplified by the oligonucleotide primers T7
(nucleotides 208 to 229) and T10 (nucleotides 858-878). The exon corresponding to a
deletion in the rat TRH-R is depicted in red. Introns are represented by lines. Fig. 6.5B:
Ethidium bromide-stained agarose gel showing the PCR products amplified by the
oligonucleotide primers T7 and T10. MG = mouse genomic DNA, HG = human genomic
DNA, RG = rat genomic DNA. The human TRH-R cDNA (Duthie et al., 1993a) acted as a
positive control. Blank = negative control with no DNA added to the PCR reaction. The
numbers to the right are standard DNA size markers in kilobases.
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(CCAATCT) or TATA (TATAA) boxes were identified in the 5'UTR.
However, sequencing did reveal an interesting d(TG)i6.d(AG)2i
dinucleotide repeat sequence 351bp upstream of the ATG codon (Fig. 6.6).
The intron/exon boundaries of the second and third introns were
identified at positions 1176 and 1405 respectively (Fig. 6.5). Almost the
entire coding region of the gene (392 amino acids) appeared to be
contained on a single exon, Exon 2. The terminal amino acid (asparagine),
stop codon (TAA) and 222bp of 3'UTR were encoded by Exon 3, separated
from the rest of the coding region by the second intron (Fig. 6.6).
Sequencing several times in both directions confirmed the boundaries as
consensus splice junctions (Table 6.1).
The 3'UTR sequence in Exon 4 of the mouse gene revealed a region
with 87% homology to the nucleotides encoding the final 20 amino acids
and stop codon of the rat TRH-R412 (Fig.6.6 and Fig. 6.7). The 3'UTR did
not contain consensus sequences for polyadenylation (AATAAA), see Fig.
6.6.
6.3.4 The TRH-R gene in other species
A commercially prepared ZOO-BLOT (Clontech) containing genomic DNA
from nine eukaryotic species, digested with EcoRl, and Southern blotted,
was probed with a 32P-labelled PCR fragment representing the human
TRH-R coding region. The probe hybridised to human, monkey, rat,
mouse, dog, cow, rabbit, and chicken, but no signal could be detected in
yeast (Fig. 6.8). At least two restriction fragments were identified in each
species. The hybridisation signal detected in the chicken was low in
comparison to other species suggesting sequence divergence in the TRH-R
between mammals and birds.
6.4 Discussion
Analysis of the mouse TRH-R gene indicated at least four exons separated
by three introns. The first intron (~645bp) occurred at position -95 in the
5'UTR. The second intron (~1800bp) was found at position 1176,
separating the last amino acid (asparagine) and stop codon from the rest
of the coding region. The third intron (~350bp) was situated between
Exons 3 and 4 in the 3'UTR at position 1405 (Fig. 6.5). The mouse TRH-R
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Schematic representation of the mouse TRH-R showing the putative seven
transmembrane domain topology. The nucleotide sequences for the 5' untranslated
region (UTR) and 3'UTR are shown. The dinculeotide repeat in the 5'UTR is underlined.
Exon 3 (corresponding to a 228bp deletion in the rat TRH-R cDNA) is shown in bold
italics, and inlcudes the final asparagine codon (AAC) and stop codon (TAA) of the mouse
gene. Flanking intronic sequence is represented by lower case letters and dotted lines.
The mouse sequence homologous to the final 20 amino acids of the rat TRH-R COOH tail
is represented as triplet codons. This sequence could be translated if Exon 3 were
removed by alternative splicing. A potential stop codon (TGA) is underlined.
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Intron
Donor Acceptor Size (bp)
GAAGAG"96gtaagagaga.... ....ggcttttcacag-95 GGGAAA ~ 650
TCTGAG1176gtggcctttagt acttaccacag1177 AACTAA* -1800
ATGGAT1405gtgcgtactca tctctcttatag1406 AAAAAT -350
Table 6.1
Donor and acceptor splice junctions of the mouse TRH-R gene. Intronic sequences are
represented by lower case letters and dotted lines. The stop codon TAA is indicated by
(*).
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Fig. 6.7
(On following page)
Diagrammatic representation of the COOH terminus of the TRH-R gene. Introns are
represented by lines, exons are represented as boxes, stop codons are represented by (*),
arrows indicate the coding regions in mouse and rat TRH-R cDNA sequences. The red
box indicates Exon 3 of the mouse TRH-R gene which corresponds exactly to a 228bp
deletion in the rat TRH-R cDNA. The black box in Exon 4, from nucleotides 1406 to 1494
in the mouse gene has 87% homology with the rat cDNA sequence from nucleotides 1177
to 1265, also shown as a black box. Alternative splicing of the mouse Exon 3 (red box)
would remove the first stop codon (i*) and extend the 393 amino acid mouse receptor
protein into Exon 4. This would result in a 412 amino acid receptor with 95% homology
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Fig. 6.8
Southern blot hybridisation analysis of a panel of genomic DNAs isolated from several
species (Clontech - ZOOBLOT). The commercially prepared blot contained genomic DNA
digested with EcoRl. The blot was probed with a 3^p_ia};)enecj human TRH-R PCR
fragment representing the coding region of the human TRH-R from nucleotides -18 to
1238. The numbers to the left are standard DNA size markers in kilobases.
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gene therefore belongs to an increasing number of GPRs that contain
introns, for examples see Chpt 2.6.32.
The 5'UTR of the mouse TRH-R gene
Exon 1 was untranslated but did not appear to contain consensus sites for
promotor elements such as CAT or TATA boxes, suggesting that the
transcriptional start site was situated further upstream than the 440bp
sequenced. There may be further exons upstream of putative Exon 1 as
was found for the angiotensin II receptor (Curnow et al., 1992). Exon 1
did contain however, a repeat sequence d(TG)i6-d(AG)2i situated 351bp
upstream from the ATG initiation codon (Fig. 6.6). Alternating purine-
pyrimidine (APP) sequences such as the TG repeat, may allow DNA to
assume its lowest energy confirmation as Z-DNA (Rich et al., 1984). DNA
is polymorphic in structure, and can exist in conformations other than the
characteristic, right-handed helical B-DNA. Left-handed Z-DNA is the
best characterised of these alternative structures and is often found in
controlling regions of genes such as promotors and enhancers, (Schroth et
al.,1992). Alteration between B-DNA and Z-DNA requires negative
supercoiling of the helix which has been implicated in the modulation of
gene replication, transcription and recombination (Liu & Wang, 1987).
Genbank/EMBL database searches found at least twenty genes
with a d(TG)n.d(AG)n repeat, either in the same, or the reverse
d(CT)n.d(CA)n orientation, and many of the repeats were localised to
control regions. Regions containing similar dinucleotide repeats in both
the rat prolactin gene 5'UTR (Naylor & Clark, 1990) and the rat
ceruloplasmin gene 5'UTR (Fleming et al., 1992) were found to exert
negative effects on gene transcription, whilst a d(TG)n.d(AG)n repeat was
located in a 3' tissue specific enhancer region of the CD3-5 gene
(Georgopoulos et al., 1988). The rat substance P receptor, a member of the
GPR superfamily, also encoded a d(GT)n repeat in the 5'UTR and a
d(CT)n.d(CA)n repeat in the 3'UTR (Yokota et al., 1989), although its
function is unknown. Functional studies with reporter genes should help
to determine whether the d(TG) i6-d(AG)2i repeat in the mouse TRH-R
5'UTR plays a regulatory role in controlling gene transcription.
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Exon 3 of the mouse TRH-R corresponds to a deletion in the rat TRH-R
cDNA
The mouse TRH-R cDNA (Straub et al., 1990) encodes a putative protein
of 393 amino acids, and the long form of the rat TRH-R encodes a receptor
protein of 412 residues (Zhao et al., 1992; de la Pena et al., 1992a).
Although the rat cDNA encodes a longer protein, it actually contains a
228bp deletion relative to the mouse sequence. This 228bp deletion in the
rat corresponds exactly to Exon 3 of the mouse TRH-R gene, which
contains the stop codon (TAA) for the mouse receptor protein. Deletion of
this region in the rat sequence removes the stop codon resulting in a
longer protein of 412 amino acids encoding 20 amino acids after residue
392, as compared to the the mouse TRH-R cDNA, which encodes only one
residue after this point (Fig. 6.7).
Interestingly, the nucleotide sequence for the final 20 residues and
stop codon of the rat receptor is found encoded in the mouse gene at the
beginning of Exon 4 (Fig. 6.7). Splicing out Exon 3 of the mouse TRH-R
gene would remove the terminal amino acid (asparagine) and the stop
codon allowing the mouse gene to read directly into Exon 4. The
nucleotide sequence for the final 20 residues would then be in-frame with
the rest of the coding region, resulting in a mouse TRH-R protein of 412
amino acids with 95% homology to the rat TRH-R412 sequence (Fig. 6.7).
To date, only one form of the TRH-R has been isolated from the mouse,
and although there is no direct evidence, it is possible that the mouse gene
could produce at least two forms of TRH-R mRNA encoding different
COOH tails, as a result of alternative splicing. Alternative splicing has
been demonstrated in other GPR genes including the dopamine D2
receptor (Giros et al., 1989; dal Toso et al., 1989; O'Malley et al., 1990,
Mack et al., 1991), the angiotensin II receptor (Curnow et al., 1992), the
PACAP receptor (Spengler et al., 1993) and the prostaglandin EP3
receptor (Namba et al., 1993).
Until recently, functional signficance for such splicing events had
not been demonstrated, however alternative splicing in the third
cytoplasmic loop (CL3) of both the D2 receptor (Montmayeur et al., 1993),
(see Chpt. 7) and the PACAP receptor (Spengler et al., 1993) were shown
to affect G-protein coupling and second messenger activation. Of
relevance to the TRH-R gene, probable alternative splicing of the
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prostaglandin EP3 receptor occurs at the 3' end of the COOH tail (Namba
et al., 1993). There are at least four isoforms of the EP3 receptor, all
identical up to amino acid 358 and differing only at the 3' end of their
COOH tails in a similar manner to the TRH-R subtypes. These isoforms
were shown to have different specificities for coupling to G-proteins, but
identical ligand binding characteristics and it is possible that further
studies with the different TRH-Rs may produce similar findings.
Evolution of the TRH-R gene
Results obtained from Southern hybridisation of the human TRH-R cDNA
with a panel of genomic DNAs froma variety of species (zooblot) showed a
certain conservation of the TRH-R gene between mammals, and to a lesser
extent, birds, as the hybridisation signal was much lower in the chicken.
No signal was detected in yeast, although PCR analysis of the TRH-R
gene in different species (Murray-Mcintosh et al., 1993) did obtain a
positive result from yeast.
Mouse genomic DNA revealed two restriction fragments hybridising
to the human TRH-R probe indicating the presence of an EcoRl site
within the TRH-R gene (Fig. 6.8). No EcoRl sites have been reported
within the coding region of the mouse TRH-R (Straub et al., 1990), nor
were any EcoRl sites found within the 3 introns of the mouse TRH-R
gene. One possibility is that an unidentified intron exists within the gene.
This is unlikely as repeated PCR experiments with different sets of
primers failed to discover any introns other than at the COOH tail, and no
introns have been found within the coding region by others (M.C.
Gershengorn, personal communication, see Appendix IV). Alternatively,
the two bands could represent a restriction fragment polymorphism if the
mouse cDNA (Straub et al., 1990) was cloned from a different species than
the mouse gene, which was cloned from a BALB/c mouse.
The rat gene has been analysed by PCR (de la Pena et al., 1992b)
and no introns other than the retained intron in the coding sequence, have
been described. There do not appear to be any EcoRl sites within the
coding region of the rat TRH-R, but again, two restriction fragments were
obtained from the zooblot, raising similar possibilities as suggested for
the mouse gene above.
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The human TRH-R gene has recently been isolated by Yamada et
al. (1993) and has one intron in the third cytoplasmic loop. No intron was
described at the breakpoint residue 392 for the human TRH-R gene
vYamada et al., 1993) or the rat gene (de la Pena et al., 1992b). Three
EcoRl restriction fragments were detected in human (Fig. 6.8) and though
there are no EcoRl sites within the coding region of the human TRH-R,
these restriction sites may occur within the intron discovered in the third
cytoplasmic loop (Yamada et al., 1993). The TRH-R genes reported for the
three species, mouse, rat and human are quite different in organisation
(Fig. 6.9) and appear have diverged to a greater extent during evolution
than have the dopamine D2-R genes described in Chpt. 7.
TRH-R subtypes in vitro and in vivo
It has been shown that TRH-R-stimulation of TSH in thyrotrophs and
prolactin in lactotrophs occurs by different Ca2+-mediated mechanisms
(Geras et al., 1982) which suggests that subtypes of the mouse TRH-R
may exist and have yet to be discovered. An attempt to isolate other forms
of the mouse TRH-R from a lactotroph, rather than a thyrotroph, cell line
may provide interesting results.
The study of receptors cloned from tumour-derived cell lines and
the analysis of their second messenger systems in vitro may not reflect the
situation in vivo. Results obtained from transfection studies in
heterologous cell lines, such as COS-1 cells or 293 kidney fibroblast cells,
do not always agree with results obtained from cell lines expressing
endogenous receptors, such as GH3 cells, or from results obtained in vivo.
Yamada et al. (1992) found that TRH-R mRNA was downregulated by
thyroid hormones in vivo, but found no effect on downregulation of the
mRNA in GH3 cells, although TRH-Rs themselves were downregulated in
both systems. Ultimately, it will be necessary to study the regulation of
the TRH-R gene in an in vivo system. It may be possible to target the
mouse TRH-R gene to thyrotrophs or lactotrophs using tissue-specific
promoter elements such as the TSH or prolactin promoters, and then to
study the regulation of the TRH-R gene in transgenic mice.
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Fig. 6.9
Diagram comparing the reported organisation of the coding regions of the mouse, human
and rat TRH-R genes. Boxes indicate coding sequence, solid lines indicate intronic
sequence, the shaded box represents the 'retained intron' in the rat sequence, dashed
lines indicate untranslated regions.
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6.5 Summary
In conclusion, this chapter has reported the cloning and characterisation
of a gene encoding the mouse TRH-R focusing on the COOH tail region of
the receptor. Three introns of ~645bp, ~1800bp and ~350bp were
discovered within the gene. The putative first exon was untranslated and
almost the entire coding region of the receptor appeared to be contained
on Exon 2 except for the final amino acid and stop codon found on Exon 3.
The remainder of Exon 3 and Exon 4 encoded 3' untranslated sequence.
The lack of promotor elements or a poly A tail allows the possibility of
further exons up or downstream of those reported. The mouse TRH-R
cDNA is highly homologous to the rat and human TRH-Rs except at the
COOH tail where the terminal amino acids show sequence divergence
after residue 392. The rat TRH-R412 subtype encodes 20 amino acids after
this point and the nucleotide sequence for these residues was found to be
encoded by Exon 4 of the mouse gene. Exon 3 of the mouse TRH-R
corresponds exactly to a 228bp deletion in the rat cDNA. A splicing event
in this region of the mouse gene would produce the same deletion in the
mouse TRH-R as occurs in the rat TRH-R412, resulting in a mouse TRH-
R412 with 96% homology to the rat TRH-R412 receptor. It is possible that
more than one form of mouse TRH-R may be produced from the TRH-R
gene by alternative splicing of the mRNA.
7 Structural analysis of the mouse
dopamine D2 receptor gene
7.1 Introduction
Dopamine was initially considered to be only a precursor in the
catecholamine pathway, however it is now known to be an important
neurotransmitter and neurohormone in its own right, exerting its effects
through multiple dopamine receptor subtypes (Kebabian & Calne, 1979;
Civelli et al., 1991; Civelli et ah, 1993). In the anterior pituitary gland,
dopamine plays an important role in reproduction by inhibiting the
release of prolactin from lactotrophs (Chpt 2.5), and dopamine agonist
therapy can be used to treat prolactin-secreting adenomas of the pituitary
(Bevan et al., 1992). Dopamine is also associated with neurological
disorders such as Parkinson's disease, schizophrenia, susceptibility to
drug abuse and alcoholism. The involvement of dopamine in the
pathophysiology of these neuronal and endocrine disorders has resulted in
intensive research into the biochemistry, pharmacology and, more
recently, the molecular biology of the dopamine receptors.
By 1979, the dopamine receptors had been classified as Dl-like and
D2-like receptors (Kebabian & Calne, 1979) on the basis of their
biochemistry and pharmacology (Chpt 2.4.8) however, the advent of
molecular cloning techniques revealed multiple dopamine receptor
subtypes. Dopamine receptors belonged to the G-protein-coupled receptor
(GPR) family, as both Dl-like and D2-like receptors were known to
interact with G-proteins to induce second messenger systems (Vallar &
Meldolesi, 1989; Civelli et al., 1993). The dopamine D2 receptor (D2-R)
was the first to be cloned in 1988 (Bunzow et al., 1988) using an approach
based on the transmembrane sequence homology observed between
members of the GPR family. The hamster (3-adrenergic receptor (PAR)
was used as a hybridisation probe to isolate a 415 amino acid D2-R from a
rat brain cDNA library. The molecular cloning of the rat D2-R cDNA
launched a new approach to dopamine receptor research by making it
possible to isolate receptor subtypes that could not be detected by ligand-
binding techniques. The subsequent characterisation of four more
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dopamine receptor genes has shown that the dopamine receptor family is
indeed more diverse than the original D1/D2 receptor classification.
Soon after the isolation of the rat brain D2-R cDNA, a second
isoform of the D2-R was detected in rat pituitary (Eidne et al., 1989), rat
brain (Rao et al., 1990), bovine brain (Chio et al., 1990), human brain
(Grandy et al., 1989) and human pituitary (Dal Toso et al., 1989). This
second form of the D2-R (D2-R444) was longer by 29 amino acids which
were encoded on a separate exon. This extra exon was inserted in the
third cytoplasmic loop of the receptor, a domain that had been implicated
in receptor coupling to G-proteins (Dixon et al., 1988). The two forms of
the D2-R were shown to be alternatively spliced versions of the same gene
(Giros et al., 1989; Monsma et al., 1989; Dal Toso et al., 1989; O'Malley et
al., 1990) and it was proposed that this event was possibly a selective
mechanism for coupling to different G-proteins and activating different
signalling pathways. There was considerable evidence that the D2-R
could couple to the phosphoinositide (PI) pathway as well as to the cAMP
pathway (Kebabian & Calne,, 1979; Senogles et al., 1987; Ohara et al.,
1988; Vallar & Meldolesi, 1989; de Keyser et al., 1989; Elazar et al., 1989),
lending support to this theory.
Expression studies with the long (D2-R444) and short (D2-R415)
forms of the dopamine D2-R demonstrated that the two isoforms appeared
to coexist in all regions of the brain and pituitary studied. The relative
proportions of the two isoforms varied in different reports, but all agreed
that the D2-R444 was the most abundant transcript in the pituitary (Giros
et al., 1989; Dal Toso et al., 1989; O'Malley et al., 1989). The genomic
structure of the rat (Giros et al., 1989; O'Malley et al., 1990) was then
characterised and was found to be encoded by 8 exons. The first exon was
untranslated and was separated from the coding region of the gene by a
large (>25kb) intron. Chromosome walking techniques were unable to
close the gap between the first and second exons, and the size of this first
intron was undetermined at this time. The remaining 7 exons were
clustered together, spanning approximately 13kb of the genome and the
alternatively spliced 29 amino acids were encoded by exon 6.
Linkage of the dopamine D2-R to several neuronal and endocrine
human pathologies underlines the importance of obtaining detailed
information regarding the structure-function relationships of this gene,
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and the regulation of its two isoforms. Ultimately, the creation of
transgenic animal models of human D2-R-related diseases may be
possible. As discussed in Chpt. 6 for the mouse TRH-R gene, the eventual
aim of this project was to examine the functioning of the D2-R gene using
transgenic mice. Constructs created from the D2-R gene driven by the
prolactin promotor could be used in an attempt to specifically target
lactotrophs of the anterior pituitary. As the first step in this process, the
cloning and characterisation of the mouse D2-R gene was undertaken, the
mouse being the species of choice for the creation of transgenic animal
models.
7.2 Materials and methods
The mouse D2 receptor (D2-R) gene was cloned from a commercially
available genomic library as described in the general materials and
methods section in Chpt. 3. This section will, therefore, only give specific
details regarding the library, host cells and probe used to isolate the gene.
7.2.1 Screening an EMBL3 mouse genomic library
A commercially prepared library of mouse genomic DNA (Mouse BALB/c
Liver, Adult) cloned into the Bam HI site of the X vector EMBL3 SP6/T7
(Clontech) was used to infect the Ecoli host strain NM538 (Clontech).
Approximately 6xl05 plaques were screened with a 32P-labelled 3kb
EcoRl-digested fragment of the rat dopamine D2-R cDNA, isolated as
described previously (Eidne et al., 1989). The probe was double-labelled
with both a32P dCTP and oc32P dATP. Positive plaques were isolated and
purified as described in Chpt. 3.3.
7.2.2 Restriction digestion of positive clones
To determine the size of each clone, purified bacteriophage DNA was
digested with the restriction enzymes Xhol and Sacl, which released the
genomic insert. The digested clones were electrophoresed on a 0.7%
agarose gel (Chpt. 3.7), Southern blotted (Chpt. 3.7.4) and reprobed with
the rat D2-R cDNA probe to confirm the presence of positively hybridising
clones. The X vector EMBL3 can accommodate inserts ranging from 8 to
22kb and high molecular weight markers (X EcoRl/Hindlll [Promega])
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ranging from 21.2kb to 125bp, were run alongside the digested clones. A
standard curve was used to determine the sizes of the restriction
fragments. In an attempt to map the gene, one of the positive clones was
chosen for further digestion with BamHl, EcoRl and Xhol, Southern
blotted and probed with 32P-end-labelled oligonucleotides (Chpt. 3.8.5)
corresponding to each of the 8 D2-R exons in the rat. The oligonucleotides
were chosen by referring to the published rat D2-R genomic structure
(O'Malley et al., 1990).
7.2.3 PCR analysis
To compare the mouse D2-R gene with the rat D2-R gene, the genomic
clones were amplified by PCR (Chpt. 3.9) using primers that would
amplify the introns described by O'Malley et al. (1990). The following
primers were used: Intron 2: sense primer 2B (nucleotides 157 to 173)
5'dGTGCTGGTGTGCATGGC3' and antisense primer 3A (nucleotides 311
to 328) 5'dAGATGTCACAGTGAATCC3'; Intron 3: sense primer 3B
(nucleotides 323 to 340) 5'dACATCTTTGTCACTCTGG3' and antisense
primer 4A (nucleotides 480 to 497) 5'dATGGTGAAGGACAGGACC3';
Intron 4: sense primer 4B (nucleotides 430 to 447)
5'dACAGCTACAGCTCCAAGC3' and antisense primer 5A (nucleotides
615 to 632) 5'dTTGATATAGACCAGCAGG3'; Intron 5: sense primer 5B
(nucleotides 565 to 582) 5'dTTCGTGGTCTACTCCTCC3' and antisense
primer 6A (nucleotides 744 to 765) 5'dAACGGTGCAGAGTTTCATGTCC3';
Intron 6: sense primer 6B (nucleotides 742 to 762)
5'dGAGGACATGAAACTCTGCACC3' and antisense primer 7A
(nucleotides 1085 to 1102) 5'dTCTGCTGGGAGAGCTTCC3'; Intron 7:
sense primer 7B (nucleotides 1025 to 1042)
5'dTTGAGATCCAGACCATGC3' and antisense primer 8A (nucleotides
1157 to 1174) 5'dTGAAGAAGGGCAGCCAGC3'.
7.2.4 Genomic sequence analysis
The purified PCR fragments (Chpt. 3.9) were sequenced several times in
both directions using the automated ABI DNA sequencer (Chpt. 3.10) to
confirm the positions of the splice junctions at the intron/exon boundaries.
The computer program GeneJockey was used to analyse the sequence
data.
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7.3 Results
7.3.1 Isolation and restriction analysis of the mouse D2-R gene
Fourteen positively hybridising clones were initially isolated from the
mouse X EMBL3 genomic library, but only five hybridised to the D2-R
cDNA probe following restriction digestion and Southern blotting (Fig.
7.1). Restriction digestion analysis of purified DNA with Xhol and Sacl
indicated that all five clones were approximately 12kb in size (Fig. 7.2).
Southern blots of the digested clones were probed with oligonucleotides
representing each of the eight exons as reported in the rat D2-R gene
(O'Malley et al., 1990) and results showed that none of the clones
represented Exon 1 of the D2-R. Clone 7 consisted of Exon 2 and
approximately lOkb of intron 1. The other four clones hybridised
positively to oligonucleotides for Exons 2 to 8 (Fig. 7.3). A restriction map
of the mouse D2-R gene as encoded by these five clones was derived from
digestion with BamHl, EcoRl, and Xhol (Fig. 7.3).
7.3.2 PCR analysis of the mouse D2-R gene
PCR amplification of the positive clones indicated that the mouse D2-R
gene is organised in the same way as the rat and human genes (Fig. 7.4),
intron sizes varying only slightly (Table 7.1). Intron 2 proved too large
(>4kb) to amplify by PCR and its size was determined from restriction
digestion analysis. Exons 2 to 8 of the mouse D2-R gene were clustered in
approximately 11 to 12kb of the genome.
7.3.3 Sequence analysis of the mouse D2-R gene
The intron/exon boundaries of the purified PCR fragments were sequenced
and were found in the same positions as the rat (O'Malley et al., 1990) and
human (Gandelman et al., 1991) D2-R genes. Like the rat, but unlike the
human gene, the mouse D2-R had a variant donor splice site between
Exons 4 and 5, with a gc instead of the more usual gt dinucleotide
(Ohshima & Gotoh, 1987) as the first two nucleotides of the intron (Table
7.1). The initiation codon was found in Exon 2, following 30bp of 5'
untranslated region (5'UTR) and the termination codon occurred at
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Restriction digestion and Southern blot analysis of one dopamine D2-R genomic clone.
Fig. 7.1A: Ethidium bromide-stained agarose gel showing clone 11 digested with Xhol
and Sacl to release the genomic insert from the X EMBL3 vector. The numbers to the
left indicate standard DNA size markers in kilobases. Fig. 7. IB showing the Southern
blot is on the following page.
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Restriction digestion and Southern blot analysis of one dopamine D2-R genomic clone.
Fig. 7.IB: Autoradiograph of Southern blot hybridisation of clone 11. The DNA was
digested as indicated in Fig. 7.1A, blotted and probed with the 32P-labelled 3kb rat
dopamine D2-R cDNA (Eidne et al., 1989). The numbers to the left indicate standard
DNA size markers in kilobases.
\
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Ethidium bromide-stained agarose gel showing the five dopamine D2-R genomic clones
digested with Sacl. The numbers to the left indicate standard DNA size markers in
kilobases.
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Restriction mapping of the mouse dopamine D2-R gene. Fig. 7.3A: Organisation and
restriction map of the mouse dopamine D2-R gene showing the regions spanned by the
isolated genomic clones determined by restriction digestion with Xhol (X), EcoRl (E) and
BamHl (B). The exons were ordered on the restriction map using Southern blot analysis
as depicted in Fig. 7.3B on the following page. Exons are represented by boxes, the
alternatively spliced exon (Exon 6) is shown in red. Fig. 7.3B: Autoradiograph showing
Southern blot hybridisation of genomic clone 8 to end-labelled oligonucleotide probes
spanning the intronic sequence of the dopamine D2-R gene. The nucleotides represented
by each probe were as follows: (i) Exon 2 [165 to 182]; (ii) Exon 3 [292 to 309]; (iii) Exon 4
[502 to 519]; (iv) Exon 5 [615 to 632]; (v) Exon 6 [744 to 765]; (vi) Exon 7 [993 to 1010;
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Fig. 7.4
Polymerase chain reaction (PCR) analysis of the mouse dopamine D2-R gene indicating
the presence of introns: Fig. 7.4A: Diagram indicting the positions of the PCR primers
(indicated by arrows) used to amplify the D2-R genomic clones. Introns are represented
by lines and exons by boxes. Fig. 7.4B: Ethidium bromide-stained agarose gel showing
PCR products amplified by the primer pairs in Fig. 7.4A. The pairs of PCR primers used
were as follows: Intron 3 [3B/4A]; Intron 4 [4B/5A]; Intron 5 [5B/6A]; Intron 6 [6B/7A];
Intron 7 [7B/8A], see text for details. cDNA = rat D2-R cDNA (Eidne et al., 1989) as
positive control, no DNA = negative control. The numbers to the right indicate standard
DNA size markers in kilobases.
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Donor and acceptor splice junctions of the mouse dopamine D2 receptor gene. Intron
sequences are represented by lower case letters and dotted lines. The variant donor
splice junction is in bold type.
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position 1333 in Exon 8. The remainder of Exon 8 represented 3'
untranlsated region.
7.4 Discussion
Organisation of the mouse gene:
This chapter has reported the cloning of the mouse dopamine D2-R gene
spanning approximately 12kb of the genome and including 7 exons
interrupted by 6 introns. The first untranslated exon was not identified.
Reports of both the rat (O'Malley et al., 1990) and human (Gandelman et
al., 1991) genes described a large (greater than 25kb) intron between
Exons 1 and 2, and neither group obtained any overlapping clones in this
region, despite extensive walking along the gene. The mouse D2-R gene
structure was published during this project (Mack et al., 1991) and was
also found to have a large intron in this region. More recently, a paper
reporting the structure and linkage relationships of the human D2-R gene
(Eubanks et al., 1992) indicated that the D2-R gene extends over 270kb in
the human, with the first intron encompassing approximately 250kb. The
positions of all introns in the D2-R gene are conserved between the rat,
mouse and human (Fig. 7.5) and this close structural relationship between
the D2-R genes of the three species suggests that the rat and mouse may
also encode similarly large first introns. Interestingly, the human D2-R
also appeared to contain 'nested' genes, ie. genes transcribed from within
the region of the genome spanned by the D2-R (Eubanks et al., 1992).
Like the rat gene (O'Malley et al., 1990), the mouse gene encodes a
variant donor splice site at the end of Exon 4 (a gc dinucleotide instead of
the consensus gt). Detailed analysis by O'Malley et al. (1990) confirmed
that this gc dinucleotide was an active splice junction and not a cloning or
sequencing artefact. Mack et al., (1991) also reported a gc donor site for
the mouse D2-R. The human gene encodes the usual gt dinucleotide at
this position (Gandelman et al., 1991).
The D2-like genes (D2, D3 and D4) all contain introns, while the
Dl-like genes (D1 and D5) do not (Civelli et al., 1993). The intronic
dopamine receptor genes are closely related to one another and also
appear to be related to other members of the GPR superfamily such as
rhodopsin (Nathans & Hogness, 1984), the opsins (Nathans et al., 1986),
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Fig. 7.5
Comparison of the organisation of mouse (Duthie, unpublished results; Mack et al.,
1991), human (Gandelman et al., 1991) and rat (O'Malley et al., 1990) dopamine D2-R
genes. Exons are represented by boxes, introns are represented by lines. Shading
indicates untranslated sequence. The alternatively spliced Exon 6 is depicted in red.
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the substance K receptor (Gerard et al., 1990) and the substance P
receptor (Gerard et al., 1991), based on the conserved positions of several
of their introns (Probst et al., 1992).
Alternative splicing of the mouse D2-R gene
Analysis of the mouse D2-R gene indicated that the extra 29 amino acids
found inserted in the third cytoplasmic loop of the D2-R444 (Eidne et al.,
1989; Giros et al., 1989; Rao et al., 1990; Chio et al., 1990; Grandy et al.,
1989; Dal Toso et al., 1989; O'Malley et al., 1990) was encoded on a
separate exon, Exon 6 (Fig. 7.4), as was found for the rat and human
genes. Mack et al. (1991) used reverse-transcriptase PCR to demonstrate
that Exon 6 could be transcribed or alternatively spliced out, to produce
either a D2-R444 or D2-R415 in the mouse. They found that in the mouse,
the long form of the receptor was predominant in brain, and could detect
no expression of the short form of the receptor in mouse pituitary, a
similar finding was reported in the rat (Eidne et al., 1989). Other groups,
however, have found both isoforms in the pituitary in human (Dal Toso et
al., 1989), rat (Giros et al., 1989; O'Malley et al., 1990) and mouse
(Montmayeur et al., 1991) with the long form as the most abundant
transcript.
The presence of an extra 29 amino acids in the third cytoplasmic
loop does not appear to influence ligand recognition by the D2-Rs (Grandy
et al., 1989; Giros et al., 1989), but is more likely to affect G-protein
coupling, as this region has been implicated in second messenger
activation by GPRs (see Chpt. 2.6.18). The Dl-like and D2-like receptors
each activate two types of signal transduction pathways. One is
obligatory and is found in all cell types in which the receptor is expressed.
The other depends on the cellular background of the receptor (Vallar et
al., 1990; Civelli et al., 1993). The obligatory pathway for the D2-Rs
involves inhibition of adenylate cyclase activity via the G-protein, Gaj. In
GH4C1 pituitary tumour cells, the D2-R inhibits adenylate cyclase, does
not affect phosphoinositide hydrolysis, and induces a decrease in [Ca2+]j
due to a hyperpolarising effect mediated by the activation of K+ channels.
In Ltk- cells, the activated D2-R produces an increase in [Ca2+]j, partly
due to the release of Ca2+ from intracellular Ca2+ stores following the
stimulation of the PI pathway, and partly due to an influx of extracellular
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Ca2+ (Civelli et al., 1993). In Chinese hamster ovary cells (CHO cells), D2-
Rs mediate the release of arachidonic acid by a mechanism involving
protein kinase C, independently of the inhibition of adenylate cyclase
(Kanterman et al., 1991). This ability to activate different second
messenger pathways implies that the D2-R either couples to one G-protein
that can activate multiple second messenger pathways, or that the
receptor can couple to more than one G-protein (Birnbaumer, 1990;
Milligan, 1993), see Chpt .2, Fig. 2.10.
A recent study reported that the extra 29 amino acids in the long
form of the D2-R allow the receptor to couple to a specific G-protein
isoform, Goc^ (Montmayeur et al., 1993). This confirms that the two D2-R
isoforms are functionally distinct, exerting their specific effects at the
level of intracellular signalling.
The D2-R and disease
One of the major reasons for cloning and characterising the D2-R gene is
related to the importance of the D2-R in several disease states. The D2-R
has been implicated in the pathogenesis of some pituitary tumours such as
prolactin-secreting adenomas (prolactinomas). Hyperprolactinaemia can
lead to infertility as high levels of prolactin result in the partial
suppression of GnRH release and loss of GnRH pulsatility. High levels of
prolactin also interfere with the action of LH and FSH on the gonad, cause
an increase in adrenal androgen secretion and result in the inhibition of
positive oestrogen feedback on GnRH and LH secretion in women (Fig.7.6)
(Thorner, 1987).
Most prolactinomas respond to dopamine agonists, such as
bromocriptine, as shown by a decrease in prolactin release and by the
inhibition of tumour growth (Bevan et al., 1992). Some tumours
(approximately 11%) however, do not shrink in response to dopamine
agonist therapy (Bevan et al., 1992) although many of these do show a
reduction in prolactin secretion. A study by Pellegrini et al., (1989) found
that 5 resistant prolactinomas had reduced numbers of D2-Rs, and also
that dopamine unusually stimulated adenylate cyclase in these tumours.
Disruptions at different stages in the dopaminergic regulation of prolactin
secretion may be responsible for tumours that are resistant to dopamine
therapy. Mutations in the D2-R itselfmay affect ligand-binding or cause
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Fig. 7.6
Mechanisms of hyperprolactinaemic hypogonadism. Hyperprolactinaemia causes
hypogonadism by several mechanisms: (i) High prolactin (PRL) levels lead to partial
suppression of GnRH release, as well as loss of its pulsatility, and (ii) prolactin also
interferes with the action of LH and FSH on the gonad, (iii) Prolactin causes an increase
in adrenal androgen secretion, and (iv) leads to inhibition of positive oestrogen feedback
on GnRH and LH secretion. PIF = prolactin inhibiting factor, PRF - prolactin releasing
factor (from Thorner, 1987).
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the receptor to activate Gp instead of Gj, resulting in the stimulation of
adenylate cyclase instead of its inhibition. If an aberrant receptor is
involved in the pathogenesis of such tumours, it is imperative to first
understand the organisation of the normal gene.
The D2-R has also been implicated in neuronal disorders including
Parkinson's disease, schizophrenia, manic depression, and susceptibility
to drug abuse and alcoholism (Civelli et ah. 1991: Civelli et al.,1993). The
identification of restriction fragment length polymorphisms in the D2-R
gene has been used to look for linkage relationships between the D2-R and
these pathologies (Uhl et ah, 1993; Iversen, 1993). There is no direct
evidence that schizophrenia is associated with the D2-R, although some
recent research has implicated the D4-R. a D2-hke receptor (Seeman et
ah, 1993). Alcoholism does appear to be linked to the D2-R (Blum et ah,
1993) although the evidence is still controversial. Direct sequencing of
DNA from patients suffering from alcoholism and comparison with the
sequence and organisation of the normal gene may reveal mutations in
the D2-R. 11 would then be informative to look at similar mutations in
mouse models of these human diseases.
7.5 Summary
This chapter has reported the cloning and organisation of the mouse
dopamine D2-R gene. The coding region of the gene spans approximately
12kb of the mouse genome and consists of 7 exons (Exons 2 to 8)
interrupted by six introns. The untranslated Exon 1 was not identified. It
is reported to be separated from the rest of the gene by a very large intron
(greater than 250kb in the human) thus it is technically impossible to
isolate the entire gene in one clone. The positions of all introns are
conserved between the mouse, rat and human D2-Rs. All three species
are capable of alternative splicing of Exon 6 which encodes 29 extra amino
acids in the third cytoplasmic loop, a region implicated in G-protein
coupling. Knowledge of the sequence and organisation of the D2-R will he
useful in comparing the genes from patients suffering from the various
neuronal and endocrine pathologies associated with the D2-R. The mouse
may prove a useful animal model for studying some of these diseases.
8 General Discussion
The molecular cloning of increasing numbers of G-protein-coupled
receptors and their subtypes has had an enormous impact on the
understanding of the systems in which they operate. GPRs are involved
in transducing signals to every major system in the body, and are often
targets for drugs used in the clinical therapy of a wide variety of human
diseases. Much of the research in the GPR field has been stimulated by
pharmaceutical companies interested in developing drugs that act as
selective agonists or antagonists for specific receptors. This requires
specialist knowledge of the structure/function relationships of the GPRs
with their ligands and second messenger pathways.
The GPRs described in this thesis, the TRH-R and dopamine D2-
R, occupy key positions in physiological, and potentially pathological,
systems and there is an obvious need for the development of selective
agonists and antagonists for clinical use. It is important to study the
structure/function relationships of human, as well as animal receptors, as
relatively minor differences in the binding site of GPRs can affect the
response of the receptor to a particular drug. The replacement of one
amino acid residue between the human and rat serotonin 5-HTib
receptors produced major pharmacological variation in the responses of
the two receptors (Oksenberg et al., 1992). Sequence information from
human GPRs is also critical when looking for receptor mutations that
cause human disease, such as the constitutively activating mutations in
the TSH-R (Parma et al., 1993) and LH-R (Shenker et al., 1993) discussed
in Chpt. 2.6.30.
The cloning and characterisation of the human TRH-R (Chpt. 4)
has revealed significant primary sequence differences in the cytoplasmic
COOH tail of the receptor as well as minor differences at the extracellular
NH2 terminus and in the third cytoplasmic loop with respect to the
published rodent TRH-R sequences. Stable expression of the receptor in a
transfected cell line is one of the first steps towards studying its
structure/function relationships, and will allow comparisons to be made
between the different TRH-R subtypes. Site-directed mutagenesis of the
putative ligand binding domain in combination with radio-labelled binding
studies will then provide further information as to exactly which residues
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are involved in mediating the effects of agonists, antagonists and partial
agonists. The action of some ligands as partial agonists is reported to be
species-specific (Freidinger, 1989) further emphasising the importance of
studying the human receptor.
Once the primary DNA sequence is known the 3-dimensional
structure of GPR binding domains can be studied by molecular modelling
using the reported structure of the seven transmembrane protein,
bacteriorhodopsin (Henderson et al., 1990) as a reference protein. There
are some limitations involved in using this approach: bacteriorhodopsin
does not couple to G-proteins and there is no apparent sequence homology
between this protein and GPRs. The mammalian opsins, however, are G-
protein-coupled and are activated in the same way as bacteriorhodopsin
(Ovchinnikov, 1982). Although major advances towards understanding
the 3-dimensional interactions of receptors with their ligands has been
achieved in this way, the models provide only a static picture of the
receptor. A recent suggestion was that GPRs are not static molecules, but
exist in a dynamic equilibrium. The 7 transmembrane helices are
proposed to 'wobble' around hinge residues such as glycines or prolines
found in key positions in the middle of some of the a-helices. The
connecting extracellular and cytoplasmic loops act as structural buffers to
maintain the equilibrium. In this model, ligand-binding might trigger a
chain of reactions that disturbs the equilibrium, causing the receptor to
adopt another stable conformation that allows G-protein coupling (Hibert
et al., 1993).
Ligand binding analysis of the human TRH-R may help to develop
non-peptide ligands that could be used in clinical practice. As a peptide,
TRH has a short half-life and is rapidly degraded by metabolic peptidases.
Non-peptide ligands with greater stability, oral availability and longer
duration of action than endogenous TRH would therefore be useful. Most
of the successes in this field have been achieved with peptides that bind to
GPRs including the development of synthetic, non-peptide analogues for
somatostatin and GnRH, the opioids and gastrin/cholecystokinin
(Freidinger, 1989).
TRH and DA have functions other than their roles as
hypothalamic releasing/inhibiting factors. Dopamine functions as a
classical neurotransmitter in the central nervous system and may also
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function in the heart and kidney (Civelli et al., 1993 for review). TRH
appears to be widespread throughout the nervous system, gastro¬
intestinal system and reproductive tracts (Jackson, 1982; Sharif, 1985;
Scanlon & Hall, 1989 for reviews). The TRH-R has been localised to rat
(Zabavnik et al., 1993) and human brain (Eymin et al., 1993), rat retina
(Satoh et al., 1993), testis (Feng et al., 1993) and human prostate (Chpt. 5)
using Northern analysis and in situ hybridisation techniques. When
considering analogue design for these receptors it is important to develop
ligands that will activate only one particular pathway without affecting
others. Obviously it is important to clone the receptors from these varied
locations and to compare them with the known pituitary receptors as
there may be significant differences that can be utilised. A human brain
TRH-R does appear to be identical to the pituitary receptor (Matre et al.,
1993), but it is equally possible that other receptor subtypes exist.
In the pituitary gland both DA and TRH appear to operate
through more than one receptor subtype. There are at least two forms of
the TRH-R in the rat pituitary generated by alternative splicing of a
retained intron (de la Pena et al., 1992b), and one subtype each in mouse
(Straub et al., 1990) and human (Duthie et al., 1993a, Martre et al., 1883;
Yamada et al., 1993) with the possibility of further unidentified subtypes
in these species. The D2-R expresses two receptor subtypes in the
pituitary generated by alternative splicing of the D2-R gene (Eidne et al.,
1989; Giros et al., 1989; Rao et al., 1990; Chio et al., 1990; Grandy et al.,
1989; Dal Toso et al., 1989; O'Malley et al., 1990). DA and TRH are both
capable of coupling to more than one second messenger pathway and there
appears to be some form of cross-talk between the signalling systems
activated by the two hormones, with respect to the regulation of prolactin
secretion from pituitary lactotrophs (de la Escalera et al., 1992). The
dissociation of DA from its receptor and the subsequent activation of the
adenylate cyclase signalling pathway appears to potentiate the
stimulatory effect of TRH on prolactin secretion (de la Escalera et al.,
1992).
DA and TRH receptors are also expressed in pituitary thyrotrophs
where they regulate the secretion of TSH. Prolactin and TSH secretion
are not linked physiologically and so there must be specific factors in each
cell type regulating the expression of these receptors and their signalling
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pathways. It is also possible that there are different DA and TRH
receptor subtypes operating in the two cell types to allow for the
differential regulation of prolactin and TSH. Experiments have indicated
that TRH stimulation of prolactin and TSH secretion appears to operate
via different calcium-mediated mechanisms in lactotrophs and
thyrotrophs respectively (Geras et al., 1982).
The cloning strategies employed to isolate these pituitary
receptors have made it difficult to determine conclusively whether
lactotrophs and thyrotrophs express different receptor subtypes. For
example, the mouse TRH-R393 (Straub et al., 1990) was cloned from a
thyrotroph cell line that produces TSH (TtT cells), while the two forms of
the rat receptor, TRH-R412 and TRH-R387 (de la Peha et al., 1992b) were
isolated from a clonal tumour cell line that secretes prolactin and growth
hormone (GH3 cells). A third form of the rat receptor, TRH-R411, was
isolated from a pituitary cDNA library (Sellar et al., 1993) as was the
human TRH-R398 (Duthie et al., 1993a; Yamada et al., 1993). These cDNA
libraries, prepared from pituitary tissue, should represent transcripts
expressed in more than one pituitary cell type, making it impossible to
distinguish between lactotrophs and thyrotrophs. A human TRH-R was
also isolated from a human brain cDNA library (Matre et al., 1993) but
the brain is a large tissue with so many different cell types that it is
impossible to represent all expressed transcripts in a single library.
Northern blot analysis cannot be used to solve the problem either, and can
only confirm that more than one receptor subtype is expressed in the
pituitary as was found for both the DA-R and TRH-R.
Most functional studies with the TRH-R have been performed in
GH3 cells in which TRH stimulates the secretion of prolactin by activating
the phosphoinositide intracellular signalling pathway via the G-proteins,
Gq/Gn (Hsieh & Martin, 1992). TRH has also been shown to activate the
adenylate cyclase second messenger system via the stimulatory G-protein,
Gs (Paulssen et al., 1992). It is becoming apparent that the genetic
background of the host cell into which a receptor is transfected can greatly
influence the signalling systems activated (Buckley et al., 1990; Milligan,
1993). In the case of the D2-R, the same transfected receptor can couple
to the PI pathway or the adenylate cyclase pathway depending on the
background of the host cell (Vallar et al., 1990), see discussion in Chpt. 7.
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There are not only multiple subtypes for different receptors, but multiple
subtypes of each of the components of the different signalling pathways
within the cell. The regulation of gene expression is one of the central
means of controlling metabolic pathways in a temporal and tissue-specific
manner and each cell-type is likely to have a specific pattern of expression
of receptor subtypes, G-proteins and effector enzymes.
Another problem observed with the use of clonal cell lines in
receptor analysis is the commonly observed over-expression of a particular
receptor with respect to the in vivo situation (Buckley et al., 1990). High
levels of receptor expression may distort the signalling responses in the
cell making it difficult to draw relevant conclusions from functional data.
In the case of TRH, the activation of large numbers of receptors could
result in the cell being flooded with calcium, overloading the system, and
disturbing the delicate balance between different components of the
signalling pathway (L Anderson: personal communication).
Not only are the components within a cell important for receptor
function and regulation, but in vivo, external factors are also involved in
receptor regulation. For example, peripheral hormones such as oestrogens
and glucocorticoids affect the responses of lactotrophs to TRH and DA,
and thyroid hormones feedback on thyrotrophs inhibiting the secretion of
TSH (Burrow, 1991). A study on the effects of thyroid hormones in vivo
and in GH3 cells gave different results. In vivo, thyroid hormones
appeared to down-regulate TRH-Rs at the level of transcription, while in
vitro, down-regulation at this level was not observed and may occur post-
translationally (Yamada et al., 1993). These findings demonstrate the
importance of considering whether information obtained from receptor
structure/function analysis in transfected cells provides accurate
information with respect to the physiological situation.
Factors affecting the functional regulation of receptors may also
dictate which receptor subtype is expressed in a particular cell, or there
may be other components of the cell which are themselves temporally and
tissue-specifically regulated. It is likely that a complex combination of
factors is responsible for determining the response of a cell to a particular
ligand. The D2-R subtypes are transcribed from a single gene as a result
of an alternative splicing event in the third cytoplasmic loop (Giros et al.,
1989; Rao et al., 1990; Chio et al., 1990; Grandy et al., 1989; Dal Toso et
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al., 1989; O'Malley et al., 1990). These two subtypes have recently been
shown to be functionally diverse, the long form of the receptor having an
extra cassette of 29 residues that enables it to couple to a specific G-
protein isoform (Montmeyeur et al., 1993). The TRH-Rs all exhibit a high
degree of sequence homology except at the 3' end of the COOH tail where
all receptor subtypes show sequence divergence after a specific residue.
This finding suggests that a similar alternative splicing event may occur
in the TRH-R. Structural analysis of the TRH-R gene lent some support
to this theory, at least in the mouse (Chpt. 6) although no second form of
the mouse TRH-R has yet been reported. PCR analysis of the rat gene (de
la Pena et al., 1992b) and cloning of the human gene (Yamada et al., 1993)
has revealed different genomic organisation of the coding regions for the
TRH-R gene of all three species. The mouse appears to have one intron in
the coding region at the extreme 3' end of the COOH tail (Duthie et al.,
1993b). The rat gene seems to have no extra intronic sequence, encoding a
'retained intron' within the coding sequence instead, with the 3' junction
of this 'intron' occurring in the same position as the mouse COOH tail
intron (de la Pena et al., 1992b). The human TRH-R gene has an intron in
the third cytoplasmic loop like the D2-R gene, but no reported intronic
sequence at the COOH tail (Yamada et al., 1993).
This genomic organisation contrasts with the situation for the D2-
R gene where the positions of the intron/exon boundaries have been
strictly retained between the three species (O'Malley et al., 1990; Mack et
al., 1991; Gandelman et al., 1991; Chpt. 7). The mouse TRH-R gene was
analysed in part using PCR amplification, while information for the rat
gene was entirely due to PCR analysis, and although results appeared
clear-cut it is possible that small introns may have been overlooked or
very large introns missed due to 'looping out' of intervening sequence.
Another possibility is that there is more than one TRH-R gene. Since
TRH, like DA, exerts more than one function in more than one location it
is quite likely that there are several TRH-R genes expressed in different
cell types as occurs in the different dopaminergic systems.
GH3 cells have been reported to coexpress the long and short
forms of the rat TRH-R. Both receptors appear to have similar ligand
binding characteristics in an oocyte expression system, but the variation
observed at the COOH tail may be important in directing the coupling of
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the receptor to a particular G-protein subtype as was reported for the D2-
R (Montmeyeur et al., 1993) and the prostaglandin EP3 receptor (Namba
et al., 1993). Expression of the two forms of the receptor in transfected
cells may help to answer this question, although, as stated earlier, it is
difficult to draw firm conclusions from this type of analysis.
In spite of the problems encountered with clonal cell lines and
their various trans-acting factors they still provide the most useful method
of studying receptor structural and functional relationships and can also
be helpful in studying the cis-regulatory elements responsible for
controlling receptor gene transcription. A standard approach is to
transfect constructs of putative receptor regulatory elements linked to
reporter genes into an appropriate host cell and to monitor expression of
the reporter gene. This system will be useful for studying the TRH-R gene
promotor elements such as the dinucleotide repeat sequence observed in
the 5' untranslated region (Chpt. 6).
Ultimately, the role of a particular genomic sequence in
regulating gene activity can be more completely assessed by constructing
a transgenic mouse model. It is also becoming possible to use the
transgenic approach to study mutated receptors in the whole animal,
providing an opportunity to analyse functional receptor domains in a
physiological situation. Establishing colonies of transgenic mice however,
is time-consuming and expensive, while transfected cell lines are easily
manipulated, provide valuable information very quickly and can also be
used for screening appropriate constructs before their expression in
transgenic mice.
The report published by Hibert et al., (1993) was entitled "This is
not a G protein-coupled receptor", on the basis that all the evidence
gathered from primary sequence alignments of GPRs, from ligand-binding
studies, from site-directed mutagenesis and from 3-dimensional molecular
modelling represents only the merest suggestion of an actual GPR.
However, the increasing amount of structural and functional information
becoming available together with the rapid advances in technical methods
used for receptor analysis, suggest that there will come a time when a
realistic model for the activation of GPRs and transduction of the signal
within the cell may be confidently put forward, together with the
statement 'This is a G-protein-coupled receptor!'.
Appendix I
Buffers and Stock Solutions
Biodyne A - High salt denaturing solution
0.5M NaOH, 1.5M NaCl
Biodyne A - Neutralising solution
0.5M Tris/HCl pH7.4, 1.5M NaCl
Chloroform
24:1 (v/v) mixture of chloroform and isoamyl alcohol. Stored at room
temperature.
50XDenhardt's
2% (w/v) Ficoll™, 2% (w/v) polyvinylpyrrolidone, 2% (w/v) bovine serum
albumin (BSA), Pentax Fraction V. Stored at -20°C.
15% Formamide hybridisation buffer (cDNA probes)
200mM phosphate buffer pH7.2, ImM EDTA, 7% (w/v) SDS, 1% (w/v)
BSA, 15% (v/v) deionised formamide, 65ml water.
20% Formamide hybridisation buffer (oligonucleotide probes)
5XDenhardt's, 5XSSC, 50mM sodium phosphate pH 6.8, ImM sodium
pyrophosphate, 20% (v/v) deionised formamide. Add lOOpg/ml freshly
boiled, sonicated salmon sperm DNA just before use (Ullrich et al., 1984).
6XGel-Loading buffer (Agarose Gels)
0.25% (w/v) bromophenol blue, 0.25% (w/v) xylene cyanol FF, 30% (v/v)
glycerol in water, stored at 4°C.
LB (Luria-Bertani) Broth
12.5g Luria Broth Base in 500ml water (autoclaved).
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LB soft top agarose
12.5g Luria Broth Base, in 500ml water (autoclaved), then add 4g
SeaqKem agarose and re-autoclave.
LB bottom agar
18.5g Luria Agar in 500ml water (autoclaved).
Phosphate buffer pH7.2
Add 400ml of 1M Na2HPC>4 solution to 150ml 1M NaH2PO4.2H20 while
stirring and monitoring pH (autoclaved).
ss-phenol (stock solution phenol)
Phenol is removed from -20°C, warmed to room temp, and melted at 68°C.
Add hydroxyquinoline to final conc. of 0.1% (w/v). To melted phenol, add
an equal volume of buffer (0.5M Tris/HCl, pH8.0) at room temp., stir for
15mins. and leave to separate. Remove upper layer and add an equal
volume of 0.1M Tris/HCl, pH8.0, repeat extractions until pH of the phenol
is >7.8. After equilibration, add 0.1% (v/v) 0.1M Tris/HCl, pH8.0
containing 0.2% P-mercaptoethanol. Store in dark at 4°C for 1 month.
Phenol/chloroform
1:1 (v/v) phenol & chloroform equilibrated with TE buffer (pH8.0). Stored
at 4°C, protected from light.
20% SDS (sodium dodecyl suphate/lauryl sulphate)
20% SDS (w/v) in distilled water (autoclaved).
SM buffer
1.0M NaCl, 0.1M MgS04.7H20, 0.35M Tris/HCl pH 7.5, 0.01% (v/v)
gelatin (autoclaved).
SOC medium
2% Bacto tryptone (w/v), 0.5% Bacto yeast extract (w/v), lOmM NaCl,
2.5mM KC1, lOmM MgCl2, lOmM MgSC>4, 20mM glucose.
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20XSSC (sodium salt citrate)
3M NaCl, 0.3M Na3 citrate.2H2O, 0.02M EDTA, pH 7.0 (autoclaved)
TM buffer
50mM Tris, pH7.4, lOmM MgSC>4. (autoclaved).
TE buffer
lOmM Tris/HCl, pH7.8, O.lmM EDTA (autoclaved).
10XTBE Electrophoresis Buffer
108g Tris base, 55g boric acid, 40ml 0.5M EDTA in 11 water (autoclaved).
Plasmid lysis buffer
20mM Tris/HCl pH8.5, 2mM EDTA, 1% (v/v) Triton-X-100.
Tissue culture solutions
Assay Buffer - receptor binding assay
20mM Tris/HCL pH7.4, 2mM MgCl2.
Buffer A - inositol phosphate production assay/calcium imaging
NaCl (127mM), KC1 (5mM), MgCl2 (2mM), NaH2P04 (0.5mM), NaHC03
(5mM), CaCl2 (1.8mM), HEPES (lOmM), and BSA (0.1%) pH 7.2.
DMEM medium (COS-1 cells)
To a 500ml bottle of Dulbecco's modified Eagle's medium (DMEM) add
10ml stock L-glutamine (0.3mg/ml final conc.), 5ml stock
penicillin/streptocmycin (P/S) solution (100IU penicillin final conc., 100pg
streptomycin final conc.) and 10% (v/v) dialysed heat inactivated foetal
calf serum (HIFCS).
Trypsin-EDTA solution
Trypsin-EDTA is available as a X10 liquid solution (GIBCO-BRL) containing
5.0g trypsin (0.5% w/v) and 2g EDTA in 100ml and is stored at -20°C. The
working concentration of trypsin is 0.1% w/v and the stock solution is
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working concentration of trypsin is 0.1% w/v and the stock solution is
diluted 1/5 with phosphate buffered saline (PBS). Aliquots are stored at
-20°C.
Buffers and solutions for RNA extraction/Northern blots
Dye solution - RNA gel electrophoresis
7.5% (w/v) Ficoll 400, 0.1% (v/v) bromophenol blue, lmg/ml ethidium
bromide
10X MOPS/EDTA running buffer - RNA gel electrophoresis
8.36g MOPS (200mM), 0.744g EDTA (10mM), 0.82g sodium acetate
(50mM), dissolved in 150ml double-distilled water and adjusted to pH 7.0
with sterile 5M NaOH.
Phenol (water-saturated)
lOOg highly purified stock solution phenol (Gibco-BRL) stored at -20°C.
Before use, melt in water bath at 65°C, fill bottle with double-distilled
water, shake well and leave overnight at 4°C to separate. Remove most of
the water and store at 4°C for one month.
Sample buffer - RNA gel electrophoresis
200pl (10X) MOPS/EDTA running buffer, 1ml deionised formamide, 356jil
formaldehyde (37% v/v)
Sodium acetate (2M)
Molecular biology grade sodium acetate (Sigma), adjusted to pH 4.0 with
glacial acetic acid (autoclaved).
Solution D - RNA extraction
Dissolve 250g of Guanidinium thiocyanate (Fluka) in 293ml double-
distilled water and add 17.6ml 0.75M sodium citrate pH 7.0 (previously
prepared in baked glassware and autoclaved) and 26.4ml 10% (w/v)
sarcosyl (at 65°C to dissolve). This solution can be stored at room
temperature for three months. Before use, add 0.36ml (3-mercaptoethanol
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(in fume-hood) to 50ml of this stock solution in a sterile Falcon tube. This
is now solution D and can be stored at room temperature for one month.
Final solution: 4M guanidinium thiocyanate, 25mM sodium citrate, 0.5%
sarcosyl, 0.1M (3-mercaptoethanol.
Buffers and solutions for in situ hybridisation
All glassware used must be washed and baked to inhibit RNAses and
gloves must be worn to prevent contamination of RNAses from hands.
1M dithiothreitol (DTT)
lg DTT dissolved in 6.49g distilled water.
Hybridisation buffer
50% (v/v) deionised formamide, 10% (v/v) dextran sulphate, 4XSTE buffer,
IX Denhardt's solution, 125|ig/ml yeast tRNA, 125pg/ml salmon sperm
DNA, lOmM dithiothreitol (DTT) and distilled water. Filter through
0.2pM millipore filter and store at -20°C.
4% paraformaldehyde (make fresh)
400ml phosphate buffered saline (without Ca2+ or Mg2+) heated to 65°C,
add 16g paraformaldehyde (wear carbon-filter mask), with 1 to 2ml 5M
NaOH to dissolve. When cool, pH with conc. HC1 and filter before use
through Nalgene filters under vacuum.
0.1M phosphate buffer (make fresh)
9g NaCl, 3.5g Na2HPC>4, 11.88g NaH2PO4.2H20, O.lg thiomersalate in 11
sterile water, pH to 7.4 with 5M NaOH and filter before use.
Prehybridisation buffer
50% (v/v) deionised formamide, 4XSTE buffer, IX Denhardt's solution,
125pg/ml yeast tRNA, 125pg/ml salmon sperm DNA, lOmM dithiothreitol
(DTT) and distilled water. Filter through 0.2pM millipore filter and store
at-20°C.
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RNAse buffer
lOOmM Tris/HCL pH 8.0, 0.5M NaCl, ImM EDTA pH 8.0 made up to 11
with distilled water (autoclaved).
20XSTE
0.1M NaCl, lOmM Tris/HCl pH8.0, ImM EDTA PH8.0.
Triethanolamine (TEA) buffer
10.4g TEA, 700ml distilled water, pH 8.0 (autoclaved).
Buffers and solutions for F.I.S.H.
Hybridisation buffer
50% (v/v) deionised formamide, 10% (v/v) dextran sulphate, 1XSSC.
Aliqoted and stored at -20°C.
Wash A
100ml 20XSSC, 250pl Tween 20 (BDH), 25g dried skimmed milk (Marvel)
made to 500ml with dH20. Mix on low heat until dissolved. Spin 50ml
aliquots at 2000rpm for 10 mins. and use supernatant.
FITC-avidin solution.
FITC-avidin (Vector Labs), 5pg/ml. in Wash A.
Biotinylated anti-avidin solution
Biotinylated anti-avidin (Vector Labs), 5pg/ml in Wash A.
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Chemical and Equipment Suppliers
Amersham International pic, Amersham Place, Little Chalfont, Bucks.
HP7 9NA, U.K.
Appligene, Pinetree Centre, Durham Road, Birtley, Chester-le-Street,
Co. Durham DH3 2T1, UK.
Bio-Rad Laboratories Ltd., Bio-Rad House, Maylands Ave. Hemel
Hempstead, Herts. HP2 7TD, UK.
Biosoft, Cambridge, Cambs, U.K.
Boehringer Mannheim UK (Diagnostics and Biochemicals) Ltd., Bell
Lane, Lewes, E.Sussex BN7 1LG, UK.
Clontech - Cambridge BioScience, 25 Signet Court, Stourbridge Common
Business Centre, Swann's Road, Cambridge CB5 8LA, UK.
Costar, 205 Broadway, Cambridge, MA 02139, USA.
Falcon, Becton Dickinson UK Ltd., Between Towns Road, Cowley,
Oxford, UK.
Flow Laboratories Ltd., PO Box 17, Second Avenue, Industrial Estate,
Irvine, Ayrshire, Scotland KA12 8NB.
Flowgen, FMC Bioproducts, High Wycombe, Bucks, UK.
Gmco-BRL, Life Technologies Ltd., PO Box 35 Trident House, Renfrew
Road, Paisley PA3 4EF, Scotland, UK.
Greiner Labortechnik, Greiner GmbH, Maybachstrasse 2, D-7443,
Frichkenhausen, Germany.
178
Appendix II Chemical and Equipment Suppliers 179
Hybaid Ltd., 111-113 Waldegrave Road, Teddington, Middlesex, UK.
Invitrogen - British Bio-technology Products Ltd., 4-10 The Quadrant,
Barton Lane, Abingdon, Oxon 0X14 3YS, UK.
Joyce Loebl Ltd., Dukesway, Team Valley, Gateshead, Tyne and Weir,
UK.
Kodak - IBI Ltd., 36 Clifton Road, Cambridge CB1 4ZR, UK.
Kontron Instruments, 52 Telford Road, Lenziemill, Cumbernauld, UK.
National Diagnostics, 305 Paton Drive, Atlanta, Georgia, USA.
NBL, Northumbria Biologicals Ltd., Enzymes Division, South Nelson
Industrial Estate, Cramlington, Northumberland NE23 9HL, UK.
Novagen, 593 Science Dr. Madison WI 53711, USA
Nunc, A/S Nunc, Kamstrupvej 90, Kamstrup, DK-4000 Roskilde,
Denmark.
O. Kindler GmBH & Co., ZiegelhofstraBe 214, D07800 Freiburg,
Germany.
Pall, BioSupport Division, Pall Process Filtration Ltd., Europa House,
Havant Street, Portsmouth POl 3PD, UK.
Peninsula, 611 Taylor Way, Belmont, CA 94002, USA.
Perkin Elmer Cetus, 761 Main Ave., Norwalk, CT 06859.
Promega Ltd., 2800 Woods Hollow Road, Madison, WI 53711-5399, USA.
Raymond A. Lamb, 6 Sunbeam Road, London, UK.
Appendix II Chemical and Equipment Suppliers 180
Promega Ltd., 2800 Woods Hollow Road, Madison, WI 53711-5399, USA.
Raymond A. Lamb, 6 Sunbeam Road, London, UK.
SEMAT, Semat Technical (UK) Ltd., 1 Executive Park, Hatfield Road, St.
Albans, Herts. AL1 4TA, UK.
Sigma Chemical Company Ltd., Fancy Road, Poole, Dorset BH17 7NH,
UK.
Stratagene Ltd., Cambridge Innovation Centre, Cambridge Science
Park, Milton Road, Cambridge CB4 4GF, UK.
Stratech Scientific, Luton, UK.
USB - United States Biochemical Corporation, Cambridge, UK.
Vilber Lourmat, 77202 Marne la Vallee, Cedex 2, France.






Before [Ca2+]i measurements could be determined, cells first had to be
loaded with the fluorescent calcium dye fura-2. Trypsinized single cells
were plated on to sterile glass coverslips. After 2 days attached cells were
washed (X2) with Buffer A (Appendix I). Cells were loaded with fura-2
AM ester (4fiM final conc. in Buffer A) for 30min. at 37°C in a 5% CO2
humidified incubator. Unincorporated dye was removed by washing (X3)
with Buffer A. Coverslips were then transfered to the heated stage (37°C)
of an inverted epifluorescence microscope (see below).
Stimulation ofcells with TRH and [Ca2+]i Imaging
Dynamic video imaging was carried out using the MagiCal hardware and
Tardis software provided by Joyce Loebl Ltd. A Nikon Diaphot microscope
with a X40 quartz oil immersion objective, operated in epifluorescence
mode, was used to image the cells.
Fluorescent images were obtained by exposing cells to 340nm and
380nm light, alternated under computer control, at a speed of
approximately 0.6Hz. The images, viewed at wavelengths of 510nm (with
a 40nm wide band filter), were focused on to the face of an intensified
charge-coupled device camera (Photonic Sciences, UK) interfaced in turn,
to an analogue hardware averager and 8-bit analogue-to-digital converter,
both operating at video frame rate. Typically, eight images were averaged
at each wavelength. A similar number were collected for background
images which were subsequently subtracted on a pixel-by-pixel basis from
the image samples. These images were held in dynamic random access
memory for subsequent processing and analysis.
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Fluorescence excitation shifts occur when fura-2 binds calcium, i.e.
the excitation efficiency increases at 340nm and 380nm. Ratios of values
obtained at 340/380nm represent changes in [Ca2+]i. The 340/380nm ratio
was calculated from averaged video frames on a pixel-by-pixel basis, and
were proportional to the intracellular ionized Ca2+ concentration.
Calibration was performed on cells loaded with dye which had been made
permeable to extracellular Ca2+ using l|iM ionomycin. Exposure of cells
to solutions containing either lOmM Ca2+ or lOmM EGTA provided an
estimate of the minimal and maximal fluorescence at 340nm and 380nm.
A dissociation constant of 225nm for fura-2 and Ca2+ at 37°C was used.
Possible errors in [Ca2+]i determination were estimated to be 5% from
frame to frame, and were measured by collecting data from known
standards of Ca2+/EGTA buffers, containing 50-100|iM fura-2 free acid.
Within a single frame, the maximal pixel-to-pixel standard error (spatial
variation) was less than 3% in concentration for an average of 4 frames,
and this fell to under 2% for an average of 8 frames.
Data Analysis and Presentation
Software-based image analysis using MagiCal allowed quantitation of
ionized Ca2+ either in the whole cell or in selected regions of the cell
versus time. This was accomplished by the use of a light pen accessed into
dynamic memory to define a pixel data-set on a given image frame and the
software then automatically constructed a graphical presentation of Ca2+
concentration with time. AscII files of quantitative data could also be
derived, and these were used to derive plots of [Ca2+]i versus time for
either single cells, or the averges of several cells.
Fluorescence in situ hybridisation (F.I.S.H.)
In situ hybridisation to chromosomes (F.I.S.H.) provides a direct approach
to chromosome mapping. A probe is labelled with biotin by nick-
translation. Following hybridisation, the probe is detected by incubation
with avidin-FITC. Prior to hybridisation, approximately fifty normal male
chromosome spreads are banded and photographed. Each photographed
cell is re-located after hybridisation and examined by phase-contrast
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microscopy. Any hybridisation signals present on the post-hybridisation
chromosomes are marked in the appropriate position on the corresponding
pre-hybridisation photographs.
Chromosome preparation
Using standard cytogenetic methods, metaphase chromosome spreads
were obtained from two human males of normal karyotype. Chromosome
spreads in marked slide areas were banded using the Lipsol method (1%
Lipsol for 10-15 seconds, rinse with saline, 1:4 Leishmann's stain in pH6.8
buffer for 2.50 mins., rinse with pH6.8 buffer), mounted in buffer, blotted
dry and photographed within a marked 2cm2 area. Coverslips were
removed in buffer and the slides de-stained in an ascending series of
alcohols and air-dried prior to hybridisation (Garson et al., 1987; Boyd et
al., 1989).
DNA probe labelling
Probes were labelled with biotin-ll-dUTP (Sigma) by nick-translation
using the BRL Nick Translation Kit 8160SB, according to manufacturer's
instructions, and precipitated with 4.6pl 3M sodium acetate pH5.2, ljil
20mg/ml glycogen and 122pl cold ethanol. The reaction was vortexed to
mix, centrifuged for 30min. at 12,000rpm and the supernatant removed.
The pellet was freeze-dried and resuspended at a concentration of
lOOng/pl in TE buffer.
In situ hybridisation
The method used was essentially that described by Pinkel et al. (1986)
with modifications by Carter et al., (1992) although the pre-hybridisation
step was omitted for these single copy probes. The probes were diluted to
a concentration of 10 to 30ng/pl in hybridisation buffer (Appendix I). The
probe (lOOng/slide area) was applied to the slide, a coverslip added and
sealed with Cow Gum. The probe and chromosomal DNA were denatured
together by incubation at 80°C for lOmin. and quenched in cold ethanol.
Slides were incubated on a metal tray floating in a water-bath at 37°C
overnight.
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Post-hybridisation washing and detection
Coverslips were carefully removed from slides before soaking in 2X SSC
for 5mins. The slides were washed for only 1.5mins in 50% formamide (in
2X SSC) at 42°C, and rinsed in 2X SSC for a further 5mins. before
incubating in Wash A (Appendix I) at 37°C for 30mins. During the wash
period, detection agents were diluted and incubated for lOmins. at room
temperature, then microcentrifuged for lOmins. to pellet any precipitate
and only the supernatants used.
To detect the biotinylated probe, lOOjil FITC-avidin solution (Vector
Laboratories) was pipetted on to the hybridisation area, which was
overlaid with a coverslip and incubated at 37°C for 20mins. in a
humidified box. Coverslips were removed and the slides washed for
3x5mins. in Wash A at 42°C. Following this wash, lOOpl biotinylated
anti-avidin solution (Vector Laboratories) was pipetted on to the
hybridisation area, the slide coverslipped and incubated for 20mins. at
room temperature in a covered (to prevent FITC fading) humidified box.
The coverslips were again removed and the slides washed for 2x5mins. in
Wash A at 42°C. Slides were again incubated with lOOpl FITC-avidin
solution at room temperature for 20mins. in a covered, humidified box.
Washes were repeated for 2x5mins in Wash A at 42°C. The signal was
amplified twice by two further incubations with biotinylated anti-avidin,
followed by FITC avidin. Slides were rinsed 2x5mins. in 4X SSC
containing 0.05% Tween-20 at room temperature ready for counter-
staining.
Slides were briefly dehydrated in an ascending series of alcohols,
air-dried and the chromosomes were counterstained by mounting the
slides in 25pl antifade AF1 (Citfluor) containing 0.8|ig/ml 4,6-diaminidino-
2-phenylindole (DAPI) and 0.4pg/ml propidium iodide. The hybridisation
area was overlaid with a coverslip and sealed with nail varnish.
Microscopy and analysis
For best results, the slides were stored at 4°C overnight before microscopy
and were examined using a Zeiss Axioplan fluorescence microscope. FITC
and propidium iodide were excited at 490nm (Zeiss filter combination 9)
and the hybridisation signals appeared as yellow-green spots. Previously
photographed, DAPI-stained cells were relocated using Zeiss filter
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combination 1. Signals visualised on the post-hybridisation metaphases
using filter set 9 were marked on the photographs of pre-hybridisation
banded metaphases. Each signal was then plotted on a chromosome
ideogram and the distribution of hybridisation in chromosome spreads
was analysed statistically using the chi-square (%2) test.
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Congratulations again on a very nice research project
I can offer the following observations regarding the mouse TRH-R gene. These
data confirm your findings. Using a mouse genomic clone that we isolated from a
different library than the one you used, we find the same size PCR products in our
genomic and cDNA clones with the forward primer from extracellular loop 2 and reverse
primers from transmembrane helix 7 or the cartxixyl tail. Therefore, we also find no
evidence for an intron in this region of the mouse gene.
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